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PREFACE
The study ’Exposure and risk assessment for fine and ultrafine particles in ambient air’,
acronym ULTRA, is a European collaborative project which aims to improve knowledge on
human exposure to ambient air particulate matter of different sizes and different chemical
composition in Europe, and to evaluate the associated health risks.
This study manual and data book has three parts. The first part is ’Study manual’ and it
describes the background, rationale, and methods of the ULTRA project. In the project,
standard operation procedures (SOP) were developed and used to standardize the methods.
These SOPs are included as appendices in this book. The chapters 1-8 and the appendices A1
– A13 have been written before the field work of the project, and the chapter 9 'Statistical
analyses' has been written during the preliminary phase of the statistical analyses of the data.
The second part of the manual 'Remarks and recommendations' has been written after the
field work of the study in order to discuss and comment the methods used, and when
appropriate, to give recommendations for future studies. The third part 'Data book' gives
descriptive statistics of the data collected.
The development of the methods used in ULTRA and the writing of this book was a truly
collaborative effort, which involved intense discussions and participation from all partners.
However, some key players and their role can be pointed out. Gerard Hoek, Ph.D., was
responsible for the PM2.5 and spirometry SOPs. Jyrki Mäkelä, Ph.D., from the Department of
Physics, University of Helsinki, together with Marko Vallius, M.Sc., was responsible for the
CPC SOP. The SOP for determination of absorption coefficient using reflectometric method
was developed by Marko Vallius. Kirsi Timonen, M.D., was responsible for the ambulatory
ECG and clinic visit SOPs. The operation procedure for DAS was finalized by Andrey
Khlystov, Ph.D., for MAS by Wolfgang Kreyling, Ph.D., and for EAS by Aadu Mirme, Ph.D.
Annette Peters, Ph.D., coordinated the development of the diary and Joachim Heinrich, Ph.D.,
the characterization questionnaires. Pekka Tiittanen, M.Sc., designed the procedures for the
data transfer and management of the health data and Timo Lanki, M.Sc., did the same for the
air hygiene data. Juha Pekkanen, M.D., drafted the chapters 1.1-1.3 of this manual and the
chapter 1.5 together with Marko Vallius. Kirsi Timonen drafted the chapters 1.4 and 1.6 and
edited the second part 'Remarks and recommendations'. Pekka Tiittanen wrote the chapters
1.7-1.9. For the part 'Remarks and recommendations' those who were responsible for a
particular SOP drafted a paragraph on that SOP first. After that, all participants gave their
comments. Mr. Harri Sinkko did the tables for the data book.
The study was coordinated at National Public Health Institute, Kuopio, Finland, by Juha
Pekkanen with the help of Kirsi Timonen. At the coordinating center, Pekka Tiittanen was
responsible for the overall data management. Timo Lanki was responsible for air hygiene data
and Kirsi Timonen for the health data. Esko Vanninen, M.D., and Tuula Tarkiainen, M.D., at
the Kuopio University Hospital, Department of Clinical Physiology and Nuclear Medicine,
were responsible for the analyses of the ambulatory ECG recordings. The urinary CC16
samples were analysed in the laboratory of prof. Alfred Bernard at the Unité de Toxicologie
Industrielle et de Médicine du Travail, Brussels, Belgium. During the field work in Helsinki,
Aadu Mirme, Ph.D., was responsible for the EAS measurements, Gintautas Buzorius, Ph.D.,
and Ismo Koponen, M.Sc. for CPC measurements, and Marko Vallius for other central site
measurements. Kirsi Timonen was responsible for the clinic visits with the help of the study
nurse Mr. Sami Penttinen, and Timo Lanki, Ms. Kati Oravisjärvi, and Annalea Lohila, M.Sc.
Mrs Anita Tyrväinen weighed the PM2.5 filters and measured the absorption coefficients
from them. Päivi Aarnio, Lic.Tech., and Tarja Koskentalo, Lic.Tech., Helsinki Metropolitan
Area Council, Helsinki, were responsible for the network air pollution data in Helsinki.
At GSF - Forschungszentrum für Umwelt und Gesundheit, Neuherberg, Germany, Joachim
Heinrich was the principal investigator. He was helped by Annette Peters and Wolfgang
Kreyling. Dr. Kreyling was also responsible for the overall coordination of the aerosol
measurements in ULTRA. Angela Ibald-Mulli, M.P.H. was responsible for the data
management and quality control. Gabi Wölke, MA, coordinated the fieldwork in Erfurt.
Martina Stadeler, M.D., was the physician overseeing the study conducted at the FSA with
the help of the nurses Regina Müller and Cornelia Engel. Thomas Tuch, Ph.D., was
responsible for the ambient air pollution measurements.
At the University of Utrecht, the Netherlands, prof. Bert Brunekreef was the principal
investigator. He delegated most of the task to Gerard Hoek. Jeroen de Hartog, M.Sc., was
responsible for the field study in Amsterdam, including data management. He was assisted by
Carolien Mommers, M.Sc., Marloes Jongeneel, M.Sc., Ms Boukje de Wit, Ms Isabella van
Schothorst and Ms Veronique van den Beuken for the clinical visits. Ms Marieke
Oldenwening performed the ambient PM2.5 measurements. Nicole Janssen, Ph.D., and Mr
Jean Pierre van Mulken contributed to the PM2.5 measurements. Saskia van der Zee, Ph.D.,
Willem Roemer, Ph.D., and Joop van Wijnen, M.D., from Environmental Medicine,
Municipal Health Service Amsterdam, contributed significantly to the selection of the study
population, the examination site, the sampling location and supplied data on ambient air
quality of Amsterdam. Measurements of particle number counts were the responsibility of
Gerard Kos, M.Sc., Andrey Khlystov and Harry ten Brink, Ph.D., (ECN).
The project has been funded by European Commission contract No ENV4-CT97-0568 (DG
12 – ESCY). In addition, the coordinating center got funds from the Finnish Research
Programme on Environmental Health (SYTTY), Academy of Finland.
The field work of the ULTRA project was conducted during October 1998 – June 1999.
Before this, intercomparisons of the aerosol spectrometers used in the current project were
done during a previous ULTRA project funded by the European Commission contract No
ENV4-CT96-0205.
December, 2000
Juha Pekkanen                                   Kirsi Timonen
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1 STUDY MANUAL
1.1 INTRODUCTION
A large number of studies have reported that daily changes in particulate air pollution are
associated with a variety of adverse respiratory outcomes, like symptoms, declines in lung
function, hospital emergency admission and mortality (Dockery et al, 1993; Dockery and
Pope, 1994; A Committee of the Environmental and Occupational Health Assembly of the
American Thoracic Society, 1996). Recently, similar associations have also been reported
with cardiovascular outcomes, like hospital admissions and mortality (Schwartz, 1994;
Burnett et al, 1995).
The goal of the project is to improve knowledge on human exposure to particulate matter of
different sizes and of different chemical composition in Europe, and to evaluate the
associated health risks. These results can then be used to develop standards for air quality in
Europe, for better and more efficient monitoring of air quality, and as a bases for designing
control strategies to improve urban air quality and reduce the health effects associated with
exposure to particulate matter in ambient air.
Specifically, the aims of the project are
1. to improve exposure assessment to fine particles in Europe by assessing the size
distributions, including ultrafine particles, and elemental compositions of fine particles in
ambient air in three European cities with different sources of particulate air pollution, i.e.
a) to describe the levels, variations in time, and intercorrelations of different types
particles with each other and with other air pollutants
b) to describe the elemental composition of particle mass collected with PM2.5
impactors
2. to improve risk assessment of exposure to fine particles of different sizes and of different
elemental composition with focus both on respiratory and cardiovascular outcomes.
Specifically, to test the following null hypotheses:
a) there is no difference between the health effects associated with all fine particles
(PM2.5) or size fractions of ultrafine and fine particles
b) there is no difference between the health effects associated with fine particles of
varying elemental composition
1.2 JUSTIFICATION AND DEFINITIONS OF MAIN EXPOSURE AND OUTCOME
VARIABLES
1.2.1 Exposure variables
In addressing the above aims, the main variables used in the final analyses are 24-hour
averages of PM2.5 and PM10, total particle number concentration, particle number
concentration in size ranges 0.01  	
 			

blackness of PM2.5 particles.
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It is unknown, what characteristics of the airborne particles are responsible for their health
effects. Currently, the two probably most hotly debated theories are the findings that suggest
that the large number of ultra-fine particles in urban air are responsible for the health effect of
particulate air pollution (Oberdörster et al, 1995; Peters et al, 1997). The second possibility is
that the chemical composition of particles, especially the transition metal content on the
surface of the particles determines their health effects (Tepper et al, 1994; Dusseldorp et al,
1995; Dreher et al, 1996; Osornio-Vargas et al, 1996). Both of these issues are addressed in
the present study.
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'coarse'. Fine particles can be divided into two modes: ultrafine particles, with diameter below
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particles are mainly wind blow dust, e.g. Scandinavian countries suffer from high levels of
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early spring. These particles are mainly resuspended dust from street sanding and dust created
from the use of studded tires. Ultrafine particles are mostly generated by local traffic exhaust
emission and the particles in the accumulation mode are (outside inversion situations) mainly
from long-range transport. Particle size affects exposure to particles by influencing lung
deposition rates, indicates the source of the particles and possible chemical composition.
The main size ranges used in the analyses of the present ULTRA study are therefore 0.01-0.1
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al. 1997), data are calculated for these cut points. Also one hour averages of particle number
concentrations will be analyzed to more clearly define the lag time of different health effects.
1.2.2 Respiratory end points
The main variables used in the final analyses are FVC, FEV1, PEF, MMEF from biweekly
measurements of spirometry and respiratory symptoms from daily diaries. These end points
have been repeatedly used in previous studies.
1.2.3 Cardiovascular end points
Main outcomes are 1) the angina pectoris (AP) symptom and medication data collected in the
daily diary and during the clinic visit and 2) electrocardiograph (ECG) data collected with
ambulatory ECG recordings (Holter) during the clinic visits. The main ECG variables used in
the final analyses are ST-changes, ectopic beats / arrhythmia and indexes of heart rate
variability (HRV, see below).
Especially HRV analyses provide a large number of indexes. One method to validate different
measures of HRV is to look at predictive capability: those measures of ambulatory ECG
recordings that predict future risk of death because of cardiovascular disease (CVD) are the
most important. Based on the literature, most measures of HRV (both time and frequency
domain analyses) predict mortality in elderly subjects (Tsuji et al.1994) or survival in MI
patients (Bigger et al. 1993). The VLF seems to have best predictability, but the differences
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are not large (Task Force 1996). Also, the correlations between different measures of HRV
are very high, often above 0.75. Also measurements taken for a random 2-, 5- or 10-minute
time frame have high correlations with 24-h measurements (Bigger et al.1993).
High frequency (HF) component of HRV is thought to reflect mainly vagal (parasympathetic)
and low frequency (LF) component both sympathetic and parasympathetic part of the
autonomous nervous function. The physiological basis of very low frequency (VLF)
component is not well understood. HF is defined as frequencies 0.15-0.40 Hz, LF as
0.04-0.15 Hz, and VLF as 0.04 Hz or below. (Task Force 1996).
Air pollution could be hypothesized to lead to two different types of changes in HRV, either a
change in the measured indexes of HRV measured during the whole 1 hour recording or 5
minute recording on rest (this is the kind of measurements that are done to evaluate prognoses
after MI), or to changed responsiveness of HRV indexes to different stress tests causing
autonomic modulation, i.e. the variable of interest would be the difference between the 5
minute resting HRV and 5 minute exercise HRV.
HRV is decreased early after myocardial infarction and begins to recover within a few weeks
(Task Force 1996) and depressed SDNN is associated with survival after myocardial
infarction. Also spectral analyses of HRV after myocardial infarction show a decrease both in
the total power and in the individual power of spectral components. Therefore, a decrease in
these indicators can be interpreted as an adverse outcome. However, also an increase in heart
rate variability may indicate overreaction of autonomic control. Given the limited knowledge
of the effects of air pollution on heart and that air pollution most likely does not have a
beneficial effect on the heart, this can also be a harmful effect.
ST-changes reflect degree of myocardial ischaemia and have also prognostic value (Dekker et
al. 1995). Daily variations of air pollutants can result in increased myocardial ischaemia with
several mechanisms (arrhythmias, effect on haemostatic factors). QT-time reflects
repolarization of the heart and long QT-time increases the risk of sudden death. PR-interval is
a measure of atrio-ventricular conduction of the heart. Carbon monoxide (CO) can
specifically increase myocardial ischaemia by forming carboxyhemoglobin. Ectopic beats
reflect directly the status of the heart.
Due to the relative simplicity of the time domain analyses of HRV, HRV analyses will focus
first on time domain analyses, and only in the second phase on spectral analyses. Based on the
above considerations, the end points for the ECG analyses are:
Definitions:
-SDNN (ms): standard deviation of the length of all NN intervals
-RMSSD (ms): square root of the mean of the squared differences between adjacent NN
intervals
-area of ST-depression: cumulative area of ST-depressions (ST-depression is defined as
depressions over 0.05 mV (’0.5 mm’) lasting longer than 1 minute, when measured 60 ms
after the J-point)
-max ST- depression: largest amplitude of ST- depression during the measuring period
(both area of ST- depressions and max ST- depressions are coded as absolute units and
corrected for the baseline level during the 5 minute rest).
-QT-intervals (ms): is measured in three different ways: Absolute QT-interval, corrected QTc
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interval (corrected for heart rate using Bazett’s formula: QT divided by square root of R-R
interval), and QT-peak.
-pNN50 (%): number of pairs of adjacent N-N intervals differing by more than 50 ms divided
by the total number of N-N intervals
-PR-interval: average of three PR intervals during the rest
1. During 5 minutes of exercise:
Primary:
-SDNN
-RMSSD
Secondary:
-LF/HF ratio
-pNN50
-high frequency (HF)
-low frequency (LF)
-normalized HF
-normalized LF
-total power
-ventricular ectopic beats
-supraventricular ectopic beats
-area of ST-depression
-max ST-depression
-QTc-time
2. During 5 minutes of rest, paced breathing, standing up and rest after exercise:
As during exercise, but not:
-ventricular and supraventricular ectopic beats
-ST-depressions
-QTc-interval (only rest and rest after exercise)
In addition, only from the 5-minute rest period:
-Heart rate (HR)
-PR-interval
3. During the whole Holter monitoring period (incl. exercise)
Primary:
-ventricular ectopic beats
-supraventricular ectopic beats
-area of  ST-depression
-very low frequency (VLF)
Secondary:
-QTc interval
-Heart rate (HR)
-SDNN
-SDANN
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-RMSSD
-pNN50
-high frequency (HF)
-low frequency (LF)
-normalized HF
-normalized LF
-total power
-LF/HF ratio
1.2.3.1 Additional variables/analyses
In addition to the above variables/analyses, following exploratory analyses will be done and
following data made available:
-difference in the HRV indexes calculated between the 5 minute rest and exercise and
standing up
-RR interval data for each recording in ASCII format
-from all Holter analyses following information will be also be provided: details of each ST-
depression episode (duration, max amplitude, slope, area, data on heart rate, extrasystolia)
1.2.4 Biomarkers
There has previously been no toxicity biomarker to monitor populations exposed to
pneumotoxicants at the workplace or in the environment. A lung toxicity biomarker, Clara
cell protein (CC16), applicable not only on bronchoalveolar lavage (BAL) fluid but also on
serum or sputum has recently been identified (Hermans and Bernard, 1996). When no serum
samples can be obtained, changes of CC16 in serum could yet be estimated by measuring the
protein in urine. The influence of the renal function can be neutralized by dividing the urinary
concentration of CC16 by that of retinol-bing protein (RBP). The concentration of Clara cell
protein CC16 and RBP will be measured on spot urine samples by an automated nonisotopic
assay relying on the agglutination of latex particles (Bernard and Lauwers, 1983; Bernard et
al. 1991). In addition, measures of renal function will be determined from urine at the
beginning and at the end of the study.
1.2.5 Blood pressure
Blood pressure will be measured both in rest and after standing up.
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1.3 PLACE AND TIME
The field work of the ULTRA study will be carried out in three cities: in Helsinki, Finland,
Erfurt, Germany, and Amsterdam, the Netherlands. It will last six months. In Helsinki, the
field work will take place from November, 1998 to April, 1999; in Erfurt it will be from
October, 1998 to March, 1999, and in Amsterdam from mid October, 1998 to mid April,
1999.
The participating centres of the ULTRA study are Unit of Environmental Epidemiology,
National Public Health Institute, KTL, Kuopio, Finland (coordinator); Institute of
Epidemiology, GSF-Forschungszentrum für Umwelt und Gesundheit (contractor),
Neuherberg, Germany; Environmental and Occupational Health Unit, University of Utrecht,
Utrecht, the Netherlands (contractor); the Energy Research Foundation, Petten, the
Netherlands (associated contractor) and Environmental Medicine, Municipal Health Service
Amsterdam (associated contractor), Amsterdam, the Netherlands. The other participating
parties are Unité de Toxicologie Industrielle et de Médicine du Travail, Bruxelles, Belgium;
Department of Environmental Sciences, University of Kuopio, Kuopio, Finland; Department
of Environmental Physics, University of Tartu, Tartu, Estonia (subcontractor for KTL);
Department of Physics, University of Helsinki, Helsinki, Finland; Helsinki Metropolitan Area
Council, Helsinki, Finland; Department of Clinical Physiology, Kuopio University Hospital,
Kuopio, Finland; Institute of Inhalation Biology, GSF-Forschungszentrum für Umwelt und
Gesundheit, Neuherberg, Germany;
1.4 OVERALL QUALITY CONTROL
1.4.1 General
The aim of the quality control in ULTRA is to ensure that those procedures done similarly in
all centers will be conducted in a comparable way to allow pooling of the data in the
combined analyses. Therefore, the quality control puts less emphasis on procedures that are
not done exactly the same way in different centers, e.g. aerosol spectrometry or are done only
in one center or laboratory, e.g. Clara protein analyses, analyses of the ambulatory ECG
recording, or the analysis of the elemental composition of the PM2.5 filters. In these cases,
quality control measures of each individual unit or laboratory will be used.
The main ways to ensure comparability between centers are the introduction of standard
operating procedures (SOP) for the main procedures, the training of the field workers in a
common session, the site visits by the coordinating center, and the quality control procedures
of individual measurements, as specified in the respective sections. For aerosol spectrometers,
operating procedures (OP) will be available.
Within each center, the number of field workers should be as few as possible to avoid
between worker variation.  Further, in each center, a daily log book or diary should be kept
throughout the study. In this diary, all exceptions from the protocols and other remarks should
be mentioned. All deviations form the SOPs have to be reported on the form >Local and
temporal deviation from or local change of a SOP= of the respective SOP.
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1.4.2 SOP for making SOPs
All SOPs in ULTRA study are done according to SOP for making SOPs, Appendix A1.
1.4.3 Training session
The field workers who will take care of the clinic visits will be trained in a common
workshop in Kuopio in 28.9. - 29.9.1998. The programme of the training session is in
Appendix A9. A special emphasis will be given on ambulatory ECG recording. The training
session will be guided by the Department of Clinical Physiology, Kuopio University Hospital.
1.4.4 Site visits
Kirsi Timonen from the coordinating center will visit all centers by the mid of December
1998 to ensure that all instructions in this manual are followed. In addition, Wolfgang
Kreyling, the coordinator of the air hygiene in ULTRA, will visit all centers by the end of
February -99 to check the air quality measurements. The form to be completed during these
visits is attached as Appendix A10.
1.4.5 Quality control in individual procedures
The individual SOPs or OPs of the procedures include the respective quality control
measures. When possible, cross comparisons will be conducted between the study centers,
e.g. in weighing the filters, determining the reflectance of the filters, and comparing the
spirometers used to a >reference= spirometer that circulates in all centers.
As quality control of CC16 urine measurements, one urine sample from one person in each
center is divided into 5 tubes to control for laboratory error. This is done twice, both in the
first and second half of the field work.
Data checks and data transfer checks will follow the instructions of the PEACE study
(Roemer et al. 1995)
1.5 AIR HYGIENE MEASUREMENTS
1.5.1 Overview of measurements
This section of the ULTRA field work manual describes the air hygiene measurements which
are carried out during the study. The measurement of PM2.5 and determination of absorption
coefficients from PM2.5 filters are done according to specific Standard Operating Procedures
(Appendices A2, A5). Operating procedures will be followed for aerosol spectrometers and
CPC 3022A particle counter (Appendices A3-1, A3-2, A3-3, A4). Measurements of PM10,
NOX, CO, SO2 and O3 will be collected from existing networks.
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Comprehensive data of the features of all air pollution and meteorological measurements,
their location and measurement equipment will be included in the descriptive report on the
measurement site and equipment (Appendix A11-a, A11-b). Descriptive reports should be
sent to the coordinating center not later than in December 1998.
1.5.2 Sampling site
The most important criterion is that the selected site is representative of the exposure to
ambient air of the target population. Sites that are not strongly influenced by local sources in
the vicinity of the site will be used. In air pollution monitoring literature this type of site is
referred to as "urban background". Concentrations of pollutants with urban sources measured
at such a site will be higher than the "regional background" measured outside the city. All
sampling sites are at least 40 meters away from busy streets. In addition, within 40 meters of
the site no other important sources of combustion gases or particulate matter are present
(construction work, small industries).
All sites have been selected to fulfill as closely as possible the following criteria; samplers are
located at least twice the distance from an obstacle as the height of the obstacle (buildings,
etc.), air flow around the sampler is unrestricted, sampling inlets are at least 2 meters away
from a high volume sampler inlet, samplers are not placed near exhaust flues or vents.
The measurement sites used in ULTRA study centers are described in separate report sheets
(Appendix A11-a).
1.5.3 Aerosol spectrometers
In Germany, MAS consists of two different sensors covering different size ranges. Fine
particles are measured using a differential mobility analyzer (DMA, TSI model 3071) in
combination with a condensation particle counter (CPC, TSI model 3760). Larger particles
are classified by a Laser Aerosol Spectrometer (LAS, PMS model LAS-X).
In the Netherlands, DAS will be used, i.e., Mobility Analyzer together with a Laser aerosol
spectrometer. Fine particles are measured and classified by the Mobility analyzer, and larger
particles are measured and classified by the Laser aerosol spectrometer (LAS, PMS model
LAS-X).
Electric Aerosol Spectrometer (EAS) used in Finland is based on an electric measurement
principal similar to the principle of EAA model 3030 of TSI. EAS is significantly modified in
order to take into account the needs of atmospheric aerosol studies in urban and rural
environment.
More detailed descriptions of the aerosol spectrometers and their operation are given in the
respective operating procedures (Appendix A3- 1-3; parts A3– 1-3 -a, A3- 1-3 -b and A3- 1-3
-c).
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1.5.4 CPC 3022A
Condensation Particle Counter (CPC) TSI 3022A is used in all centers to measure the total
concentration of particles. Upon entering the instrument, the sample passes through a heated
saturator, where butanol evaporates into the air stream and saturates the flow. The aerosol
sample then passes into a cooled condenser tube, where vapor supersaturates and condenses
onto the airborne particles. This produces large, easily detectable aerosol droplets. These
droplets pass through an optical detector immediately after leaving the condenser.
Instructions for operation and maintenance of CPC’s are given in operation procedure
‘Measurement of particle number concentration in ambient air using the Condensation
Particle Counter’ (Appendix A4).
1.5.5 PM2.5
During ULTRA, 24-hour samples of PM2.5 will be collected with Harvard impactors
(Appendix A2). Filter change should take place at 12:00 a.m. ∀ 1.50 hours (resulting in a
minimum of 21 hours and maximum of 27 hours of effective sampling time per one diurnal
sample).
The filter type used should have a collection efficiency of at least 99% for 0) 
- 
  	
	
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  	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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.3. In
addition, no artifact formation as observed on glass fibre, cellulose and many quartz filters
(resulting from SO2, HNO3 and NO2) should occur.  Teflon filter with a polymethylpentene
		
 /are therefore used in sampling. Low chemical background,
low pressure drop during sampling and excellent aerosol retention ability are the properties
which make it the best choice for this study.
1.5.6 SO2, NO, NO2, CO, O3 and PM10
Concentrations of gaseous pollutants SO2, NO, NO2, CO, O3 must be measured continuously
at the measurement site or at another representative site (existing monitoring networks).
Measurement of PM10 can be done either continuously (Finland, The Netherlands) or as
diurnal sampling (Germany).
For continuous monitors probably the most important determinant of performance is the
calibration practice. Detailed documentation of calibration practice in all centers is considered
necessary, in order to determine whether differences can be expected. The guiding principle is
that measurements should be conducted according to the manual of the manufacturer. As
measurements are conducted in the framework of existing networks, no major changes can be
introduced for this study. Standard calibration procedures are done according to the
instructions of the local authorities.
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1.5.7 Meteorological data
For meteorological variables, data measured in networks operated by meteorological
institutes or air pollution monitoring agencies can be used, but the most recommended
method is to use a movable meteorological station located close to the sampling site.
Temperature and humidity data should preferably be collected at a height of about 1.50-3
meters. Wind speed and wind direction are generally collected higher above the ground.
At least hourly average values of ambient temperature, relative humidity, ambient air pressure
and wind speed and direction should be collected.
1.5.8 Reflectance
Reflectance of all of the PM2.5 filters are measured. This measurement is a good surrogate
for measurement of Black Smoke. The reflectance of the filters reflects the ambient
concentration of elemental carbon.
A detailed description of the measurement method is given in the SOP ULTRA/KTL-L-1.0
‘Determination of absorption coefficient using reflectometric method’ (Appendix A5).
1.5.9 Elemental composition
Every second PM2.5 filter will be analyzed for a set of elements by ICP-MS or XRF. The
elemental analysis will be done together in the same laboratory after the sampling periods.
The proper storage of the filter samples has to be provided to avoid contamination, losses etc.
After the measuring period the filters should be stored (e.g. in the plastic petri dishes) for
chemical analyses at -20 ΕC. Detailed instructions on how to transport the filter samples to
the analytical  laboratory will be distributed by the coordinating center.
1.5.10 Submitting data to coordinating center
Cleaned datasets are sent to coordinating center from all study centers for combined analyses.
Submitted data must be in MS-Excel 5.0 format (if Excel is not possible, ASCII with comma
(,) separator should be used). The coordinating center will send a blank Excel data entry sheet
with variable names to all study centers. Study centers have to fill in the sheet and send it
back to the coordinating center. The data should be stored on 3.5≅ discs and unnecessary
compression of the data should be avoided. A sample file will be distributed to all centers
before the end of the field work periods.
At least 2/3 (66 %) of valid raw data are required to calculate hourly averages. Daily average
number concentrations are valid, if at least 16 hourly average values are available from noon
to noon.
Definitely erroneous data must be cleaned from the dataset. If there are data points with
special features, but which should not be rejected from the data, it is advisable to insert an
elucidating remark into the corresponding data cell.
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The timescale of the data must be continuous and shift to summertime corrected by inserting
a missing hour into the data files. Data are marked by the starting time of the corresponding
measurement period. For example, hourly datum from 4th of January 14:00 to 15:00 is marked
as 4.1.1997 (first column in Excel data sheet) 14:00 (second column in Excel data sheet).
The datasets must contain data of  following variables:
A. AS HOURLY ARITHMETIC AVERAGES
1) Meteorological data:
a. Mean temperature (0C)
b. Relative humidity (%)
c. Wind speed (m/s)
d. Wind direction (0)
e. Ambient air pressure (mbar)
2) Gaseous pollutants:
a. NO  (µg/m3)
b. NO2  (µg/m3)
c. CO (mg/m3)
d. SO2 (µg/m3)
e. O3 (µg/m3)
3) Particles:
a. Particle total number concentration, CPC3022A
b. Aerosol spectrometers, number concentrations
Main particle size ranges
NC0.01-0.1 ; NC0.1-1.0 ; NC1.0-2.5 ; NC0.01-2.5
Sub particle size ranges
NC0.01-0.03 ; NC0.03-0.1 ; NC0.1-0.5 ; NC0.5-1.0
c. Aerosol spectrometers, mass concentrations from MAS (Germany) and DAS (the
Netherlands), volume concentrations from EAS (Finland)
Main particle size ranges
MC0.01-0.1 ; MC0.1-1.0 ; MC1.0-2.5; MC0.01-2.5
Sub particle size ranges
MC0.01-0.03 ; MC0.03-0.1 ; MC0.1-0.5 ; MC0.5-1.0
d. PM10 (only Finland and the Netherlands)
B. DAILY ARITHMETIC AVERAGES FROM NOON TO NOON
1) Meteorological data:
a. Mean temperature (0C)
b. Relative humidity (%)
c. Wind speed (m/s)
d. Wind direction (0)
e. Ambient air pressure (mbar)
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2) Gaseous pollutants:
a. NO  (µg/m3)
b. NO2  (µg/m3)
c. CO (mg/m3)
d. SO2 (µg/m3)
e. O3 (µg/m3)
3) Particles:
a. Particle total number concentration, CPC3022A
b. Aerosol spectrometers, number concentrations
Main particle size ranges
NC0.01-0.1 ; NC0.1-1.0 ; NC1.0-2.5 ; NC0.01-2.5
Sub particle size ranges
NC0.01-0.03 ; NC0.03-0.1 ; NC0.1-0.5 ; NC0.5-1.0
c. Aerosol spectrometers, mass concentrations from MAS (Germany) and DAS (the
Netherlands), volume concentrations from EAS (Finland)
Main particle size ranges
MC0.01-0.1 ; MC0.1-1.0 ; MC1.0-2.5; MC0.01-2.5
Sub particle size ranges
MC0.01-0.03 ; MC0.03-0.1 ; MC0.1-0.5 ; MC0.5-1.0
d. PM2.5, 24-hour data from noon to noon
e. Absorption coefficients from PM2.5 filters
f. Elemental composition data from PM2.5 filters
g. PM10
C. DAILY ARITHMETIC AVERAGES FROM MIDNIGHT TO MIDNIGHT
h. Mean daily aerosol size distribution spectra, 24-hour data calculated from midnight to
midnight
1.6 PANEL STUDY
1.6.1 Study population
In the ULTRA study, people with coronary artery disease will be selected. Specifically, the
inclusion criteria for the study population are:
-free living people of an age of 50 or more years
-a self report of a doctor diagnosed CHD (coronary heart disease), e.g. angina pectoris,
past myocardial infarction (MI), a PTCA (percutaneous transluminal coronary
angioplasty) or a coronary by-pass surgery
-non-smoking
-able to perform spirometry in an acceptable way
-preferably, people who also have respiratory problems will be selected, but this is not
an inclusion criteria
The specific exclusion criteria of the study are:
-fresh (less than 3 months) cardiac event (MI, stroke, by-pass)
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-exclusion based on a physician evaluation: subjects that are too sick i.e. have an
unstable angina (NYHA 4) or are unable to perform the exercise challenge; have poor
cooperation e.g. dementia, have Parkinson disease, or have difficulties in filling in the
diaries and questionnaires (cooperation can also be checked as the ability to blow to
the spirometer); or for any other reason are likely to have problems with the study, e.g.
leaving for holidays during the winter for weeks or months or have a severe infectious
disease such as HIV or tuberculosis, should not be included; (Standard questions
could be included in the characterization questionnaire filled in/ checked during the
first (screening) clinical visit when also ability to blow to the spirometer and to do the
exercise challenge are checked)
-insulin-dependent diabetes mellitus (DM), as DM affects autonomic nervous system,
which in turn regulates HRV (remark: adult onset DM also affects HRV, but the
prevalence is so high that excluding these may cause problems)
-there will be no exclusion based on medication. However, preferably patients without
beta-blockers should be selected. Beta-blockers affect the sympathetic nervous input
to the heart, and therefore affects HRV, as do beta-agonists, too. Beta-blockers also
lower HR and affect exercise capacity. Due to sympatho-vagal interactions,
sympathetic outflow, affected by beta-agonists, is able to reduce the variations in HR
generated by vagal modulation, too. During the course of the study, changes in
medication are not preferably, but we cannot affect this.
-bundle branch block is not included in the exclusion criteria, but it can be used as an
optional exclusion criteria, as it disturbs ST-analyses
-subjects with cardiac pacemakers are also preferably excluded, as HRV analyses can
not be done in these subjects
The aim of the study is to achieve at least 500 repeated ambulatory  ECG recordings per
center. Considering drop out, this could be achieved with 12 - 13 biweekly recordings over a
6-month period in 50 subjects.
1.6.2 Characterization
The subjects will be characterized with a questionnaire (Appendix A12). In addition, resting
12-lead ECGs are taken from all subjects.
1.6.3 Instructing the subjects on the first visit
After screening, every possible subject is invited to a clinical visit. The purpose of this first
visit is to check for the eligibility criteria and let the subjects go through the procedures
before deciding whether to participate to the study or not. During this visit, a physician will
interview the subject and check for inclusion and exclusion criteria. If the criteria are met,
there will also be a medical examination and the whole clinical visit procedure will be
followed. If there are not any problems in following the flow of the visit, the subject will be
guided to fill in the diary. After this, the subject is asked if he/she is willing to continue in the
ULTRA study. If yes, a written consent is asked, a diary will be given to the subject and the
clinical visits scheduled. If problems emerge, the subject will not be asked to participate.
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1.6.4 Daily measurements at home
The panelists will fill in a diary on symptoms every day. The diary will be changed during the
clinical visits. The diary is attached as Appendix A13. It will be taken care of that a panelist
will always have a diary to fill even if she or he would not attend the clinical visit at a certain
time, e.g. by having spare diaries at home.
Instructions for filling out the diary:
The diary should be filled out every day in the evening before going to bed. Your answers
should reflect the occurrence of symptoms over the whole day. Please use a black marker and
write clearly and legible in each square. Please fill out all squares, even if you did not
experienced the symptom at this day. Please bring the filled out diaries with you to each
examination. You will be supplied with new diary forms at the visit. Please fill out a diary on
the evening of the day at which the examination has taken place. The diary contains
additional questions which are important for the study.
1.6.5 Biweekly visit to the clinic
The subjects will have a clinical visit every two weeks. The visit will last about 1.5 hours. For
each subject, the visit is aimed to be always on the same weekday at the same time (∀ 1 h). If
this is not possible, e.g. because of an illness, the next choice is to move the particular visit to
another day at the same time. When the latter is also impossible, the clinical visit should be
placed whenever possible. During the visit, autonomous nervous system will be stimulated by
paced breathing (parasympathetic stimulation) and standing up from supine position
(sympathetic stimulation), urine samples will be collected, spirometric lung function of the
subject will be measured, and electrocardiograph (ECG) will be recorded over the time of the
visit. The visit includes also a at least 6-minute exercise challenge at a pace aiming at a level
of 90 - 100 heart beats / min (Appendix A7). The field worker, e.g. a nurse, will take care of
the visit, but a consulting physician should be easily available. The detailed flow of the visit,
instructions for specific procedures, and safety precautions are described in respective SOPs
(Appendices A6, A7, A8).
1.7 DATA MANAGEMENT
This chapter gives guidelines for data management. A proper data management is important
to reduce the number of errors in data. It is also important to achieve standardization in data
management, because the data sent from the participants to the coordinating center have to be
in identical format. Finally, a proper data protection is required.
1.7.1 Limiting errors in data during the fieldwork
Errors in data can be reduced already during the fieldwork before the actual data entry. Field
personnel have to be clearly instructed and well trained. Field protocols have to be as detailed
as possible and they have to be followed. All exceptions from a protocol have to be marked in
a fieldwork diary. All basic data (diaries, questionnaires) have to be checked as soon as
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possible after a researcher has them to detect obvious errors. Detailed fieldwork instructions
are given in separate standard operating procedures (Appendixes A2, A3- 1-3, A4, A5, A6,
A7, A8).
1.7.2 Data entry
1.7.2.1 Limiting errors in data entry
It is not necessary to standardize the software to be used for the data entry. However, it is
preferable to use such software (e.g. SPSS Data Entry), which offers a possibility to use
build-in checks of impossible values. The subject numbers and study dates should be filled in
advance to limit the amount of routine work.
A researcher has to check all the forms before a keyboard operator starts the data entry.
Especially, forms with blank spaces which should have been filled in, all forms with written
remarks and forms with crossed/changed questions have to be checked carefully. Unclear
responses have to be clarified. If a response is questionable, it has to be coded as missing.
Keyboard operators have to be given clear guidelines how to enter the data. The keyboard
operators have to contact the researcher if things have to be interpreted. The keyboard
operators have to keep track of unclear diaries detailing what item was unclear and how it
was coded. This is important specially if the researcher cannot be contacted immediately in
unclear situations.
1.7.2.2 Double entry
The quality of data entry has to be checked by a double entry of a 10% random sample of at
least the original diary and clinic visit forms. Double entry has to be done preferably by a
different person in order to check the amount of typing errors. The values that have been
entered twice have to be compared. The error rate is calculated as follows:
1. Determine the number of pairs with different values for the same variable for the same
observation (d).
2. Determine the total number of entered variables (n).
3. Calculate error rate as d/n * 100%.
For example, when diary data have been collected from 50 subjects for 25 weeks (total of
1250 weeks), 125 randomly selected weeks should be entered for a second time. The diary
contains 20 variables per day. Thus, the total number of entered variables is 2 entries * 125
weeks * 7 days * 20 variables = 35000 (=n). First, the logical checks on possible values have
to be conducted and all unclear values have to be checked by the researcher on both sets of
entered data. Suppose that after these checks there are 400 pairs for which the value of a
variable is not the same for the same observation. The error rate is then calculated as
(400/35000)*100 = 1.14%.
An error rate of 1% is considered acceptable for diaries and questionnaires. If the calculated
error rate exceeds that value (as in the example), first the reasons for this should be
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investigated. For example, it may be that one of the keyboard operators has performed badly.
The data of that keyboard operator should then be entered again. Alternatively, specific
variables might have been entered badly. These could then be entered again. However, if no
specific reason could be detected, all data should be entered a second time. Differences
between data entered twice for documenting error rates should not be used to correct errors in
the data, as all data have not been checked. The observed error rate has to be marked in the
data transfer form.
1.7.3 Data validation and verification
The following checks for impossible values and the logical checks in Appendix A15 have to
be done before transferring data to the coordinating center:
After the data entry has been completed a checking program has to be run to check impossible
values. Summary statistics (number of observations, arithmetic mean, standard deviation,
minimum and maximum values) of all variables have to be calculated. Also, frequencies of
all categorical variables have to be checked. Observations with impossible values have to be
checked on the forms and typing errors have to be corrected.
There are logical connections between some variables in questionnaires. Observations with
impossible combinations have to be displayed and checked. If the impossible combination is
due to the typing error, it has to be corrected. If an impossible combination has been saved as
it is in the questionnaire, then the inconsistency has to be solved according to the decision
rules in the Appendix A15.
It is important to store original data in order to be able to go back to the original data in case
of doubt or inconsistencies in the data. Therefore, all the changes should be made in a
working copy of the original data. A log should be kept of all the changes made in the
working copy of the original data.
1.7.4 Data transfer
1.7.4.1 Data to be transferred
The individual centers need to send following data to the coordinating center:
- baseline questionnaires 1 and 2 (physician and self-administered)
- diary
- clinical visit questionnaire
- clinical visit log book
- medication sheet
- spirometry
Each data have to be transferred in separate files. The guidelines and check forms are in
Appendices A16 and A17. Because of the data protection, a subject’s name must not be
included in data. All data have to be identified only by a subject’s identification number. The
variables needed and the coding of the responses are described in the Appendices A14 and
A15. The variables in files have to be in same order as in the Appendix A14.
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Of diary data all available days of all study subjects have to transferred. Those days when a
subject has not answered to any question have to be also included to preserve the time
structure in the data.
The data files have to be named as follows:
Amsterdam Erfurt Helsinki
Baseline questionnaire 1 BQ1AMS.DAT BQ1ERF.DAT BQ1HEL.DAT
Baseline questionnaire 2 BQ2AMS.DAT BQ2ERF.DAT BQ2HEL.DAT
Diary DIARYAMS.DAT DIARYERF.DAT DIARYHEL.DAT
Clinical visit questionnaire CLQAMS.DAT CLQERF.DAT CLQHEL.DAT
Clinical visit log book CLLOGAMS.DAT CLLOGERF.DAT CLLOGHEL.DAT
Medication sheet MEDICAMS.DAT MEDICERF.DAT MEDICHEL.DAT
Spirometry SPIROAMS.DAT SPIROERF.DAT SPIROHEL.DAT
The correctness of the data transfer is checked by data transfer check forms (Appendix A17).
The individual centers have to fill in the forms and send them to the coordinating center by
fax. The individual centers also have to send summary statistics (number of observations,
arithmetic mean, standard deviation, minimum and maximum values) for all variables and
also frequencies of categorical variables.
1.7.4.2 Form of data transfer
Data files have to be transferred in comma-delimited ASCII format. The files can be zipped
(PKZIP 2.04 or WinZip 6.3) before sending them to the coordinating center. Files can be sent
by E-mail or alternatively by well packed 3.5 inch floppy disks. The data transfer check forms
have to be sent by fax to the coordinating center.
An example of a file to be transferred (diary ):
101,8,12,1998,0,0,0,1,0,0,2,0,0,0,2,1,1,4,.,1,0.5,1,.,.,.,.,.,.,1,1,0
102,8,12,1998,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,.,.,.,.,.,.,.,.,.,.,10,0
1.8 ANALYSES
1.8.1 Analyses of the ambulatory ECG recordings in Kuopio
From all centers, the recorded ambulatory ECG tapes are sent weekly to Kuopio University
Hospital, Department of Clinical Physiology, for analyses. In the department, there are trained
nurses who take care specifically of the ULTRA Holter analyses. The tapes recorded last with
each recorder should have been marked before sending and are analyzed first in order to
check the functioning of the recorders. If malfuctioning occurred, the nurses will inform the
study centre immediately.
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All recordings consist of the following periods:
-Rest, supine, spontaneous breathing (= REST SPONTANEOUS BREATHING)
-Rest, supine, paced breathing (=REST PACED BREATHING)
-Standing (=STANDING)
-Bicycle exercise (=STRESS)
-Rest, supine, spontaneous breathing (=REST RECOVERY)
In the recordings, there are event marks in the beginning and at the end of each period. In
addition, all time points are marked also in the clinical visit log book. A stopwatch and the
recorder’s clock should have been started at the same time, but in practice there are small
differences between these two times. Primarily, the event marks will be used to identify the
beginning and the end of each period.
Some of the analyses are based on the whole recorded data, some on both specific short
periods and the whole recorded data.
The short analyses are done from selected, representative 5-minute epochs (high signal
quality, as few ectopic beats as possible).
Step-by-step flow of the analysis:
1. The ULTRA preference file is used in the Oxford II Medilog workstation.
2. The tape is read into the database in the workstation.
3. The templates are checked and corrected if necessary.
4. The correctness of the shortest and longest R-R –intervals are checked.
5. Specific analyses are performed as follows:
 
 Heart rate variability
 -The whole period and all five specific 5-minute periods (rest spontaneous breathing, rest
paced breathing, standing, stress, and rest recovery) will be analyzed.
 -If the subject has atrial fibrillation or large number of ectopic beats (e.g. bigeminy) the HRV
analysis will be omitted (because the results are useless).
 
 ST-analysis
 -The whole recording will be analyzed. Only channel 1 will be used for the analysis.
 -If the true baseline is below isoelectric level (0-level), the baseline will be set according to
the true baseline level during the rest spontaneous breathing period.
 -If a new baseline is set, the actual baseline will be marked in the ST-trend figure (in mV).
 -A significant ST-depression is defined as a more than 1 min ST-depression below 0.053 mV
(= 0.53 mm). ST-depression is measured 63 ms after J-point (slope 55 ms).
 -ST-analysis will be done also to subjects with bundle branch blocks, WPW-syndrome, non-
specific intraventricular conduction defects or prior myocardial infarcts (Q-, non-Q-wave).
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The effect of these abnormalities will be taken into account in the final statistical analyses.
 
 QT-analysis
 -The whole recording and 3 specific periods (rest spontaneous breathing, stress, rest recovery)
will be analyzed.
 -Primarily, the channel 1 will be used for the analysis. If the amplitude of the T-wave is very
low, and it is difficult to detect the end of T-(U)-wave, the channel  2 will be used. The use of
the same channel in every subsequent recordings will be taken care of.
 -The measurement points with a 5-minute window (whole recording) and with a 30 sec
window (specific 5 min periods) will be check.
 -QT-analysis will be done also to subjects with bundle branch blocks, WPW-syndrome, non-
specific intraventricular conduction defects or prior myocardial infarcts (Q-, non-Q-wave).
The effect of these abnormalities will be taken into account in the final statistical analyses.
 
 VES, SVES
 -The whole recording and the stress period will be analyzed. The latter has to be done by
manual counting from the full disclosure screen.
 -The number of the ectopic beats will be marked on the front page of the printout.
 
 PR-interval
 -The PR-interval will be measured manually from 3 consecutive beats during the rest
spontaneous breathing period.
 -The PR-interval from subjects with atrial fibrillation or with atrio-ventricular conduction
defects (except patients with first-degree block) will not be measured.
 -The PR-interval (average of 3 measurements) will be marked on the front page of the
printout.
 
6. All ECG data will be converted to ASCII format for possible further analysis.
7. The original and converted ASCII data will be saved on the KLF-server (NT-server;
directory T:\users\KLF-OXFORD\ULTRA). A DAT-recorder will be used for back-up.
Ultimately, all data will be written on CD-R:s.
After the analyses, all the tapes will be stored in the National Public Health Institute, Kuopio.
A printout of the results will be stored in the Department of Clinical Physiology, and a copy
of it will be sent to the respective study center. All the ECG data will be keypunched by the
coordinating center.
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1.8.2 Analyses of the PM2.5 filters
The filters will be weighed according the PM2.5 SOP. In addition, the absorbance of the
filters will be measured according the respective SOP. The absorbance of the Finnish filters
will be measured at the National Public Health Institute, Finland, and of the Dutch and
German filters in the University of Utrecht, the Netherlands. The elemental composition
analyses will be conducted in a laboratory in Antwerpen, Belgium, using the XRF method.
1.8.3 Urinary samples
After the field work all urinary samples will be sent to Brussels for analyses according
instructions in the SOP. The results will be sent to the coordinating center. Urinary CC16
concentrations will measured by an automated latex immunoassay (Bernard A, et al. 1992).
From all samples, creatinine concentrations will also be determined.
1.9 STATISTICAL ANALYSES
The most essential part of the ULTRA data consists of repeated measures (i.e. longitudinal).
The diary data is a typical example of longitudinal data: the subjects have kept diary on their
symptoms on a daily basis about six months. The clinic visit data are rather similar to diary
data. However, there are some differences: the response variables are mainly continuous, the
number of observations per subject is much smaller and the time between repeated
observations is longer (two weeks). Basically, both the diary and clinic data will be analysed
in a similar way, although above mentioned small differences affect the modeling.
1.9.1 Regression models
Longitudinal models are models in which all observations from subjects are used as such. In
aggregated models a daily mean response (eg. daily prevalence or incidence of cough) is used
as a dependent variable. In longitudinal data it is important to take into account the
dependence of the observations from a same subject, which can be modeled with a proper
covariance structure. It is also important to pay attention to differences between subjects,
especially individual levels.
In the analyses of ULTRA data, mainly longitudinal models will be used because they are
more powerful, they include more information and differences between subjects can be taken
into account. However, aggregated models can be used to examine long-term time trends,
seasonal effects and other possible covariates, and they can be used also as a part of
sensitivity analysis. In general, fixed effects model will be used for taking care of the
differences in average level across subjects. The convergence may really be a problem in the
random effects model, especially if the number of cases is small (eg. when modeling
incidence of symptoms).
The dependence of the observations within a subject has to be taken into account using a
proper covariance structure. If the correlation fades away with time, then an autoregressive
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structure (eg. AR(1) or AR(2)) could be used. If the correlation between observations in a
subject arise mainly as a consequence of variation in the regression intercept between
individuals then compound symmetry could be the correct structure. Autoregressive
covariance structure is typically used in diary studies. However, if the number of symptoms is
small (eg. incidence of symptoms in diary) or the number of observations per subject is small
(as in clinic visit data), compound symmetry may be the correct choice. Log likelihood can be
used for comparing different covariance structures.
Subject spesific levels of response variable will be handled by including in a model a dummy
variable for each subject. Another alternative would be to explicitly spesify the covariance
structure as compound symmetry and to leave out the dummies for the subjects.
Both S-PLUS and SAS will be used. S-PLUS will be used as a main tool, because non-linear
associations will be explored with generalized additive models (gam), which are available
only in S-PLUS. Generalized linear regression models (gam and glm functions in S-PLUS,
the GENMOD procedure in SAS) will be used for continuous (eg. HRV variables), binary
(eg. symptoms in diary) and count response variables (eg. arrhytmias in ECG). The
appearance of ST-segment depression can be examined with survival analyses, like Cox
regression (the PHREG procedure), as earlier appearance of ST-depression during the
exercise test can be interpreted as more severe ischaemia. For survival analyses a variable,
which indicates the time to onset of the ST-depression during the exercise test, is created.
Subject is used as strata. The assumption of proportional hazards needs to be tested by
plotting log(-log) survival curves.
1.9.2 Modeling strategy
Confounder models for different health endpoints will be established for each center
separately. First, covariates are used to build a ‘basic model’ without an air pollution variable
in the model. Then individual pollutants are added to the model one at a time.
If long term effects (such as trend) are still disturbing the short-term confounders (such as
temperature) no proper estimate can be made for the function of the latter. Thus, only before
long-term confounding is dealt with properly, shorter term effects can be filtered out.
Therefore, the sequence of modelling will start with long-term confounders towards short-
term confounders.
In modeling the diary data at least following covariates will be considered: a dummy for each
subject, long-term time trend, influenza (external data), weather (temperature, relative
humidity and ambient air pressure, lags 0, 1, 2 and 3), weekday (or weekend) and public
holidays. In modeling the clinic visit data at least following covariates will be considered: a
dummy for each subject, long-term time trend, weather (temperature and relative humidity,
lags 0, 1, 2 and 3), weekday, time of visit and public holidays, infections (from clinic visit
questionnaire).
The basic model will be build by entering covariates into the model one by one according to
the order above. In each step the association of the covariate entered last will be evaluated
and the most appropriate form of the covariate will be included in the following steps. Trend,
temperature, relative humidity and ambient air pressure are going to be included as
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confounders in the model independent of the direction of the association. Influenza/infections
will only be included when a relationship in the expected direction occurs in the exploring
analyses. The shape and lags of these covariates will be explored in S-Plus using lowess
functions.
The criteria for building the basic model are AIC, partial autocorrelation (PACF) plots of the
residuals (only for diary) and exposure-response plots. In principle the model with the lowest
AIC is selected from a predefined range of alternatives. In previous analyses it has been
observed that AIC may select a too detailed trend model. Therefore, the exposure-response
and PACF plots will be checked. If the response trend plot is too detailed (patterns with a
period of less than a month) or at smaller lags (0-10 days) of the autocorrelation plots of the
residuals negative autocorrelation occurs, a less detailed model than the one indicated by the
lowest AIC will be selected.
In the analysis of both the clinic visit and diary data 24-h mean concentrations of the
pollutants (lags from 0 to 3 days and 5-day average) will be used first as an exposure
estimate. In the analysis of the clinic visit data also subject specific exposure estimates will be
used as concentrations of the previous 1 hour (the hour before coming to the clinic), the
averages of the previous 1-2, 3-4, 1-4, 5-8, 9-12, 13-16, 17-20, 21-24 hours and the average
of the previous 24 hours.
Sensitivity analyses will be done using different lags and functions of trend, influenza,
temperature, relative humidity and ambient air pressure for interesting combinations of
exposure and health outcome. As we are looking for robust results, the results from the
selected basic model should not give substantially different results from other reasonable
models. Pollen counts will also be included in the sensitivity analyses to check possible
confounding. However, it is the assumption that this variable does not confound the model
because of the probably low correlation with air pollution; the lacking of summer period in
Germany and Finland; and the nature of the population with probably low numbers of allergic
subjects. The effect of ambient air pressure will be examined. Also the effect of imputed air
pollution will be checked. The interaction of temperature and air pollution will be explored
and two-pollutant models will be checked. A part of the analysis will be run for the
subpopulations of the subjects (e.g. prior MI, diabetes, medication: use of beta-blockers,
antiarrhythmic, asthma medication).
1.10 TIME TABLE
-Meeting in Helsinki 29.-30.6.1997
-planning of the project
-Telephone meeting 17.2.1998
-outline of the field work
-Meeting in Athens 21.3.-22.3.1998
-the first draft of the health study protocol
-Air hygiene meeting in June 25-26, 1998 in Munich, organized by Wolfgang Kreyling
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-air hygiene protocols and SOPs / OPs
-Telephone meeting in 9.6.1998
-draft of the study protocol, instrumentation
-Meeting in Helsinki 31.8. - 1.9.1998
-final protocols
-Training workshop in Kuopio 28.9. - 29.9.1998
-training of the field workers / clinical visit
-Field work of the study  October 1998- June 1999
-Telephone meeting 18.5.1999
-status of the study
-Meeting in Athens 5.9.1999
-statistical analyses plan
- Aim: Data in the coordinating center by the end of 1999
-Telephone meeting 10.1.2000
-status of the data
-Workshop in Kuopio 27.2.-1.3.2000
-analyses of the almost final data, publication plan
-Telephone meeting 25.5.2000
-discussion on SOP deviations
-Telephone meeting 17.8.2000
-status of analyses and manuscripts
-Meeting in Munich 28.-30.9.2000
-draft manuscripts
-Telephone meeting 14.12.2000
-draft manuscripts
-End of the contract - end of year 2000
-Telephone meeting 8.2.2001
-Final report to EU- 2/2001
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2 REMARKS AND RECOMMENDATIONS
As in all studies, in advance carefully prepared plans may change during the course of the
field work for a reason or another. The field work in practice can reveal things that could be
done better or could be taken into account in another way as planned. In this chapter these
topics are discussed and some recommendations are given.
All SOP deviations are listed in the respective SOPs on the SOP deviation sheet.
2.1 MEASUREMENT OF PM2.5
PM2.5 measurements using the SOP have been of good quality in the three centers, judged by
the limits of detection and precision of field duplicates. The SOP is therefore in principle
suitable. At some points the SOP could be improved. We prescribed the use of Andersen
Teflon filters instead of the more widely available Gelman Teflon filters based upon previous
experiences that Andersen filters were much less curved (which is advantageous for
reflectance measurements). The current batch was as curved as the earlier Gelman filters, so
that there is no advantage anymore in using Andersen filters. More detailed criteria with
respect to flow meter calibration and use (ambient temperature and pressure adjustment)
should be provided (section 7.1). If the pump does not leak, an alternative configuration
including a dry gas meter at the outlet of the pump could be used to determine sample
volumes. In addition, it is recommend that all participating centers would use the same
method to measure flow. In 7.1.3 the target weight from the external mass piece should be
specified as the (certified) weight provided by the manufacturer. In 7.1.3 point 6 it should
read that ‘the same’ instead of  ‘other’ filters should be reweighed at the end of the session. In
calculations, the formulas for adjusting for buoyancy should be added.
2.2 AEROSOL SPECTROMETERS
2.2.1 Aerosol measurements in Erfurt by MAS
Aerosol spectrometer measurements have been of good quality and were performed according
to the OP. It proved very suitable that the performance of the MAS was checked multiple
times during work shifts of working days due to the presence of operating staff and also once
at both days of weekends. This resulted in a minimal number of missing data (4%). The
missing data was caused predominantly by usual maintenance like flow controls, mobility
calibration, laser alignment and monodisperse particle calibration. More importantly, the
concept of comparing the total number concentration determined by MAS and the CPC
multiple times per weekday provided an additional instantaneous information of the operator
on the performance of either instrument.
Laser of the LAS-X and its adjustment caused some difficulties. However, both the mobility
calibration and the routine checks of the LAS-X using monodisperse Latex spheres provided
a means to control and correct for those deviations.
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The site visit of the coordinator for aerosol measurements after about one third of the study
period proved useful to stimulate efforts of the operators to improve maintenance and control
of MAS.
2.2.2 Aerosol measurement in Amsterdam by DAS
DAS measurements have been of good quality and were performed according to the OP with
a few exceptions. DAS was not physically checked every day by an operator but only once a
week. However, the performance of DAS was checked daily by remote control. A
malfunction which resulted in a severe lack of data during more than a week occurred in the
beginning of the study. This happened because of two consecutive power failures within a
minute. After the first failure the PC that controlled all the instruments and communications
via the modem started to reboot when yet another power failure occurred resulting in a severe
corruption of several system files and the PC had to be taken away from the site. Overall,
during the whole study period a total of 14 % of data are missing. A substantial improvement
of quality assurance was the continuous monitoring of essential flows of the instruments of
DAS, which is far superior to periodically performed checks of the various flows. The lessons
for the future out of the long malfunction period are 1) use UPS to avoid such cases; 2) have a
duplicate PC with all the software installed such it can be used for replacement if the PC at
the site fails.
The version of LAS-X used in Amsterdam appeared to have a principal short come because
of the low aerosol sampling flow and the limited number of channels for particle sizes. The
former resulted in a limitation of the upper detectable aerosol concentration of < 5000 cm-3.
This could be compensated by (1) using the LAS in 3 separate size ranges (one integrated was
used), such that the high counts in the smallest size channel will not interfere with the other
two ranges. In this way the smallest range can be discarded without affecting the other two
larger particle size ranges, and (2) discarding LAS-X data when SMPS showed high
concentrations in the according size channels – the latter was possible due to the overlap of
SMPS and LAS-X in the size range of 0.1 – 0.4 µm.
Principally the concept of comparing the total number concentration measured by DAS and
CPC provides an excellent option on data quality assurance to remotely control for changes in
the performance of either of the instruments on a daily basis.
The site visit of the coordinator for aerosol measurements after about one third of the study
period proved useful to stimulate efforts of the operators to improve maintenance and control
of DAS.
2.2.3 Aerosol measurement in Helsinki by EAS
EAS measurements have been of good quality and were performed according to the OP with
a few exceptions. EAS requires far less maintenance than the other spectrometers. Another
big advantage is the fact that Dr. Mirme, who had constructed the EAS performed the
measurements during the study. EAS is therefore particularly useful for these kinds of studies
because it has less vulnerable parts, and check controls every ten minutes are stored on file
for eventually necessary later reconstruction. Therefore less effort was undertaken than
required in the OP, e.g. field forms of EAS and CPC were combined. As a permanent modem
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connection was not available, only a very limited bi-daily check was done followed by a more
thorough check every week. The transfer of the data to processing center in Tartu was made
manually by a servicing person regularly downloading the data files from EAS computer and
sending them via Electronic Mail to the center.
There was a major loss of data (a 5-day break) that resulted from a mechanical failure of the
level on which EAS was placed. Still, overall there was a minimal number of missing data
(3%).
After the site visit at about the middle of the study period, comparison between the total
number concentration measured by EAS and CPC were introduced on a weekly base which
had not occurred before. These comparisons indicated a slightly non-linear relation between
the EAS and CPC at higher particle concentration. Calibration of the CPC at the end of the
measurement period suggested that this was not due to the calibration of CPC. A similar
association has been observed earlier, and it may be due to a relative decrease in ambient
particle concentration in size range below 20 nm at high particle concentrations, particularly
in the size range between the cut off sizes of the two instruments that are 6-7 nm for CPC and
~10 nm for EAS.
The site visit of the coordinator for aerosol measurements after about the middle of the study
period proved useful to stimulate efforts of the operators to improve maintenance and control
of EAS.
2.3 MEASUREMENT OF NC WITH CPC
The CPC SOP was basically suitable for the ULTRA study and the measurements were of
good quality. Some of the details need, however, some discussion.
First of all the SOP is based on the assumption that the details of instruments are known. For
a less experienced scientist, this is not necessarily true and therefore some reference material
should be pointed out. An example of this is the use of flow meter (7.3. b).
A second general comment is that the campaign time was not clearly defined (e.g. UTC, local
time, local winter time, etc.). In addition, some guidelines are needed for setting the computer
time, e.g. what is acceptable inaccuracy of time (10 sec., 1 min).
A third general comment is that this SOP was based on the fact that there was a
complementary aerosol instrument available, namely aerosol spectrometer. Therefore this
guide can not be taken as general instructions for using a CPC.
Detailed comments:
7.2. Item c, it is recommended that all the leds are checked (Temperatures, laser and liquid
level). If any of them is not green, it is advisable to check that parameter at the site.
7.2. item d, to check the flow one should first see that the leds are green.
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7.2. One should also check that the particle led is flashing or on all the time, indicating that
CPC is detecting particles.
7.2.1. It should be added that the incorrect sample flow can be detected first from the flow led
being yellow.
7.3. item b, both aerosol flow (low flow) and total flow (high flow) should be measured. It is
advisable to run the instrument at the high flow mode.
Additionally the voltage of the photometric mode zero should be checked. This can be done
by switching of the flow and checking the voltage in the status menu.
8.2. The data should be plotted weekly, in order to check that it looks appropriate. Any
strange behavior, e.g. high spikes, very low concentration, very little variation in
concentration, should make the user aware of a potential problem.
The form A. daily maintenance:
All the leds should be checked.
2.4 DETERMINATION OF ABSORPTION COEFFICIENT USING
      REFLECTOMETRIC METHOD
As the results of the intercomparison samples measured both in the Netherlands and Finland
were very close to each other, the SOP seems to have worked in securing the uniformity of
the measurements. In Finland there was some uncertainty in the interpretation of chapters
7.1.2 and 7.2. The original idea was to measure several control filters only in the beginning of
the study, and then to use the selected primary control filter during the whole study period. In
this case, it would be reasonable to check every now and then that the primary control filter’s
reflective properties do not change during the study. In Finland this was done by comparing
the reflectance of the primary control filter to the other control filters occasionally. In chapter
7.3, there should be added a limit for the deviation of the primary control filter during series
of 25 samples, exceeding of which would result in a remeasurement of the filters. The
measurement of humidity during measurement session is not necessary (chapter 8.0).
2.5 RECORDING OF THE AMBULATORY ECG
The ambulatory ECG SOP functioned properly. In Erfurt the SOP was deviated so that the
time of the Holter recorder was not set to 00:00 in the beginning of the recording (instead, the
real time was used). According the SOP in the beginning and at the end of the recording a 1
min rhythm strip was recorded. However, the speed of the ECG paper could perhaps be
slower after a 10-20 second period of recording with a faster speed. This would save quite an
amount of ECG paper.
The crucial point in the recording of good quality Holter tapes is a careful preparation of the
recording, especially how the electrodes and patient cables are attached to the skin and fixed.
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It can never be emphasized too much that the electrodes and wires must be fixed properly, in
order that there will not be unnecessary disturbances in the recording. In the future, a digital
registration system should be preferred to analog system used in the present study to improve
the measurements and analyses. For example, a digital system enables a more exact
determination of time points during a registration. In addition, direct transfer of the results
from the Holter analyses to a dataset does save costs and also would increase data security.
2.6 FLOW OF THE CLINICAL VISIT
In principal, the flow of the visit was fluent. However, there have been some differences
between the centers. In Finland, the urinary samples were collected sometimes at home just
before the clinical visit. This was possible because the fieldworkers visited the subjects the
day before the visit to take indoor and personal PM2.5 measurement equipment to the
subjects and took the sample collection container with them at the same time. The
fieldworkers came back the next day to collect the equipment and drive the subject to the
clinical visit.
There were also differences in the work load during the exercise challenge test. Based on the
mean HR during the exercise the target HR was not achieved always in all three centers. In
addition, the criteria for not conducting the exercise test varied between the centers, so that
especially in Finland no exercise test was done during a large proportion of the visits. This
complicates many analyses. In future studies, it should be ensured that the subjects and the
nurse feel comfortable in performing the exercise test. Further standardization of the exercise
period would be needed for a future study.
2.7 URINARY CC16
The field workers gave urinary samples for quality control purposes, i.e. divided one sample
into several tubes and labeled the tubes differently. However, the quality control plan had to
be changed as the CC16 concentrations in these control samples were close to the detection
limit. Therefore, as duplicate samples were collected from the study subjects during the field
work in Helsinki, 50 duplicate samples were sent later to Brussels for CC16 analyses. These
duplicate samples were selected based on the values of the already analyzed original samples
to cover the whole range of the CC16 concentrations.
In the clinical visit SOP it was stated that the urinary samples are stored during the day in
room temperature, and are put into the refrigerator  (-18 °C) in the end of the day for storage.
However, because of its anionic character CC16 is extremely stable in urine and it stays stable
for days at room temperature, months at 4°C and years at -18C°. Thus it does not matter
whether the urinary samples are put into a freezer immediately or not.
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2.8 SPIROMETRY
It is difficult to evaluate whether the SOP has functioned properly. Review of the tracings of
the first tests of each subject by the SOP coordinator revealed that the measurements were
generally conducted according to the SOP and they were of good quality. Some changes
would be useful. It should be prescribed more clearly that in addition to the best selected
values also the reproducibility of the test should be available for analysis. Time of the test
should be available for analysis as well. In 7.5.2 the selection procedure could be adapted
such that the acceptable attempts are not reduced to two attempts but are all available for
analysis. Only tests with really low PEF values (e.g. 20% below the maximum) should be
excluded.
2.9 STUDY POPULATION
In Amsterdam, the study population was recruited in cooperation with the municipal health
center. Subjects were initially recruited by distribution of information letters and screening
questionnaires in senior residences. These residences are apartment buildings for free living
elderly with special facilities like a little supermarket, hairdresser and a mobile bank. In six of
these homes an information meeting was held. Participants were invited for a first
introduction, which consisted of a check of inclusion criteria by a physician and a trial
spirometry test. This first recruitment step resulted in 11 participating subjects. Because of
this response a call for participants was published in a local newspaper and letters were
distributed in areas mainly inhabited by the elderly. By the end of 1998, 33 subjects were
included in the study. Eight persons more could be included by the end of February/early
March 1999 via the department of cardiology of the Academical Medical Center (AMC)
nearby. In total, 41 subjects started the study but four dropped out after the first measurement,
resulting in a total of 37 subjects. To approach the designed number of measurements the
study period was prolonged until 18 June, 1999.
In Erfurt, the study population was recruited through Dr. Bischoff, a local cardiologist. Out of
62 subjects that were recruited, a total of 12 had to be excluded according to the exclusion
criteria: 6 were current smokers, 4 subjects had an insulin dependent diabetes and 2 subjects
were too ill. Further, one person did not want to take part because of time reasons.
In Helsinki, the study population was sought through a patient organization ’Suomen
Sydäntautiliitto' – The Finnish Heart Association. There was an advertisement in their journal
'Sydän', and information letters were distributed through gymnastic groups of the association.
Letters were also mailed through the local division of the association to members with a
postal code representing the study area in Helsinki. In addition, there was an advertisement in
a local newspaper 'Alueuutiset'.
The potential subjects were advised to call the researchers in order to inform of the interest in
participating to the study. The inclusion criteria were checked during the telephone discussion
and the contact information was collected. About 95 telephone calls were received. Some 60
subjects fulfilled the inclusion criteria and were asked to participate to information meetings
held on two evenings. In the two meetings, 48 subjects made an appointment for the first
clinical visit. One subject did not start the study after the first visit. As a consequence, 47
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subjects started the study in November, three of them did not continue until April: One
moved to another town, one was excluded based on the criterion of the health study (pace-
maker), and the third had to quit because of an illness. One new subject started in the
beginning of January 1999.
Two minor deviations concerning inclusion and exclusion criteria were allowed in the panels.
In the German panel, there were 3 subjects who were younger than 50 years. They were 40,
47 and 49 years old. In the Finnish panel, there were two subjects who had an adult onset
diabetes mellitus that was treated with insulin.
2.10 AIR HYGIENE DATA
The ULTRA measurement sites, where particles were monitored (except PM10, which was
network data in Finland and in the Netherlands) are described in the appendix A-11a. All
study subjects lived within 4 km from the measurement site in Amsterdam and within 11 km
in Erfurt. In Helsinki 43 subjects lived within 2 km and 4 subjects within 5 km from the site. 
The measurement periods of the air hygiene data in the book are 31.10.98-1.5.99 (Finland),
25.10.98-19.6.99 (the Netherlands) and  6.10.98-1.4.99 (Germany). 
2.10.1 Gaseous air pollution and continuous PM10 monitoring
In Finland the gaseous air pollution and continuous PM10 data came from the network
measurement site of Helsinki Metropolitan Area Council located 70 m away from the
ULTRA measurement site. In the Netherlands the measurements were taken from the
National Air Quality Monitoring Network, operated by the National Institute of Public Health
and the Environment, and the distance to the other measurement site was 15 km. In Germany
all measurements except CO were made by the study personnel. The CO data came from the
measurement site of Thüringer Landesanstalt für Umwelt, situated 2 km away.
MONITOR TYPES:
FINLAND:
Measuring height 4 m, except PM10 4.5 m
NOx:  Environnement SA, AC 30 M (chemiluminescense)
CO: Environnement SA, CO 11 M (IR gasfilter correlation)
O3: Thermo Environmental Instruments, 49 (UV-absorption)
SO2: Thermo Environmental Instruments, 43 A (UV-fluorescense)
PM10: ESM Eberline, FH 62 I-R (β-attenuation)
GERMANY:
Measuring height 4 m
NOx: Environnement SA, AC 30 M (chemiluminescense)
CO: Horiba 350 E APMA (IR-absorption)                   
O3: Environnement SA, O3 41 M (UV-absorption)
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SO2: Environnement SA, AF 21 M (UV-fluorescense)
THE NETHERLANDS:
Measuring height 3 m
NOx: TECO, 42 (chemiluminescense)
CO: Thermo Environmental Instruments, 48 W (IR gasfilter correlation)
O3: TECO 49 W: SO2: TECO, 43 W (UV-absorption)
PM10: FAG Eberline, FH 62 I-N (β-attenuation)
2.10.2 Remarks on air hygiene data
It was decided that the 24-h value of wind direction is not used. This is because during the
days with fluctuating wind direction the average wind direction would give a misleading
figure. It would be possible to use the average value by restricting its use to those days, when
the standard deviation of hourly values is below 75o.  However, by doing this, the amount of
data gets inconveniently low.
It turned out that the network air pollution data were normalised differently in the centers
(either 0 oC or 20 oC was used as normal condition). The network data were not changed, but
remarks will be made in the publications when appropriate.
Data on elemental composition of the particles were not yet available at the time of the
completion of this manual.
Because the amount of missing data in air pollution measurements was not negligible, it was
decided to impute the missing hours in the data. For a pollutant, a regression equation was
created between the primary measurement site and a secondary one, and the estimated values
were used for imputation. The criteria for allowing the imputation were: less than 10% of the
data missing, R2 for the pollutant between the two measurement sites >0.5. Usually, only the
same pollutant was used in the imputing. The only exceptions were PM2.5 (only in Finland)
and NC0.01-0.1, which were imputed using Eberline and CPC data, respectively. The imputed
data were 1-h data (except PM2.5), which were then used to calculate the 24-h data.
Imputed variables and percentages of the 1-h values imputed (R2):
FINLAND:
PM2.5: 7.1 % (0.94); PM10: 1.5 % (0.59); NC0.01-0.1 3.3 % (0.95); NO: 1.7 % (0.56); NO2:
1.7 % (0.68); O3: 1.6 % (0.83); temperature: 2.2 % (0.99); RH 1.1 % (0.87).
THE NETHERLANDS: 
NC0.01-0.1: 6.8 % (0.89); NO: 2.8 % (0.69); NO2: 4.2 % (0.52); CO: 1.2 % (0.55); O3: 5.6 %
(0.77).
GERMANY:
NC0.01-0.1: 1.1 % (0.93).
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2.11 STATISTICAL ANALYSES
2.11.1 Ambulatory ECG
During the course of the study it came clear that both time domain and frequency domain
variables will be used as primary endpoints. HRV-variables for the whole Holter monitoring
and recovery periods should not be used unless all 5-minute periods (spontaneous breathing,
paced breathing, standing, exercise and recovery) exist. HRV frequency domain variables
(power) during exercise will not be used at all, because there is a basic assumption of a stable
heart rate in the frequency domain analyses. Also frequency domain variables for the two
lowest frequencies (POW1 and POW2) should not be used for the analysis, because the
analyses period of 5 min is too short for the very low frequency analyses i.e. there are too few
cycles at these frequencies during the short time. However, they can be used when analyzing
the whole monitoring period. Usually in the analyses, time domain variables are used as such
and frequency domain variables are log-transformed.
In the analyses of ST-segment depressions, the primary outcome variable is the appearance of
ST-segment depression during the exercise test. In ULTRA, ST-depressions are recorded,
when the ST-segment is 0.05 mV below baseline. In contrast, in clinical practice a 0.1 mV
depression is required. If the ST-segment depression is horizontal or downward sloping, the
depression is even more specific for ischaemia. Therefore, sensitivity analyses are run using
different definitions of ST-depression.
As several subjects have a ST-depression already at the beginning of the exercise test, a
worsening of ST-segment depression by 0.05 (or 0.1) mV during stress test can be used as an
endpoint for them.
Subjects with no exercise test during the visit should be excluded from the ST-analyses.
However, as a sensitivity analysis, the association of air pollution with failure to complete the
exercise test should also be analyzed.
2.11.2 CC16
CC16/creatinine -ratio (log-transformed) should be used as an outcome variable when
analyzing CC16 to take diuresis into account.
2.11.3 Diary data
Because the prevalence of a symptom in the diary data is for most symptoms rather low,
slight and severe categories will be combined for the analysis. Recoding of the chest pain
variables is necessary since in both the Dutch and Finnish data the prevalence of chest pain is
lower than the more specific chest pain in exercise. Therefore, chest pain and chest pain in
exercise will be combined into one variable.
Most symptoms will be analyzed separately (recoded as 0/1). However, chest pain and chest
pain in exercise will be combined into one variable (1, if chest pain or chest pain in exercise),
because of the reasons above, and fever will be combined with common cold (1, if fever or
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cold), because of the low prevalence of fever.
‘Overall health today’ will be analyzed also as a binary variable. In the first place, in the
German and Finnish data ‘Overall health today‘ should be categorized as good/average (codes
1-3) and bad (4-5), and  in the Dutch data as good (codes 1-2) and average/bad (3-4) (no
observations in category 5). Also the change to a worse grade (worse than subject-specific
mode) could be used as an endpoint.
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3 DATA BOOK
3.1 BASELINE QUESTIONNAIRE 1
1. Subject identification number (ID)
Amsterdam Erfurt Helsinki
Number 101 - 144 301 -  362 514 -  580
2. Sex (B1Q3)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Female 13 35 4 9 23 49 40 31
Male 24 65 43 91 24 51 91 69
3. Are you currently working? (B1Q4)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 35 95 43 91 46 98 124 95
Yes 2 5 4 9 1 2 7 5
4. Do you work? (B1Q4P1)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Full time 0 0 3 6 0 0 3 2
Part time 2 5 2 4 1 2 5 4
Not working 35 95 42 89 46 98 123 94
5. Are you exposed to fumes, gases, dust or smoke at work? (B1Q4P1A)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 2 5 3 6 1 2 6 5
Yes 0 0 2 4 0 0 2 2
Not Working 35 95 42 89 46 98 123 94
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6. Unable to work (B1Q4P2)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
Unable to work 2 5 4 9 0 0 6 5
Unemployed 0 0 5 11 1 2 6 5
Retired 29 78 33 70 44 94 106 81
Housewife/-man 4 11 0 0 0 0 4 3
Working 2 5 5 11 1 2 8 6
7. Age: 50+ (B1Q5)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 0 0 3 6 0 0 3 2
Yes 37 100 44 94 47 100 128 98
8. Did a doctor diagnose coronary heart disease? (B1Q6)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 0 0 4 9 1 2 5 4
Yes 37 100 43 91 46 98 126 96
9. Did a doctor diagnose angina pectoris? (B1Q7)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 13 35 21 45 17 36 51 39
Yes 24 65 26 55 30 64 80 61
10. Did a doctor diagnose a myocardical infarction? (B1Q8)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 1 3 0 0 0 0 1 1
No 11 30 14 30 20 43 44 34
Yes 25 68 33 70 27 57 86 66
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11. How many infarctions did you have? (B1Q8P1)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 2 5 14 30 0 0 16 12
0 11 30 0 0 21 45 32 24
1 16 43 24 49 15 32 54 41
2 4 11 7 15 10 21 21 16
3 3 8 3 6 1 2 7 5
9 1 3 0 0 0 0 1 1
12. When did you have last infarction (year)? (B1Q8P2YY)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 13 35 14 30 21 45 48 37
Before 79 0 0 3 6 0 0 3 2
79-83 1 3 1 2 1 2 3 2
84-88 4 11 5 11 2 4 11 8
89-93 7 19 7 15 7 15 21 16
94 2 5 3 6 4 9 9 7
95 3 8 1 2 2 4 6 5
96 5 14 7 15 5 11 17 13
97 1 3 3 6 4 9 8 6
98 1 3 3 6 1 2 5 4
13. Have you had a coronary by-pass surgery or a balloon-dilatation? (B1Q9)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 20 54 13 27 24 51 57 44
Yes 17 46 34 72 23 49 74 56
14. When did you have your last coronary by-pass surgery (year)? (B1Q9P1YY)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 28 76 19 40 28 60 75 57
Before 89 1 3 3 6 1 2 5 4
89-93 3 8 2 4 1 2 6 5
94 0 0 0 0 2 4 2 2
95 1 3 4 9 3 6 8 6
96 0 0 6 13 6 13 12 9
97 2 5 8 17 6 13 16 12
98 2 5 5 11 0 0 7 5
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15. When did you have your last balloon-dilatation (year)? (B1Q9P2YY)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 24 65 38 81 39 83 101 77
Before 90 2 5 0 0 1 2 3 2
90-94 6 16 2 4 2 4 10 8
95 1 3 1 2 0 0 2 2
96 3 8 3 6 3 6 9 7
97 0 0 1 2 2 4 3 2
98 0 0 2 4 0 0 2 2
99 1 3 0 0 0 0 1 1
16. Did a doctor diagnose a stroke? (B1Q10)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 36 97 43 91 46 98 125 95
Yes 1 3 4 9 1 2 6 5
17. How many strokes did you have? (B1Q10P1)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
0 33 89 43 91 46 98 122 93
1 1 3 4    9 1 2 6 5
2 3 8 0 0 0 0 3 2
18. When did you have your last stroke (year)? (B1Q10P2Y)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 33 89 43 91 46 98 122 93
78 0 0 1    2 0 0 1 1
92 1 3 0 0 0 0 1 1
93 1 3 0 0 0 0 1 1
96 1 3 3 6 0 0 4 3
97 1 3 0 0 1 2 2 2
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19. Do you suffer diabetes? (B1Q11)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 35 95 40 85 42 89 117 89
Yes 2 5 7 15 5 11 14 11
20. Is your diabetes treated with insulin? (B1Q11P1)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 2 5 7 15 3 7 12 9
Yes 0 0 0 0 2 4 2 2
Don’t have diabetes 35 95 40 85 42 89 117 89
21. Do you have a pace maker? (B1Q12)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 37 100 47 100 47 100 131 100
22. Do you smoke now? (B1Q13)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 37 100 47 100 47 100 131 100
23. Check of NYHA criteria: cardiac diseases and symptoms (B1Q14)
1 = Only on severe exertion
2 = On moderate exertion
3 = On mild exertion
4 = Occur frequently even at rest
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 13 35 7 15 0 0 20 16
1 7 19 16 34 31 66 54 41
2 11 30 22 47 14 30 47 36
3 4 10 2 4 1 2 7 5
4 2 5 0 0 1 2 3 2
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24. Are you prepared to come every second week at the same time to the examination
for 1.5 hours? (B1Q15)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Yes 37 100 47 100 47 100 131 100
25. Do you plan to leave the city for holidays for weeks or months during the next 6
months? (B1Q16)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
No 30 81 45 96 47 100 122 93
Yes 7 19 2 4 0 0 9 7
26. Are you prepared to complete the diary daily? (B1Q17)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Yes 37 100 47 100 47 100 131 100
27. The patient understood all questions and could complete the diary. (B1Q18)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Yes 37 100 47 100 47 100 131 100
28. Is the patient able to perform an acceptable lung function test? (B1Q19)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Yes 37 100 47 100 47 100 131 100
29. Is the patient able to perform the exercise challenge? (B1Q20)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Yes 37 100 47 100 47 100 131 100
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30. Are there other reasons for exclusion? (B1Q21)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 37 100 47 100 47 100 131 100
31. Is the patient suitable for the study? (B1Q22)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Yes 37 100 47 100 47 100 131 100
32. The written consent was signed and the patient got a copy. (B1Q23)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Yes 37 100 47 100 47 100 131 100
33. Height (B1Q24)
Amsterdam Erfurt Helsinki Total
Female Mean(sd) 161 (6.6) 163 (3.8) 160 (6.6) 160 (6.2)
Min-Max 153-176 160-168 147-172 147-176
Male Mean(sd) 174 (7.7) 173 (5.5) 175 (5.2) 174 (6.1)
Min-Max 154-186 160-187 167-187 154-187
34. Weight (B1Q25)
Amsterdam Erfurt Helsinki Total
Female Mean(sd) 71 (11.8) 72 (3.5) 72 (11.6) 71 (11.0)
Min-Max 52-94 68-76 50-92 50-94
Male Mean(sd) 83 (10.8) 81 (9.2) 90 (11.5) 84 (10.7)
Min-Max 55-102 65-107 67-115 55-115
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3.2 BASELINE QUESTIONNAIRE 2
1. Marital status (B2Q2)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Married 20 54 39 83 27 57 86 66
Single 2 5 0 0 4 9 6 5
Divorced/separated 6 16 3 6 6 13 15 11
Widowed 9 24 5 11 10 21 24 18
2. Years of education (B2Q3)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 0 0 0 0 1 2 1 1
9 or less 12 32 5 11 26 55 43 33
10-12 11 30 30 64 10 21 51 39
13 or more 14 38 12 26 10 21 36 27
3. Have you had wheezing or whistling in your chest at any time in the last 12 months?
(B2Q4)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 1 2 4 9 5 4
No 25 68 36 77 28 60 89 68
Yes 12 32 10 21 15 32 37 28
4. Have you been at all breathless when wheezing noise was present? (B2Q4P1)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 1 2 4 9 5 4
No 5 14 0 0 2 4 7 5
Yes 7 19 7 15 13 28 27 21
No wheezing at all 25 68 39 83 28 60 92 70
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5. Have you had this wheezing or whistling when you did not have a cold? (B2Q4P2)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 1 2 5 11 6 5
No 5 14 0 0 4 9 9 7
Yes 7 19 7 15 10 21 24 18
No wheezing at all 25 68 39 83 28 60 92 70
6. Have you had an attack of shortness of breath that came on during the day when you
were at rest at any time in the last 12 months? (B2Q5)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
No 27 73 37 79 32 68 96 73
Yes 10 27 10 21 14 30 34 26
7. Do you usually cough first thing in the morning in the winter? (B2Q6)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 2 4 2 2
No 31 84 43 91 34 72 108 82
Yes 6 16 4 9 11 23 21 16
8. Do you usually cough during the day, or at night, in the winter? (B2Q7)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 2 4 2 2
No 30 81 35 74 26 55 91 69
Yes 7 19 12 26 19 40 38 29
9. Do you cough like this on most days for as much as three months each year? 
(B2Q7P1)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
No 1 3 9 19 10 21 20 15
Yes 6 16 3 6 12 26 21 16
Usually no cough 30 81 35 74 24 51 89 68
60
10. Do you usually bring up phlegm immediately after getting up? (B2Q8)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 23 62 42 89 30 64 95 73
Yes 14 38 5 11 17 36 36 27
11. Do you bring up phlegm like this on most days as much as three months each year?
(B2Q8P1)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 2 5 2 4 3 6 7 5
Yes 12 32 3 6 14 30 29 22
Usually no phlegm 23 62 42 90 30 64 95 73
12. Did a doctor ever tell you that you had high blood pressure? (B2Q9A)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 19 51 16 34 18 38 53 40
Yes 18 49 31 66 29 62 78 60
13. Did a doctor ever tell you that you had diabetes? (B2Q9B)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 0 0 1 2 0 0 1 1
No 35 95 38 81 42 89 115 88
Yes 2 5 8 17 5 11 15 11
14. Did a doctor ever tell you that you had cardiac rhythm disturbances? (B2Q9C)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 2 4 2 2
No 20 54 22 47 23 49 65 50
Yes 17 46 25 53 22 47 64 49
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15. Did a doctor ever tell you that you had myocardial infarction? (B2Q9D)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 1 3 0 0 0 0 1 1
No 10 27 14 30 20 43 44 34
Yes 26 70 33 70 27 57 86 66
16. Did a doctor ever tell you that you had stroke? (B2Q9E)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 36 97 43 91 46 98 125 95
Yes 1 3 4 9 1 2 6 5
17. Did a doctor ever tell you that you had angina pectoris? (B2Q9F)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 13 35 23 49 7 15 43 33
Yes 24 65 24 51 40 85 88 67
18. Did a doctor ever tell you that you had chronic ischemic heart disease? (B2Q9G)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 4 9 4 3
No 35 95 33 70 37 79 105 80
Yes 2 5 14 30 6 13 22 17
19. Did a doctor ever tell you that you had cor pulmonale? (B2Q9H)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 3 6 3 2
No 36 97 47 100 43 91 126 96
Yes 1 3 0 0 1 2 2 2
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20. Did a doctor ever tell you that you had cardiac insufficiency? (B2Q9I)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 3 6 3 2
No 36 97 41 87 29 62 106 81
Yes 1 3 6 13 15 32 22 17
21. Did a doctor ever tell you that you had congestive heart failure? (B2Q9J)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 2 4 2 2
No 37 100 41 87 45 96 123 94
Yes 0 0 6 13 0 0 6 5
22. Did a doctor ever tell you that you had valvular defect? (B2Q9K)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 4 9 4 3
No 30 81 44 94 41 87 115 88
Yes 7 19 3 6 2 4 12 9
23. Did a doctor ever tell you that you had other heart problems? (B2Q9L)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 5 11 5 4
No 35 95 34 72 31 66 100 76
Yes 2 2 13 28 11 23 26 20
24. Did a doctor ever tell you that you had asthma? (B2Q9M)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
No 36 97 47 100 37 79 120 92
Yes 1 3 0 0 9 19 10 8
63
25. Did a doctor ever tell you that you had chronic bronchitis? (B2Q9N)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 33 89 45 96 43 91 121 92
Yes 4 11 2 4 4 9 10 8
26. Did a doctor ever tell you that you had COPD? (B2Q9O)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 28 76 46 98 47 100 121 92
Yes 9 24 1 2 0 0 10 8
27. Did a doctor ever tell you that you had emphysema? (B2Q9P)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 35 95 46 98 46 98 127 97
Yes 2 5 1 2 1 2 4 3
28. Did a doctor ever tell you that you had pneumioconiosis? (B2Q9Q)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
No 37 100 48 100 43 91 127 97
Yes 0 0 0 0 3 6 3 2
29. Did a doctor ever tell you that you had nasal allergy including hay fever? (B2Q9R)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
No 26 70 42 89 30 64 98 75
Yes 11 30 5 11 16 34 32 24
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30. Did a doctor ever tell you that you had chronic renal diseases? (B2Q9S)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
No 37 100 44 94 42 89 123 94
Yes 0 0 3 6 4 9 7 5
31. Did a doctor ever tell you that you had other chronic diseases? (B2Q9T)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 3 6 3 2
No 29 78 35 74 24 51 88 67
Yes 8 22 12 26 20 43 40 31
32. In general, would you say your health is: (B2Q10)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Excellent 0 0 0 0 1 2 1 1
Very good 2 5 0 0 2 4 4 3
Good 18 49 23 49 14 30 55 42
Fair 16 43 23 49 29 62 68 52
Poor 1 3 1 2 1 2 3 2
33. How much does your health limit vigorous activities, such as running, lifting heavy
objects, particpating in strenouos sports? (B2Q11A)
Amsterdam Erfurt Helsinki Total
n % n % N % N %
Yes limited a lot 19 51 30 64 27 57 76 58
Yes limited a little 14 38 16 34 20 43 50 38
No not limited at all 4 11 1 2 0 0 5 4
34. How much does your health limit moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling or playing golf? (B2Q11B)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Yes limited a lot 5 14 5 11 7 16 17 13
Yes limited a little 17 46 27 57 15 34 60 46
No not limited at all 15 41 15 32 24 51 54 41
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35. How much does your health limit lifting or carrying groceries? (B2Q11C)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Yes limited a lot 9 24 6 13 6 13 21 16
Yes limited a little 15 41 21 45 20 43 56 43
No not limited at all 13 35 20 43 21 45 54 41
36. How much does your health limit climbing several flights of stairs? (B2Q11D)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Yes limited a lot 10 27 18 38 15 32 43 33
Yes limited a little 18 49 22 47 26 55 66 50
No not limited at all 9 24 7 15 6 13 22 17
37. How much does your health limit climbing one flight of stairs? (B2Q11E)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
Yes limited a lot 2 5 3 6 1 2 6 5
Yes limited a little 15 41 16 34 10 21 41 31
No not limited at all 20 54 28 60 35 74 83 63
38. How much does your health limit bending, kneeling or stooping? (B2Q11F)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Yes limited a lot 8 22 12 26 10 21 30 23
Yes limited a little 14 38 20 43 14 30 48 37
No not limited at all 15 41 15 32 23 49 53 40
39. How much does your health limit walking more than a mile? (B2Q11G)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 1 2 1 1
Yes limited a lot 7 19 5 11 9 19 21 16
Yes limited a little 11 30 18 38 15 32 44 34
No not limited at all 19 51 24 51 22 47 65 50
66
40. How much does your health limit walking several blocks? (B2Q11H)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Yes limited a lot 4 11 2 4 4 9 10 8
Yes limited a little 9 24 14 30 16 34 39 30
No not limited at all 24 65 31 66 27 57 82 63
41. How much does your health limit walking one block? (B2Q11I)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Yes limited a lot 2 5 0 0 1 2 3 2
Yes limited a little 3 8 7 15 10 21 20 15
No not limited at all 32 86 40 85 36 77 108 82
42. How much does your health limit bathing or dressing yourself? (B2Q11J)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Yes limited a lot 1 3 1 2 1 2 3 2
Yes limited a little 3 8 8 17 13 28 24 18
No not limited at all 33 89 38 81 33 70 104 79
43. How much bodily pain have you had during the past 4 weeks? (B2Q12)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
None 5 14 10 21 8 17 23 18
Very mild 5 14 6 12 12 26 23 18
Mild 10 27 13 28 12 26 35 26
Moderate 11 30 12 26 10 21 33 25
Severe 6 16 5 11 3 6 14 11
Extremely 0 0 1 2 1 2 2 2
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44. During the past 4 weeks, how much did pain interfere with your normal work
(Including both work outside and housework)?  (B2Q13)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 0 0 0 0 2 4 2 2
Not at all 10 27 13 28 19 40 42 32
A little bit 16 43 22 47 10 21 48 37
Moderately 6 16 9 19 10 21 25 19
Quite a bit 5 14 3 6 5 11 13 10
Extremely 0 0 0 0 1 2 1 1
45. Does your well-being depend on the weather? (B2Q14)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Not at all 14 38 10 21 17 36 41 31
Some what 18 49 23 49 22 47 63 48
A lot 5 14 14 30 8 17 27 21
46. Are you taking any capsules containing vitamins? (B2Q15)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
No 20 54 37 79 14 30 71 54
Yes 17 46 10 21 32 68 59 45
47. How often are you taking capsules containing vitamins? (B2Q15P1)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 1 2 1 1
Daily 16 43 8 17 20 43 44 34
Once a week 0 0 1 2 1 2 2 2
As needed 1 3 1 2 11 23 13 10
Never 20 54 37 79 14 30 71 54
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48. Is your home/apartment facing: (B2Q16)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Street 2 5 16 34 11 23 29 22
Backyard/park 17 46 2 4 12 24 31 24
Street and backyard 18 49 29 62 24 54 71 54
49. Is your dwelling: (B2Q17)
1 = one family house detached from any other house
2 = one family house attached to one or more other houses
3 = apartment / more family house
4 = Neubaublock (only in Germany)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
1 0 0 5 11 0 0 5 4
2 7 19 5 11 1 2 13 10
3 30 81 12 26 46 98 88 67
4 0 0 25 53 0 0 25 19
50. When was this building originally built? (B2Q18)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 1 2 1 1
1990-1997 0 0 3 6 2 4 5 4
1980-1989 20 54 12 26 7 15 39 30
1970-1979 15 40 9 19 7 15 31 24
1960-1969 2 5 8 17 12 26 22 17
1945-1959 0 0 2 4 10 21 12 9
Before 1945 0 0 13 28 8 17 19 16
51. How many floors are in this building? (B2Q19)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
1 1 3 3 6 1 2 5 4
2-3 9 24 11 23 2 4 22 17
4 or more 27 73 33 70 44 94 104 79
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52. At which floor is your home? (B2Q20)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
1 16 43 23 49 5 11 44 34
2-3 12 32 10 21 17 36 39 30
4 or more 9 24 14 30 25 53 48 37
53. Does your home have central heating? (B2Q21)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 0 0 5 11 0 0 5 4
Yes 37 100 42 89 47 100 126 96
54. Do you use coal or wood for heating? (B2Q21P1A)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 37 100 42 89 47 100 126 96
No 0 0 4 9 0 0 4 3
Yes 0 0 1 2 0 0 1 1
55. Do you use gas for heating? (B2Q21P1B)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 37 100 42 89 47 100 126 96
No 0 0 3 6 0 0 3 2
Yes 0 0 2 4 0 0 2 2
56. Do you use electric for heating? (B2Q21P1C)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 37 100 42 89 47 100 126 96
No 0 0 5 11 0 0 5 4
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57. Do you use oil for heating? (B2Q21P1D)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 37 100 42 89 47 100 126 96
No 0 0 3 6 0 0 3 2
Yes 0 0 2 4 0 0 2 2
58. Do you regularly use a gas range or gas oven for cooking? (B2Q22)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 1 2 1 1
No 9 24 36 77 41 87 86 66
Yes 28 76 11 23 5 11 44 34
59. Do you sleep with the windows open at night mostly during the winter months?
(B2Q23)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 13 35 12 26 40 85 65 50
Yes 24 65 35 74 7 15 66 50
60. How much are you annoyed by the traffic noise at home if the windows are kept
open? (B2Q24)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
0 14 38 2 4 17 36 33 25
1 5 14 3 6 3 6 11 8
2 4 11 4 9 8 17 16 12
3 2 5 9 19 2 4 13 10
4 4 11 3 6 0 0 7 5
5 1 3 7 15 5 11 13 10
6 1 3 4 9 5 11 10 8
7 3 8 3 6 2 4 8 6
8 2 5 5 11 3 6 10 8
9 1 3 1 2 2 4 4 3
10 0 0 6 13 0 0 6 5
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61. How much are you annoyed by air pollution at home i.e. smell of the traffic and
industry, when you keep the window open? (B2Q25)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
0 24 65 1 2 16 34 41 31
1 1 3 5 11 4 9 10 8
2 3 8 10 21 6 13 19 15
3 3 8 10 21 5 11 18 14
4 0 0 3 6 5 11 8 6
5 2 5 4 9 2 4 8 6
6 0 0 3 6 1 2 4 3
7 2 5 4 9 3 6 9 7
8 2 5 2 4 3 6 7 5
9 0 0 0 0 1 2 1 1
10 0 0 5 11 1 2 6 5
62. Does anyone regularly smoke inside your home? (B2Q26)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 33 89 39 83 47 100 119 91
Yes 4 11 8 17 0 0 12 9
63. How many people in your household smoke inside your home regularly? (B2Q26P1)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
0 33 89 39 83 47 100 119 91
1 4 11 7 15 0 0 11 8
2 0 0 1 2 0 0 1 1
64. How many cigarettes are smoked daily inside your home? (B2Q26P2A)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
0 33 89 39 83 47 100 119 91
5 0 0 1 2 0 0 1 1
6 0 0 2 4 0 0 2 2
10 0 0 5 11 0 0 5 4
20 3 8 0 0 0 0 3 2
30 1 3 0 0 0 0 1 1
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65. How many pipes or cigars are smoked daily inside your home? (B2Q26P2B)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
0 37 100 47 100 47 100 131 100
66. Do people smoke regularly in the room where you work? (B2Q27)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 1 2 4 9 5 4
No 1 3 3 6 11 23 15 11
Yes 1 3 1 2 0 0 2 2
Don’t work 35 95 42 89 32 68 109 83
67. Have you ever smoked for as long as a year? (B2Q28)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 7 19 10 21 21 45 38 29
Yes 30 81 37 79 26 55 93 71
68. How old were you when started smoking? (B2Q28P1)
Amsterdam Erfurt Helsinki Total
Mean (sd) 18 (6.2) 20 (6.1) 22 (9.3) 20 (7.1)
Min-max 7-45 14-46 15-53 7-53
69. When have you stopped smoking? (B2Q28P2)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 19 10 21 21 45 38 29
96-99 6 16 10 21 2 4 18 14
89-95 6 16 5 11 4 9 15 11
79-88 9 24 6 13 4 9 19 15
69-78 5 14 10 21 6 13 21 16
59-68 2 5 5 11 6 13 13 10
49-58 2 5 1 2 3 6 6 5
Before 49 0 0 0 0 1 2 1 1
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70. Before you stopped smoking, how much did you smoke on average: number of
cigarettes per day. (B2Q28P3A)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 0 0 10 21 0 0 10 8
0 8 22 2 4 21 45 31 24
1-4 3 8 0 0 1 2 4 3
5-9 2 5 5 11 4 9 11 8
10-14 4 11 7 15 4 9 15 11
15-19 3 8 9 19 2 4 14 11
20-24 12 32 9 19 9 19 30 23
25 or more 5 14 5 11 6 12 16 12
71. Before you stopped smoking, how much did you smoke on average: number of
cigarillos per day. (B2Q28P3B)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 0 0 10 21 0 0 10 8
0 36 97 36 77 47 100 119 91
5 1 3 1 2 0 0 2 2
72. Before you stopped smoking, how much did you smoke on average: number of
cigars per day. (B2Q28P3C)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 0 0 10 21 0 0 10 8
0 33 89 34 72 47 100 114 87
1 2 5 0 0 0 0 2 2
2 0 0 2 4 0 0 2 2
4 1 3 0 0 0 0 1 1
5 0 0 1 2 0 0 1 1
10 1 3 0 0 0 0 1 1
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73. Before you stopped smoking, how much did you smoke on average: pipe of tobacco
in grams per week. (B2Q28P3D)
Amsterdam Erfurt Helsinki Total
n % n % N % N %
Missing 0 0 10 21 0 0 10 8
0 36 97 37 79 46 98 119 91
50 1 3 0 0 0 0 1 1
200 0 0 0 0 1 2 1 1
74. Age
Amsterdam Erfurt Helsinki Total
Female Mean(sd) 74 (7.6) 67 (5.1) 69 (7.4) 70 (7.7)
Min-Max 63-84 59-70 54-78 54-84
Male Mean(sd) 70 (8.5) 64 (8.3) 68 (5.4) 67 (8.0)
Min-Max 54-83 40-78 58-83 40-83
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3.3 BASELINE, DOCTOR ADMINISTRATED DAILY MEDICATION
 blockers (BETABLBA)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 24 65 12 26 16 34 52 40
Yes 13 35 35 74 31 66 79 60
2. Ca++ -blockers (CABLOBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 26 70 29 62 34 72 89 68
Yes 11 30 18 38 13 28 42 32
3. ACE-inhibitors and AT-blockers (ACEBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 25 68 22 47 37 79 84 64
Yes 12 32 25 53 10 21 47 36
4. Nitrates (NITROBA)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 30 81 30 64 28 60 88 67
Yes 7 19 17 36 19 40 43 33
5. Anti-arrhythmic medication (ARRBA)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 35 94 46 98 41 87 122 93
Yes 2 5 1 2 6 13 9 7
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6. ASA (ASABA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 15 41 11 23 11 23 37 28
Yes 22 59 36 77 36 77 94 72
7. Digitalis (DIGITABA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 35 95 38 81 40 85 113 86
Yes 2 5 9 19 7 15 18 14
8. Dipyridamole (DIPYRIBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 37 100 47 100 46 98 130 99
Yes 0 0 0 0 1 2 1 1
9. Diuretics (DIURETBA)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 31 84 27 57 34 72 92 70
Yes 6 16 20 43 13 28 39 30
10. Moksonidine (MOKSOBA)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 37 100 46 98 47 100 130 99
Yes 0 0 1 2 0 0 1 1
	
	 2-agonist (AGONBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 35 95 46 98 44 94 125 95
Yes 2 5 1 2 3 6 6 5
77
12. Inhalable anticholinergs (ANTICBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 37 100 47 100 46 98 130 99
Yes 0 0 0 0 1 2 1 1
13. Inhalable glucocorticosteroids (GLUCORBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 35 95 46 98 37 79 118 90
Yes 2 5 1 2 10 21 13 10
14. Inhalable dinatriumcromoglicate / nedocromile (CROMOGBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 37 100 47 100 46 98 130 99
Yes 0 0 0 0 1 2 1 1
15. Leukotriene receptor blockers (RECBLOBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 37 100 47 100 46 98 130 99
Yes 0 0 0 0 1 2 1 1
16. Hyperlipidaemia medication (HYPLIPBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 25 68 27 57 26 55 78 60
Yes 12 32 20 43 21 45 53 40
17. Warfarine (WARFARBA)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 31 84 47 100 44 94 122 93
Yes 6 16 0 0 3 6 9 7
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18. Diabetes medication(DIAPETBA)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
No 35 95 40 85 44 94 119 91
Yes 2 5 7 15 3 6 12 9
19. Medication affecting central nervous system (CNSBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 33 89 44 94 43 91 120 92
Yes 4 11 3 6 4 9 11 8
20. Other medication (OTHMEDBA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
No 18 49 12 26 24 51 54 41
Yes 19 51 35 74 23 49 77 59
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3.4 RESTING ECG
1. Q and QS Patterns:
Anterolateral site (leads I, aVL, V6) (QLAT)
0 = not diagnosed.
111 = Q/R amplitude ratio 0.)1
	0)	
I or V6.
121 = Q/R amplitude ratio 0.)1
	0	
2)	
3
V6.
122 = Q duration 0)	
24	
356.
131 = Q/R amplitude ratio 0.	
2.)1
	0	
2)
in lead I or V6.
133 = Q duration 0)	
24(
0)	
5&
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 1 3 0 0 1 2 2 2
0 30 81 40 85 45 96 115 88
111 1 3 2 4 1 2 4 3
121 0 0 1 2 0 0 1 1
122 2 5 2 4 0 0 4 3
131 1 3 2 4 0 0 3 2
133 2 5 0 0 0 0 2 2
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2. Q and QS Patterns:
Posterior (inferior) site (leads II, III,aVF) (QINF)
0 = not diagnosed.
111 = Q/R amplitude ratio 0.)1
	0)	
33
114 = Q duration 0  	 
 333  1$
0 	 
majority of beats in lead aVF.
115 = Q duration 0	
56
121 = Q/R amplitude ratio 0.)1
	0	
2)	
33
122 = Q duration 0)	
24	
33
123 = QS pattern in lead II.
124 = Q duration 0 4  	
 2   	 
 333   1$ 0 
amplitude in the majority of beats in aVF. 125 = Q duration 04	
2
in lead aVF.
131 = Q/R amplitude ratio 0.	
2.)1
	0	
2)
in lead II.
134 = Q duration 0 )  	
 2 4  	 
 333   1$ 0 
amplitude in the majority of beats in lead aVF.
135 = Q duration 0)	
24	
56
136 = QS pattern in each of leads III and aVF.
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 2 5 0 0 1 2 3 2
0 20 54 37 79 39 83 96 73
111 4 11 3 6 1 2 8 6
114 1 3 2 4 0 0 3 2
115 0 0 1 2 0 0 1 1
121 2 5 0 0 1 2 3 2
122 1 3 2 4 0 0 3 2
123 1 3 0 0 1 2 2 2
124 0 0 0 0 3 6 3 2
125 1 3 0 0 0 0 1 1
131 0 0 0 0 1 2 1 1
134 2 5 1 2 0 0 3 2
135 0 0 1 2 0 0 1 1
136 3 8 0 0 0 0 3 2
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3. Q and QS Patterns:
Anterior site ( leads V1, V2, V3, V4, V5 ) (QANT)
0 = not diagnosed.
111 = amplitude ratio 0.)1
	0)		
52, V3, V4, V5.
112 = Q duration 04		
51, V2, V3, V4, V5. 116 = QS pattern when
initial R-wave is present in adjacent lead to the right on the chest, in any of leads V2,
V3, V4, V5, V6.
117 = QS pattern in all of leads V1 – V4 or V1 – V5.
121 = Q/R amplitude ratio 0.)1
	0	
2)		
leads V2, V3, V4, V5.
122 = Q duration 0)	
24		
52, V3, V4, V5.
127 = QS pattern in all of leads V1, V2, and V3.
128 = Initial R amplitude decreasing to 2.0mm or less in every beat between any of
leads V2 and V3, V3 and V4, or V4 and V5.
131 = Q/R amplitude ratio 0.	
2.)1
	0	
2)
in any of leads V2, V3, V4, V5.
132 = QS pattern in lead V1 and V2.
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 1 3 0 0 1 2 2 2
0 32 86 36 77 44 94 112 86
111 1 3 3 6 1 2 5 4
112 0 0 1 2 0 0 1 1
116 1 3 0 0 0 0 1 1
117 0 0 1 2 0 0 1 1
121 0 0 1 2 0 0 1 1
122 0 0 2 4 0 0 2 2
127 0 0 1 2 0 0 1 1
128 1 3 0 0 0 0 1 1
131 1 3 0 0 0 0 1 1
132 0 0 2 4 1 2 3 2
4. QRS Axis Deviation (QRSAXIS)
0 = not diagnosed.
21 = Left. QRS axis from –30° trough -90° in leads I, II, III.
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 1 3 0 0 1 2 2 2
0 33 89 45 96 46 98 124 95
21 3 8 2 4 0 0 5 4
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5. High Amplitudes R Waves (HIRWAVE)
0 = not diagnosed.
31 = Left: R amplitude > 26 mm in either V5 or V6, or R amplitude > 20.0 mm in any
of leads I, II, III, aVF, or R amplitude > 12.0 mm in lead aVL measured only on
second to last complete normal beat.
33 = Left: R amplitude > 15.0 mm but 7	
I, or R amplitude in V5 or
V6, plus S amplitude in V1 > 35.0 mm.
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 1 3 0 0 1 2 2 2
0 32 86 44 94 43 91 119 91
31 4 11 1 2 1 2 6 5
33 0 0 2 4 2 4 4 3
6. ST Junction (J) and Segment Depression: Anterolateral site (leads I, aVL, V6)
(STDEPLAT)
0 = not diagnosed.
42 = STJ depression 0	
2	
8'	/	
	

sloping in any of leads I, aVL, or V6.
43 = No STJ depression as much as 0.5 mm but ST segment downward sloping and
segment or T-wave nadir 0(			
35&56.
44 = STJ depression 0	
8'	
	%
		
leads I, aVL, or V6.
412 = STJ depression 0    2   	
 8' 	 /	 
downward sloping in any of leads I, aVL, or V6.
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 2 5 0 0 1 2 3 2
0 26 70 32 68 33 70 91 69
42 3 8 6 13 7 15 16 12
43 5 14 5 11 5 11 15 11
44 1 3 0 0 0 0 1 1
412 0 0 4 9 1 2 5 4
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7. ST Junction (J) and Segment Depression:
Posterior (inferior) site (leads II, III, aVF) (STDEPINF)
0 = not diagnosed.
42 = STJ depression 0	
2	
8'	/	
	

sloping in lead II or aVF.
43 = No STJ depression as much as 0.5 mm, but ST segment downward sloping and
segment or T-wave nadir 0(		
33
412 = STJ depression 0    2   	
 8' 	 /	 
downward sloping in lead II or aVF.
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 2 5 0 0 1 2 3 2
0 33 89 40 85 41 87 114 87
42 1 3 4 9 2 4 7 5
43 1 3 1 2 3 6 5 4
412 0 0 2 4 0 0 2 2
8. ST Junction (J) and Segment Depression:
Anterior site (leads V1, V2, V3, V4, V5) (STDEPANT)
0 = not diagnosed.
42 = STJ depression 0	
2	
8'	/	
	

sloping in any of leads V1, V2, V3, V4, V5.
43 = No STJ depression as much as 0.5 mm, but ST segment downward sloping and
segment or T-wave nadir 0(			
52, V3, V4, V5.
44 = STJ depression 0	
8'	
	%
		
leads V1, V2, V3, V4, V5.
412 = STJ depression 0    2   	
 8' 	 /	 
downward sloping in any of leads V1, V2, V3, V4, V5.
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 2 5 0 0 1 2 3 2
0 33 89 35 74 40 85 108 82
42 2 5 4 9 3 6 9 7
43 0 0 3 6 0 0 3 2
44 0 0 1 2 1 2 2 2
412 0 0 4 9 2 4 6 5
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9. T-Wave Items:
Anterolateral site (leads I, aVL, V6) (TWAVELAT)
0 = not diagnosed.
52 = T amplitude negative or diphasic (positive-negative or negative-positive type)
with negative phase at least 1.0 mm but not as deep as 5.0 mm in lead I or V6, or in
lead aVL when R amplitude is 0
53 = T amplitude zero (flat), or negative, or diphasic (negative-positive type only)
with less than 1.0 mm negative phase in lead I or V6, or in lead aVL when R
amplitude is 0
54 = T amplitude positive and T/R amplitude ratio < 1/20 in any of leads I, aVL, V6;
R wave amplitude must be 0
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 2 5 0 0 1 2 3 2
0 23 62 28 60 30 64 81 62
52 7 19 10 21 4 9 21 16
53 5 14 9 19 11 23 25 19
54 0 0 0 0 1 2 1 1
10. T-wave Items: Posterior (inferior) site (leads II, III, aVF) (TWAVEINF)
0 = not diagnosed.
52 = T amplitude negative or diphasic with negative phase (negative-positive or
positive-negative type) at least 1.0 mm but not as deep as 5.0 mm in lead II, or in lead
aVF when QRS is mainly upright.
53 = T amplitude zero (flat), or negative, or diphasic (negative-positive type only)
with less than 1.0 mm negative phase in lead II; not coded in lead aVF.
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 2 5 0 0 1 2 3 2
0 30 81 39 83 41 87 110 84
52 2 5 6 13 2 4 10 8
53 3 8 2 4 3 6 8 6
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11. T-Wave Items:
Anterior site (leads V2, V3, V4, V5) (TWAVEANT)
0 = not diagnosed.
52 = T amplitude negative (flat), or diphasic (negative-positive or positive-negative
type) with negative phase at least 1.0 mm but not as deep as 5.0 mm, in any leads V2,
V3, V4, V5.
53 = T amplitude zero (flat), or negative, or diphasic (negative-positive type only)
with less than 1.0 mm negative phase, in any of leads V3, V4, V5.
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 2 5 0 0 1 2 3 2
0 29 78 33 70 36 77 98 75
52 2 5 12 26 6 13 20 15
53 4 11 2 4 4 9 10 8
12. A-V Conduction Defect (AVCDEF)
0 = not diagnosed.
63 = P-R (P-Q) interval 0	9		
3333335&
aVF.
65 = Short P-R interval. P-R interval < 0.12 sec in all beats of any two of leads I, II,
III, aVL, aVF.
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 1 3 0 0 1 2 2 1
0 32 86 42 89 40 85 114 87
63 3 8 5 11 6 13 14 11
65 1 3 0 0 0 0 1 1
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13. Ventricular Conduction Defect (VENTCDEF)
0 = not diagnosed.
73 =Incomplete right bundle branch block. QRS duration < 0.12 sec in each of leads I,
II, III, aVL, aVF, and R’ > R in either of leads V1, V2.
74 = Intraventricular block. QRS duration 0	9		
leads I, II, III, aVL, aVF.
75 = R-R’ pattern in either of leads V1, V2 with R’ amplitude 7(
77 = Left anterior hemiblock (LAH). QRS duration < 0.12 sec in the majority of beats
in leads I, II, III, aVL, aVF, plus Q-wave amplitude 0   	
 2 ) 
duration in lead I, plus left axis deviation of -45° or more negative.
711 = Complete left bundle branch block (LBBB). QRS duration 0   	 
majority of beats (of the same pattern) in any of leads I, II, III, aVL, aVF, plus R peak
duration 0:	9!1(8	"		
333
aVL, V5, V6.
721 = Complete right bundle branch block (RBBB). QRS duration 0   	 
majority of beats (of the same QRS pattern) in any of leads I, II, III, aVL, aVF, plus:
R’ > R in V1 or QRS mainly upright, plus R peak duration 0:	51 or V2; or
V2; S duration > R duration in all beats in lead I or II.
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 1 3 0 0 1 2 2 2
0 25 68 35 74 40 85 100 76
73 0 0 3 6 1 2 3 2
74 1 3 1 2 1 2 3 2
75 3 8 3 6 3 6 9 7
77 2 5 1 2 0 0 3 2
711 0 0 2 4 0 0 2 2
721 5 14 2 4 1 2 8 6
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14. Arrhytmias (ARRHY)
0 = not diagnosed.
87 = Sinus tachycardia (over 100/min).
88 = Sinus bradycardia (under 50/min).
811 = Presence of frequent atrial or junctional premature beats (10 % or more of
recorded complexes).
812 = Presence of frequent ventricular premature beats (10 % or more of recorded
complexes).
831 = Atrial fibrillation (persistent).
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 2 5 0 0 1 2 3 2
0 30 81 42 89 42 89 114 87
87 0 0 1 2 0 0 1 1
88 1 3 0 0 1 2 2 2
811 2 5 0 0 0 0 2 2
812 1 3 1 2 0 0 2 2
831 1 3 3 6 3 6 7 5
15. ST  Segment Elevation:
Anterolateral site (leads I, aVL, V6) (STELELAT)
0 = not diagnosed.
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 2 5 0 0 1 2 3 2
0 35 95 47 100 46 98 128 98
16. ST  Segment Elevation:
Posterior (inferior) site (leads II,III, aVF) (STELEINF)
0 = not diagnosed.
92 = ST segment elevation 0		
3333356
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 2 5 0 0 1 2 3 2
0 35 95 46 98 46 98 127 97
92 0 0 1 2 0 0 1 1
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17. ST  Segment Elevation:
Anterior site (leads V1, V2, V3, V4, V5) (STELEANT)
0 = not diagnosed.
92 = ST segment elevation 0	
55 or ST segment elevation 0	
any of leads V1, V2, V3, V4.
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 2 5 0 0 1 2 3 2
0 35 95 45 96 45 96 125 95
92 0 0 2 4 1 2 3 2
18. Miscellaneous Items (MISC)
0 = not diagnosed.
95 = T-wave amplitude > 12 mm in any leads I, II, III, aVL, aVF, V1, V2, V3, V4, V5,
V6.
941 = QRS transition zone at V3 or to the right of V3 on the chest.
942 = QRS transition zone at V4 or to the left of V4 on the chest.
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 1 3 0 0 1 2 2 2
0 20 54 23 49 19 40 62 47
95 0 0 1 2 0 0 1 1
941 6 16 18 38 24 51 48 37
942 10 27 5 11 3 6 18 14
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3.5 CLINICAL VISIT QUESTIONNAIRE
1. Did you have chest pain yesterday? (CQ1)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 2 0 0 7 1 14 1
No 400 93 381 78 446 86 1227 85
Yes 22 5 110 22 65 13 197 14
2. Did you have chest pain or other symptoms of angina pectoris during the preceding
hour? (CQ2)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 8 2 0 0 7 1 15 1
No 413 96 456 93 503 97 1372 95
Yes 8 2 35 7 8 2 51 4
3. Did you have shortness of breath yesterday? (CQ3)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 7 2 0 0 7 1 14 1
No 356 83 409 83 412 80 1177 82
Yes 66 15 82 17 99 19 247 17
4. Did you have shortness of breath during the preceding hour? (CQ4)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 7 2 0 0 7 1 14 1
No 398 93 470 96 483 93 1351 94
Yes 24 6 21 4 28 5 73 5
5. Did you have wheeze during the preceding hour? (CQ5)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 2 0 0 7 1 14 1
No 417 97 487 99 500 97 1404 98
Yes 5 1 4 1 11 2 20 1
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6. Did you have an airway infection in the past two weeks? (CQ6)
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 8 2 0 0 7 1 15 1
No 328 77 427 87 415 80 1170 81
Yes 93 22 64 13 96 19 253 18
7. Do you have an airway infection today? (CQ6P1)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 343 80 427 87 424 82 1194 83
No 35 8 39 8 21 4 95 7
Yes 51 12 25 5 73 14 149 10
8. Did you have fever in the last week? (CQ7)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 2 0 0 79 15 86 6
No 411 96 484 99 427 82 1322 92
Yes 11 3 7 1 12 2 30 2
9. Question for nurse: Do you think the subject can perform the exercise? (CQ8)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 2 0 0 7 1 14 1
No 35 8 19 4 82 16 136 9
Yes 387 90 472 96 429 83 1288 90
10. Why the subject cannot perform the exercise? (CQ8A)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 394 92 474 97 436 84 1304 91
Resp. infection 2 0 9 2 20 4 31 2
Does not want to 4 1 0 0 2 0 6 0
Other 29 7 8 2 60 12 97 7
91
11. Did you visit a doctor for any acute illness during the 2 weeks? (CQ9)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 2 0 0 7 1 14 1
No 371 86 445 91 449 87 1265 88
Yes 51 12 46 9 62 12 159 11
12. Reason for visiting doctor (see table 11): Angina Pectoris (CQ9A)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 378 88 445 91 457 88 1280 89
No 49 11 46 9 57 11 152 11
Yes 2 0 0 0 4 1 6 0
13. Reason for visiting doctor (see table 11): other cardiac (CQ9B)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 378 88 445 91 457 88 1280 89
No 47 11 42 9 60 12 149 10
Yes 4 1 4 1 1 0 9 1
14. Reason for visiting doctor (see table 11): respiratory condition (CQ9C)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 378 88 445 91 457 88 1280 89
No 43 10 36 7 53 10 132 9
Yes 8 2 10 2 8 2 26 2
15. Reason for visiting doctor (see table 11): urinary tract infection (CQ9D)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 378 88 445 91 457 88 1280 89
No 39 9 46 9 59 11 144 10
Yes 12 3 0 0 2 0 14 1
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16. Reason for visiting doctor (see table 11): other reason (CQ9E)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 378 88 445 91 457 88 1280 89
No 24 6 13 3 11 2 48 3
Yes 27 6 33 7 50 10 110 8
17. Did you stay in the hospital because of this illness? (CQ10)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 2 0 0 7 1 14 1
No 418 97 488 99 502 97 1408 98
Yes 4 1 3 1 9 2 16 1
18. Has there been any changes made in your prescriptions? (CQ11)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 9 2 0 0 8 2 17 1
No 356 83 432 88 474 91 1262 88
Yes 64 15 59 12 36 7 159 11
19. Did you take your medication today as prescribed? (CQ12)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 2 0 0 7 1 14 1
No 26 6 5 1 3 1 34 2
Yes 396 92 486 99 508 98 1390 97
20. Did you use any inhalator in the last 4 hours? (CQ13)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 7 2 0 0 7 1 14 1
No 411 96 488 99 449 87 1348 94
Yes 11 3 3 1 62 12 76 5
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Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 420 98 488 99 459 89 1367 95
No 0 0 2 0 27 5 29 2
Yes 9 2 1 0 32 6 42 3
22. Inhalable corticol steroids used in the last 4 hours (see table 20) (CQ13B)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 420 98 488 99 459 89 1367 95
No 1 0 1 0 15 3 17 1
Yes 8 2 2 0 44 8 54 4
23. Inhalable anti-cholinergic used in the last 4 hours (see table 20) (CQ13C)
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 420 98 488 99 459 89 1367 95
No 9 2 3 1 44 8 56 4
Yes 0 0 0 0 15 3 15 1
24. Did you smoke during the past 2 weeks? (CQ14)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 2 0 0 7 1 14 1
No 411 96 490 100 511 99 1412 98
Yes 11 3 1 0 0 0 12 1
25. How many cigarettes in total did you smoke during the past 2 weeks? (CQ14P1)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 7 2 0 0 7 1 14 1
Didn’t smoke at all 411 96 490 100 511 99 1412 98
1-5 8 2 1 0 0 0 9 1
6-10 1 0 0 0 0 0 1 0
11-20 2 0 0 0 0 0 2 0
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26. Did you smoke in the last hour? (CQ14P2)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 8 2 0 0 7 1 15 1
No 9 2 1 0 0 0 10 1
Yes 1 0 0 0 0 0 1 0
Didn’t smoke at all 411 96 490 100 511 99 1412 98
27. Have you been in rooms where people smoked during the last 24 hours? (CQ15)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 7 2 0 0 7 1 14 1
No 320 75 432 88 484 93 1236 86
Yes 102 24 59 12 27 5 188 13
28. How long did you stay there? (CQ15P1)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 8 2 0 0 7 1 15 1
0 320 75 432 88 484 93 1236 86
1-2 28 7 43 9 20 4 91 6
3-11 36 8 16 3 4 1 56 4
12+ 34 8 0 0 0 0 34 2
29. How did you arrive to the clinical visit? (CQ16)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 7 2 0 0 8 2 15 1
Walking/cycling 100 23 124 25 5 1 229 16
Car/bus/tram 322 75 367 75 505 97 1194 83
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30. How many cups of coffee did you drink during the last 4 hours? (CQ17A)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 7 2 0 0 25 5 32 2
0 189 44 293 60 237 46 719 50
1 94 22 90 18 103 20 287 20
2 108 25 105 21 138 27 351 24
3 8 2 3 1 15 3 26 2
4 or more 23 5 0 0 0 0 23 2
31. How many cups of tea did you drink during the last 4 hours? (CQ17B)
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 9 2 0 0 81 16 90 6
0 220 51 461 94 395 76 1076 75
1 69 16 7 1 11 2 87 6
2 94 22 23 5 27 5 144 10
3 24 6 0 0 1 0 25 2
4 or more 13 3 0 0 3 1 16 1
32. Did you drink coffee during the last hour? (CQ17P1)
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 8 2 293 60 7 1 308 21
No 358 83 149 30 486 94 993 69
Yes 63 15 49 10 25 5 137 10
33. Did you drink tea during the last hour? (CQ17P2)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 9 2 461 94 7 1 477 33
No 367 86 11 2 509 98 887 62
Yes 53 12 19 4 2 0 74 5
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34. Did you drink alcohol during the last 24 hours? (CQ18)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 8 2 0 0 9 2 17 1
No 231 54 303 62 433 83 967 67
Yes 190 44 188 38 76 15 454 32
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3.5 CLINICAL VISIT LOG BOOK
1. Nurse filling out the questionnaire (QUNURSE)
Amsterdam Erfurt Helsinki
Nurse n Nurse n Nurse n
. 7 . 0 . 7
11 105 1 48 50 466
12 105 2 179 51 45
13 5 3 262
14 30 4 2
15 149
16 28
2. Was interview done? (INTERVIEW)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 2 0 0 15 3 22 2
Yes 422 98 491 100 503 97 1416 98
3. Was diary changed? (DIARYCH)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 19 4 0 0 25 5 44 3
No 0 0 47 10 0 0 47 3
Yes 410 96 444 90 493 95 1347 94
4. Was urine sample taken? (URINESA)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 19 4 0 0 51 10 51 5
No 0 0 7 1 0 0 7 0
Yes 410 96 484 99 467 90 1361 95
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5. ECG nurse identification number  (ECGNURSE)
Amsterdam Erfurt Helsinki
Nurse n Nurse n Nurse n
. 7 . 0 . 7
11 83 1 48 50 466
12 103 2 179 51 45
13 8 3 262
14 48 4 2
15 149
16 31
6. Number of Holter recorder (HOLTREC)
Amsterdam Erfurt Helsinki
n % n % n %
Missing 7 2 5 1 8 2
1 137 32 176 36 438 85
2 161 38 141 29 2 0
3 124 29 85 17 70 14
4 0 0 84 17 0 0
7. Number of patient cable (CABLE)
Amsterdam Erfurt Helsinki
n % n % n %
Missing 7 2 5 1 8 2
1 137 32 176 36 438 85
2 161 38 141 29 2 0
3 124 29 85 17 70 14
4 0 0 84 17 0 0
8. Were there difficulties to locate the electrodes like previously? (ELECTROD)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 8 2 5 1 54 10 67 5
No 369 86 480 98 453 87 1302 91
Yes 52 12 6 1 11 2 69 5
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9. The hour of real time of start of Holter recording (STRTHOUR)
Amsterdam Erfurt Helsinki Total
N 421 468 511 1418
Mean (sd) 13 (2.3) 11 (2.1) 12 (2.1) 12 (2.3)
Min-max 8-17 8-15 9-16 8-17
Median 13 10 12 12
25%-75% 11-15 9-13 10-14 10-14
10. Breathing frequency for 1 min, between about 3-4 min (BRFREQ1)
Amsterdam Erfurt Helsinki Total
N 420 486 491 1397
Mean (sd) 14 (3.7) 14 (2.5) 14 (3.1) 14 (3.1)
Min-max 3-27 8-21 6-26 3-27
Median 14 14 13 14
25%-75% 11-16 12-16 12-16 12-16
11. Systolic blood pressure 1 in supine position (SYSTSUP1)
Amsterdam Erfurt Helsinki Total
N 422 486 510 1418
Mean (sd) 140 (20) 133 (18.5) 140 (23.0) 137 (20.9)
Min-max 99-206 81-179 77-223 77-223
Median 137.5 132.5 139.5 136
25%-75% 125-152 119-145 123-153 122-150
12. Diastolic blood pressure 1 in supine position  (DIASSUP1)
Amsterdam Erfurt Helsinki Total
N 422 486 510 1418
Mean (sd) 83 (11.5) 80 (8.9) 77 (9.8) 80 (10.4)
Min-max 57-118 54-108 54-118 54-118
Median 83 80 76 79
25%-75% 75-90 74-85 70-80 73-86
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13. Systolic blood pressure 2 in supine position (SYSTSUP2)
Amsterdam Erfurt Helsinki Total
N 414 486 506 1406
Mean (sd) 141 (20.6) 133 (18.7) 143 (22.5) 139 (21.1)
Min-max 96-225 84-178 84-207 84-225
Median 137.5 133 143 138
25%-75% 127-153 119-147 125-158 123-152
14. Diastolic blood pressure 2 in supine position (DIASSUP2)
Amsterdam Erfurt Helsinki Total
N 414 486 506 1406
Mean (sd) 84 (11.4) 80 (8.3) 78 (9.6) 80 (10.1)
Min-max 62-126 54-101 53-118 53-126
Median 83 80 77 80
25%-75% 76-91 75-85 72-83 74-87
15. Systolic blood pressure at 3 min standing (SYSTSTAN)
Amsterdam Erfurt Helsinki Total
N 399 484 504 1387
Mean (sd) 144 (22.3) 138 (20.4) 150 (25.8) 144 (23.6)
Min-max 81-217 72-205 94-236 72-236
Median 143 138 147 142
25%-75% 128-158 124-151 132-165 128-158
16. Diastolic blood pressure  at 3 min standing (DIASSTAN)
Amsterdam Erfurt Helsinki Total
N 399 484 504 1387
Mean (sd) 86 (12.1) 84 (9.5) 87 (11.0) 86 (10.9)
Min-max 59-119 45-113 61-130 45-130
Median 86 85 85 85
25%-75% 78-94 78-90 79-93 79-92
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17. Heart rate in the end of 6 min exercise (HR)
Amsterdam Erfurt Helsinki Total
N 377 478 418 1273
Mean (sd) 79 (14.1) 87 (10.5) 91 (8.5) 86 (12.2)
Min-max 41-114 56-118 50-140 41-130
Median 77 86 92 87
25%-75% 69-89 81-93 86-96 78-94
18. Load in the end of 6 min exercise (LOAD)
Amsterdam Erfurt Helsinki Total
N 0 460 419 879
Mean (sd) - 52 (17.7) 53 (12.1) 52 (15.3)
Min-max - 20-100 0-100 0-100
Median - 50 50 50
25%-75% - 40-60 50-50 50-60
19. Exercise test completed (EXEOK)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 40 9 11 2 92 18 143 10
No 6 1 11 2 10 2 27 2
Yes 383 89 469 96 416 80 1268 88
20. Exercise test had to be stopped because (EXESTOP)
1=development of severe symptoms
2=equipment problems
3=other reason
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 423 99 480 98 508 98 1411 98
1 5 1 6 1 9 2 20 1
2 0 0 2 0 0 0 2 0
3 1 0 3 1 1 0 5 0
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21. Did the patient experience shortness of breath during exercise? (EXESHBR)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 47 11 15 3 95 18 157 11
No 371 86 454 92 339 65 1164 81
Yes 11 3 22 4 84 17 117 8
22. Did the patient experience chest pain during exercise? (EXECHPA)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 47 11 13 3 95 18 155 11
No 380 89 452 92 414 80 1246 87
Yes 2 0 26 5 9 2 37 3
23. Breathing frequency for 1 min, between about 7-8 min (during 10 min rest in supine
position) (BRFREQ2)
Amsterdam Erfurt Helsinki Total
N 415 486 482 1383
Mean (sd) 13 (3.6) 14 (2.4) 14 (3.2) 14 (3.1)
Min-max 5-28 7-21 8-26 5-28
Median 13 14 14 14
25%-75% 11-16 12-16 12-16 12-16
24. Number of spirometry (SPIROMET)
Amsterdam Erfurt Helsinki
n % n % n %
Missing 7 2 0 0 98 19
1 0 0 491 100 0 0
2 0 0 0 0 420 81
6 422 98 0 0 0 0
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25. Spirometry nurse identification number (SPINURSE)
Amsterdam Erfurt Helsinki
Nurse n Nurse n Nurse n
. 9 . 1 . 80
11 98 1 48 50 393
12 104 2 187 51 45
13 1 3 253
14 38 4 2
15 148
16 31
26. Spirometry maneuver completed (SPIROOK)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 7 2 0 0 80 15 87 6
No 72 17 7 1 17 3 96 7
Yes 350 82 484 99 421 81 1255 87
27. The spirometry maneuver had to be stopped, because (SPISTOP)
1=the patient was unable to perform
2=equipment problems
3=development of severe symptoms
4=other reason
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 367 86 480 98 501 97 1348 94
1 46 11 1 0 8 1 55 4
2 7 2 10 2 1 0 18 1
3 3 1 0 0 3 1 6 0
4 6 1 0 0 5 1 11 1
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28. Completeness of exercise test (EXERCISE)
1=test completed and no restraints in clinic questionnaire
2=test completed in spite of restraints in clinic questionnaire
3=test completed, but the tape has bad quality
4=test stopped because of development of symptoms
5=test stopped because of equipment or other problems
6=test not done because of cardiorespiratory symptoms
7=test not done because of other symptoms or the subject did not want to
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 8 2 0 0 7 1 15 1
1 327 77 380 77 362 70 1069 74
2 6 1 46 9 12 2 64 4
3 50 12 46 9 43 8 136 9
4 5 1 6 1 9 2 20 1
5 0 0 4 1 1 0 5 0
6 28 7 6 1 47 9 81 6
7 5 1 6 1 37 7 48 3
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3.7 SPIROMETRY AND URINE SAMPLE DATA
1. Forced vital capacity (l) (FVC)
Amsterdam Erfurt Helsinki Total
N 386 491 417 1294
Mean (sd) 3.4 (1.0) 3.7 (0.8) 3.0 (0.7) 3.4 (0.9)
Min – Max 1.4 – 5.6 2.1 – 6.6 1.6 – 5.0 1.4 – 6.6
Median 3.4 3.7 2.9 3.3
25%-75% 2.5 – 4.2 3.2 – 4.2 2.5 – 3.4 2.8 – 4.0
2. Forced expiratory volume in one second (l) (FEV1)
Amsterdam Erfurt Helsinki Total
N 386 491 417 1294
Mean (sd) 2.4 (0.8) 2.8 (0.6) 2.2 (0.6) 2.5 (0.7)
Min – Max 1.0 – 4.6 1.4 – 4.5 1.1 – 4.0 1.0 – 4.6
Median 2.4 2.8 2.2 2.5
25%-75% 1.6 – 3.0 2.4 – 3.2 2.0 – 2.5 2.0 – 3.0
3. Peak expiratory flow (l/s) (PEF)
Amsterdam Erfurt Helsinki Total
N 386 491 417 1294
Mean (sd) 6.9 (2.5) 7.5 (1.9) 7.0 (1.8) 7.1 (2.1)
Min – Max 1.9 – 12.8 3.0 – 11.6 3.6 – 12.5 2.0 – 12.8
Median 7.1 7.6 6.6 7.1
25%-75% 4.6 – 8.7 6.3 – 8.8 5.7 – 7.9 5.7 – 8.5
4. Maximal mid-expiratory flow (l/s) (MMEF)
Amsterdam Erfurt Helsinki Total
N 384 491 417 1292
Mean (sd) 1.5 (1.0) 2.2 (0.9) 1.9 (0.8) 1.9 (1.0)
Min – Max 0.3 – 5.3 0.7 – 9.1 0.6 – 4.5 0.3 – 9.1
Median 1.2 2.1 1.7 1.8
25%-75% 0.7 – 1.9 1.6 – 2.8 1.4 – 2.2 1.2 – 2.4
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Amsterdam Erfurt Helsinki Total
N 416 483 453 1352
Mean (sd) 21 (47) 48 (81) 22 (34) 31 (60)
Min – Max 1 – 330 1 – 783 1 – 271 1 – 783
Median 5 18 6 9
25%-75% 1 – 16 6 – 61 1 – 27 2 – 33
6. Urinary creatinine (g/l) (CREAT)
Amsterdam Erfurt Helsinki Total
N 416 483 453 1352
Mean (sd) 0.9 (0.5) 1.2 (0.6) 1.0 (0.6) 1.0 (0.6)
Min – Max 0.2 – 3.2 0.1 – 3.7 0.1 – 3.4 0.1 – 3.7
Median 0.8 1.1 1.0 0.9
25%-75% 0.5 – 1.1 0.7 – 1.5 0.6 – 1.4 0.6 – 1.4
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3.8 AMBULATORY ECG (HOLTER)
1. Total duration of ambulatory ECG monitoring (ECGTIME)
Amsterdam Erfurt Helsinki Total
N 413 472 509 1394
Mean (sd) 41 (4.4) 38 (2.1) 35 (4.6) 38 (4.5)
Min – Max 1 – 55 31 – 50 21 – 47 1 – 55
Median 40 38 36 38
25%-75% 38 – 43 37 – 39 35 – 37 36 – 40
2. Average heart rate during the whole monitoring period (HRAVE)
Amsterdam Erfurt Helsinki Total
N 413 472 509 1394
Mean (sd) 66 (10.1) 70 (8.9) 67 (8.3) 68 (9.3)
Min – Max 37 – 89 53 – 104 45 – 103 37 – 104
Median 65 69 67 67
25%-75% 59 – 74 63 – 76 62 – 72 62 – 74
3. Maximum heart rate during the whole monitoring period (HRMAX)
Amsterdam Erfurt Helsinki Total
N 413 472 509 1394
Mean (sd) 93 (18.9) 96 (12.3) 99 (16.9) 96 (16)
Min – Max 50 – 178 73 – 153 56 – 175 50 – 178
Median 91 95 100 96
25%-75% 80 – 101 88 – 101 90 – 105 86 – 104
4. Minimum heart rate during the whole monitoring period (HRMIN)
Amsterdam Erfurt Helsinki Total
N 413 472 509 1394
Mean (sd) 53 (8.2) 57 (8.4) 54 (6.8) 55 (8.0)
Min – Max 32 – 73 35 – 93 39 – 76 32 – 93
Median 53 57 54 55
25%-75% 47 – 59 52 – 62 49 – 59 49 – 60
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5. Ventricular ectopic beats during 5 min of exercise  (VES)
Amsterdam Erfurt Helsinki Total
N 376 464 405 1245
Mean (sd) 2.2 (5.6) 6.7 (21.4) 3.4 (11.1) 4.3 (15.0)
Min – Max 0 – 69 0 – 223 0 – 121 0 – 223
Median 0 0 0 0
25%-75% 0 – 2 0 – 2 0 – 1 0 – 2
6. Supraventricular ectopic beats during 5 min of exercise (SVES)
Amsterdam Erfurt Helsinki Total
N 355 442 404 1201
Mean (sd) 2.1 (6.5) 0.9 (3.4) 1.4 (3.5) 1.4 (4.6)
Min – Max 0 – 50 0 – 38 0 – 25 0 – 50
Median 0 0 0 0
25%-75% 0 – 1 0 – 0 0 – 1 0 – 1
7. Average PR-interval during the rest (PRINTERV)
Amsterdam Erfurt Helsinki Total
N 393 444 479 1316
Mean (sd) 189 (28) 185 (31) 189 (31) 188 (30)
Min – Max 108 – 273 109 – 307 114 – 308 108 – 308
Median 188 180 188 185
25%-75% 172 – 208 167 – 198 164 – 206 169 – 203
8. Total ventricular ectopic beats during the whole monitoring period (TOTALVE)
Amsterdam Erfurt Helsinki Total
N 413 472 509 1394
Mean (sd) 18 (35) 27 (91) 18 (61) 21 (68)
Min – Max 0 – 215 0 – 903 0 – 580 0 – 903
Median 2 2 1 2
25%-75% 0 -  17 0 – 15 0 – 5 0 – 12
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9. Single ventricular ectopic beats during the whole monitoring period (SINGLEVE)
Amsterdam Erfurt Helsinki Total
N 413 472 509 1394
Mean (sd) 17 (32) 22 (61) 12 (33) 17 (44)
Min – Max 0 – 215 0 – 651 0 – 283 0 – 651
Median 2 2 1 1
25%-75% 0 – 16 0 – 15 0 – 5 0 – 11
10. Paroxysmal supraventricular tachycardias during the whole monitoring period
(PSVT)
Amsterdam Erfurt Helsinki Total
N 413 472 509 1394
Mean (sd) 0.044 (0.20) 0.023 (0.18) 0.159 (1.03) 0.079 (0.64)
Min – Max 0 – 1 0 – 2 0 – 16 0 – 16
Median 0 0 0 0
25%-75% 0 – 0 0 – 0 0 – 0 0 – 0
11. Single supraventricular ectopic beats during the whole monitoring period
(SINGLSVE)
Amsterdam Erfurt Helsinki Total
N 413 472 509 1394
Mean (sd) 7.8 (17.5) 4.6 (14.1) 5.1 (11.1) 5.8 (14.3)
Min – Max 0 – 131 0 – 123 0 – 99 0 – 131
Median 2 1 1 1
25%-75% 0 – 5 0 – 3 0 – 4 0 – 4
12. Correction in ST level (STLEVEL)
Amsterdam Erfurt Helsinki Total
N 165 236 231 632
Mean (sd) -0.42 (0.44) -1.00 (1.24) -0.47 (0.56) -0.65 (0.90)
Min – Max -2.16 - -0.04 -5 - -0.04 -3.52 - -0.04 -5 - -0.04
Median -0.24 -0.56 -0.24 -0.32
25%-75% -0.6 - -0.08 -1.24 - -0.22 -0.52 - -0.12 -0.8 - -0.16
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13. 1st ST-depression episode (EPISODE1)
Amsterdam Erfurt Helsinki Total
n % n % N % N %
Missing 404 94 451 92 345 67 1200 83
1 25 6 40 8 173 33 238 17
14. Duration of 1st ST-depression episode (DUR1)
Amsterdam Erfurt Helsinki Total
N 24 37 167 228
Mean (sd) 6:04 (5:0) 4:41 (4:55) 6:14 (5:00) 5:58 (5:00)
Min – Max 0:30 - 22:30 0:30 - 19:30 0:30 – 25:30 0:30 - 25:30
Median 5:00 2:30 5:30 5:00
25%-75% 2:00 – 7:30 1:00 – 7:00 1:30 –9:30 1:30 – 9:30
15. Deviation of ST level in 1st ST-depression episode (STLEDEV1)
Amsterdam Erfurt Helsinki Total
N 26 38 173 238
Mean (sd) -1.06 (0.61) -1.10 (0.98) -1.17 (0.55) -1.14 (0.64)
Min – Max -3.52 - -0.56 -5 - -0.56 -3.24 - -0.56 -5 - -0.56
Median -0.84 -0.82 -1 -0.96
25%-75% -1.24 - -0.72 -1.12 - -0.68 -1.44 - -0.76 -1.36 - -0.72
16. Slope of 1st St-depression episode (SLOPE1)
1 = less than -0.2mV/s
2 = between -0.2 and +0.2mV/s
3 = more than +0.2mV/s
Amsterdam Erfurt Helsinki Total
n % N % n % n %
Missing 404 94 451 92 345 67 1200 83
1 14 3 9 2 60 12 83 6
2 8 2 22 4 63 12 93 6
3 3 1 9 2 50 10 62 4
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17. Area of 1st ST-depression episode (INTEGRA1)
Amsterdam Erfurt Helsinki Total
N 24 37 167 228
Mean (sd) 5.6 (7.3) 3.6 (4.4) 5.8 (6.5) 5.4 (6.3)
Min – Max 0.6 – 34.7 0.3 – 20.5 0.3 – 55.6 0.3 – 55.6
Median 3.6 1.6 3.7 3.6
25%-75% 1.4 – 5.6 0.7 – 4.8 1.1 – 8.0 1.0 – 7.7
18. 2nd ST-depression episode (EPISODE2)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 422 98 475 97 479 92 1376 96
2 7 2 16 3 39 8 62 4
19. Duration of 2nd ST-depression episode (DUR2)
Amsterdam Erfurt Helsinki Total
N 7 15 36 58
Mean (sd) 7 :04 (5:28) 4:38 (5:55) 4:45 (4:31) 5:00 (4:59)
Min - Max 1:30 - 16:00 1:00 - 22:30 0:30 - 23:30 0:30 - 23:30
Median 5:00 2:00 3:15 3:00
25%-75% 2:30 - 11:00 1:00 - 5:30 1:30 - 8:00 1:30 - 8:00
20. Deviation of ST level in 2nd ST-depression episode (STLEDEV2)
Amsterdam Erfurt Helsinki Total
N 7 16 39 62
Mean (sd) -1.03 (0.34) -0.84 (0.41) -1.07 (0.46) -1.01 (0.44)
Min – Max -1.6 - -0.68 -2.24 – 0.56 -2.28 - -0.56 -2.28 - -0.56
Median -1 -0.7 -1 -0.82
25%-75% -1.28 - -0.72 -0.82 - -0.64 -1.36 - -0.68 -1.16 - -0.68
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21. Slope of 2nd St-depression episode (SLOPE2)
1 = less than -0.2mV/s
2 = between -0.2 and +0.2mV/s
3 = more than +0.2mV/s
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 422 98 475 97 479 92 1376 96
1 5 1 0 0 11 2 16 1
2 2 0 13 3 16 3 31 2
3 0 0 3 1 12 2 15 1
22. Area of 2nd ST-depression episode (INTEGRA2)
Amsterdam Erfurt Helsinki Total
N 7 15 36 58
Mean (sd) 6.4 (6.0) 3.8 (6.0) 4.1 (5.2) 4.3 (5.5)
Min – Max 1.0 – 17 0.6 – 20.3 0.3 – 29.3 0.3 – 29.3
Median 3.4 0.9 2.2 1.9
25%-75% 1.7 – 10.6 0.6 – 3.5 1.0 – 5.9 0.9 – 6.2
23. 3rd ST-depression episode (EPISODE3)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 427 100 483 98 512 99 1422 99
3 2 0 8 2 6 1 16 1
24. Duration of 3rd ST-depression episode (DUR3)
Amsterdam Erfurt Helsinki Total
N 2 8 5 15
Mean (sd) 10:45 (3:11) 4:53 (3:39) 3:18 (5:12) 5:08 (4:34)
Min - Max 8:30 - 13.00 0:30 - 10:30 0:30 - 12:30 0:30 - 13:00
Median 10:45 4:30 0:30 3:00
25%-75% 8:30 - 13:00 1:45 - 7:45 0:30 - 2:30 0:30 - 8:30
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25. Deviation of ST level in 3rd ST-depression episode (STLEDEV3)
Amsterdam Erfurt Helsinki Total
N 2 8 6 16
Mean (sd) -1.14 (0.82) -0.81 (0.21) -0.94 (0.53) -0.90 (0.41)
Min – Max -1.72 - -0.56 -1.04 - -0.56 -1.96 - -0.64 -1.96 - -0.56
Median -1.14 -0.79 -0.66 -0.67
25%-75% -1.72 - -0.56 -1.02 - -0.62 -1.08 - -0.64 -1.04 - -0.64
26. Slope of 3rd St-depression episode (SLOPE3)
1 = less than -0.2mV/s
2 = between -0.2 and +0.2mV/s
3 = more than +0.2mV/s
Amsterdam Erfurt Helsinki Total
n % N % n % N %
Missing 428 100 483 98 512 99 1423 99
1 1 0 0 0 2 0 3 0
2 0 0 6 1 1 0 7 0
3 0 0 2 0 3 1 5 0
27. Area of 3rd ST-depression episode (INTEGRA3)
Amsterdam Erfurt Helsinki Total
N 2 8 5 15
Mean (sd) 9.8 (7.2) 3.4 (2.6) 2.7 (4.1) 4.0 (4.2)
Min – Max 4.8 – 14.9 0.6 – 8.0 0.3 – 9.9 0.3 – 14.9
Median 9.8 3.0 1.0 1.9
25%-75% 4.8 – 14.9 1.2 – 5.0 0.6 – 1.6 1.0 – 5.3
28. 4th ST-depression episode (EPISODE4)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 429 100 488 99 516 100 1433 100
4 0 0 3 1 2 0 5 0
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29. Duration of 4th ST-depression episode (DUR4)
Amsterdam Erfurt Helsinki Total
N 0 3 2 5
Mean (sd) - 0:50 (0:17) 4:45 (4:36) 2:24 (3:09)
Min – Max - 0:30 – 1:00 1:30 – 8:00 0:30 – 8:00
Median - 1:00 4:45 1:00
25%-75% - 0:30 – 1:00 1:30 – 8:00 1:00 – 1:30
30. Deviation of ST level in 4th ST-depression episode (STLEDEV4)
Amsterdam Erfurt Helsinki Total
N 0 3 2 5
Mean (sd) - -0.67 (0.02) -1.16 (0.11) -0.86 (0.28)
Min – Max - -0.68 - -0.64 -1.24 - -1.08 -1.24 - -0.64
Median - -0.68 -1.16 -0.68
25%-75% - -0.68 - -0.64 -1.24 - -1.08 -1.08 - -0.68
31. Slope of 4th St-depression episode (SLOPE4)
1 = less than -0.2mV/s
2 = between -0.2 and +0.2mV/s
3 = more than +0.2mV/s
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 429 100 488 100 516 100 1433 100
1 0 0 0 0 0 0 0 0
2 0 0 1 0 0 0 1 0
3 0 0 2 0 2 0 4 0
32. Area of 4th ST-depression episode (INTEGRA4)
Amsterdam Erfurt Helsinki Total
N 0 3 2 5
Mean (sd) - 0.5 (0.2) 4.9 (4.1) 2.3 (3.2)
Min – Max - 0.3 - 0.6 2.0 - 7.8 0.3 – 7.8
Median - 0.6 4.9 0.6
25%-75% - 0.3 - 0.6 2.0 - 7.8 0.6 – 2.0
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33. 5th ST-depression episode (EPISODE5)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 429 100 489 100 518 100 1436 100
5 0 0 2 0 0 0 2 0
34. Duration of 5th ST-depression episode (DUR5)
Amsterdam Erfurt Helsinki Total
N 0 1 0 1
Mean (sd) - 1:00 (0) - 1:00 (0)
Min – Max - - - -
Median - - - -
25%-75% - - - -
35. Deviation of ST level in 5th ST-depression episode (STLEDEV5)
Amsterdam Erfurt Helsinki Total
N 0 2 0 2
Mean (sd) - -0.7 (0.14) - -0.7 (0.14)
Min – Max - -0.8 - -0.6 - -0.8 - -0.6
Median - -0.7 - -0.7
25%-75% - -0.8 - -0.6 - -0.8 - -0.6
36. Slope of 5th St-depression episode (SLOPE5)
1 = less than -0.2mV/s
2 = between -0.2 and +0.2mV/s
3 = more than +0.2mV/s
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 429 100 489 100 518 100 1436 100
1 0 0 0 0 0 0 0 0
2 0 0 2 0 0 0 2 0
3 0 0 0 0 0 0 0 0
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37. Area of 5th ST-depression episode (INTEGRA5)
Amsterdam Erfurt Helsinki Total
N 0 1 0 1
Mean (sd) - 0.6 (0) - 0.6 (0)
Min – Max - - - -
Median - - - -
25%-75% - - - -
38. Mean of all filtered RR intervals during the whole monitoring period (TOTMEAN)
Amsterdam Erfurt Helsinki Total
N 367 429 433 1229
Mean (sd) 939 (160) 857 (102) 901 (103) 897 (127)
Min – Max 663 – 1580 571 – 1109 679 – 1310 571 – 1580
Median 929 862 885 886
25%-75% 817 – 1025 783 – 934 831 – 954 811 – 963
39. Standard deviation of all filtered RR intervals during the whole monitoring period
(TOTSDNN)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 94 (37) 88 (31) 125 (47) 103 (43)
Min – Max 28 – 213 14 – 192 29 – 261 14 – 261
Median 89 84 123 97
25%-75% 67 – 114 65 – 108 90 – 161 71 – 128
40. Mean of the standard deviations of all filtered RR intervals for all 5 minute
segments during the whole monitoring period (TOTSDNNI)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 56 (21) 50 (17) 57 (20) 54 (20)
Min – Max 20 – 168 5 – 108 18 – 129 5 – 168
Median 54 49 55 53
25%-75% 40 – 70 38 – 59 43 – 66 40 – 65
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41. Standard deviation of the means of all filtered RR intervals for all 5 minute
segments during the whole monitoring period (TOTSDANN)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 68 (30) 64 (26) 97 (41) 77 (36)
Min – Max 12 – 170 8 – 156 9 – 217 8 – 217
Median 63 62 94 72
25%-75% 47 – 85 46 – 82 68 – 125 50 – 97
42. Square root of the mean of the sum of squares of differences between adjacent
filtered RR intervals for all 5 minute segments during the whole monitoring period
(TOTRMSSD)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 36 (27) 29 (18) 35 (23) 33 (23)
Min – Max 9 – 224 8 – 129 10 – 139 8 – 224
Median 27 24 27 26
25%-75% 20 – 43 17 – 34 20 – 39 19 – 39
43. Percentages of differences between adjacent filtered RR intervals that are greater
than 50 ms during the whole monitoring period (TOTPNN50)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 9.2 (10.3) 6.9 (8.3) 8.7 (10.9) 8.2 (9.9)
Min – Max 0 – 54.6 0 – 52.3 0 – 67.9 0 – 67.9
Median 4.5 3.7 5.0 4.4
25%-75% 1.3 – 14.1 1.1 – 9.8 1.8 – 10.1 1.4 – 11.1
44. Number of RR intervals during the whole monitoring period (TOTINTER)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 2685 (490) 2735 (376) 2406 (412) 2604 (450)
Min – Max 1516 – 4663 1975 – 4482 1088 – 3294 1088 – 4663
Median 2674 2698 2470 2602
25%-75% 2368 – 2991 2451 – 2951 2223 – 2675 2357 – 2872
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45. Power from spectral analysis of heart rate variability, overall band (0-0.4 Hz), the
whole monitoring period (TOTPOWER)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 2618 (1770) 2149(1535) 2446 (1924) 2393 (1759)
Min – Max 338 – 9913 99 – 11537 310 – 12048 99 – 12048
Median 2218 1759 1950 1942
25%-75% 1284 – 3590 1039 – 2782 1190 – 2914 1151 – 3108
46. Power from spectral analysis of heart rate variability, band 1 (0-0.0033 Hz), the
whole monitoring period (TOTPOW1)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 276 (212) 300 (294) 404 (312) 329 (285)
Min – Max 24 – 1274 14 – 3258 10 – 1985 10 – 3258
Median 212 210 313 244
25%-75% 124 – 356 117 – 398 176 – 564 133 – 440
47. Power from spectral analysis of heart rate variability, band 2 (0.0033-0.04 Hz), the
whole monitoring period (TOTPOW2)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 1505 (1069) 1286 (968) 1240 (858) 1335 (969)
Min – Max 217 – 6132 66 -  8337 100 – 6548 66 – 8337
Median 1170 1070 1065 1089
25%-75% 772 – 1969 616 – 1628 690 – 1547 684 – 1680
48. Power from spectral analysis of heart rate variability, band 3 (0.04-0.15 Hz), the
whole monitoring period (TOTPOW3)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 522 (472) 357 (345) 433 (639) 433 (506)
Min – Max 29 – 2982 14 – 2925 17 – 5948 14 – 5948
Median 389 249 218 264
25%-75% 174 – 721 138 – 446 116 – 431 136 – 533
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49. Power from spectral analysis of heart rate variability, band 4 (0.15-0.4 Hz), the
whole monitoring period (TOTPOW4)
Amsterdam Erfurt Helsinki Total
N 366 430 433 1229
Mean (sd) 316 (390) 216 (306) 369 (598) 300 (456)
Min – Max 12 – 2664 5 – 1991 12 – 4318 5 – 4318
Median 174 110 155 143
25%-75% 74 – 406 57 – 237 76 – 332 68 – 314
50. Average absolute QT interval, the whole monitoring period (TOTQTAV)
Amsterdam Erfurt Helsinki Total
N 403 448 454 1305
Mean (sd) 372 (32) 361 (33) 379 (34) 371 (34)
Min – Max 277 – 486 283 – 478 189 – 511 189 – 511
Median 373 359 380 372
25%-75% 349 – 396 339 – 382 357 – 398 346 – 393
51. Average absolute QTc interval, the whole monitoring period (TOTQTCAV)
Amsterdam Erfurt Helsinki Total
N 403 448 454 1305
Mean (sd) 388 (28) 389 (28) 399 (31) 392 (29)
Min – Max 308 – 508 242 – 494 172 – 548 172 – 548
Median 387 390 400 391
25%-75% 372 – 400 370 – 404 379 – 416 374 – 408
52. Mean of all filtered RR intervals during the rest, spontaneous breathing
(SPOMEAN)
Amsterdam Erfurt Helsinki Total
N 366 427 468 1261
Mean (sd) 983 (175) 907 (124) 995 (126) 962 (147)
Min – Max 656 – 1650 602 – 1193 718 – 1340 602 – 1650
Median 967 902 979 948
25%-75% 848 – 1088 818 – 1002 901 – 1086 860 – 1055
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53. Standard deviation of all filtered RR intervals during rest, spontaneous breathing
(SPOSDNN)
Amsterdam Erfurt Helsinki Total
N 366 427 468 1261
Mean (sd) 48 (24) 40 (19) 44 (23) 44 (22)
Min – Max 10 – 221 8 – 139 12 – 180 8 – 221
Median 44 36 39 39
25%-75% 32 – 60 27 – 51 28 – 53 28 – 54
54. Square root of the mean of the sum of squares of differences between adjacent
filtered RR intervals for all 5 minute segments during the rest, spontaneous breathing
(SPORMSSD)
Amsterdam Erfurt Helsinki Total
N 366 427 468 1261
Mean (sd) 33 (31) 29 (24) 35 (30) 32 (28)
Min – Max 7 – 266 6 – 251 9 – 228 6 – 266
Median 23 22 25 24
25%-75% 16 – 39 15 – 32 17 – 38 16 – 37
55. Percentages of differences between adjacent filtered RR intervals that are greater
than 50 ms during the rest, spontaneous breathing (SPOPNN50)
Amsterdam Erfurt Helsinki Total
N 366 427 468 1261
Mean (sd) 8.1 (11.1) 7.3 (11.1) 10.8 (16.1) 8.8 (13.3)
Min – Max 0 -  57.1 0 – 70.1 0 – 92.5 0 – 92.5
Median 2.9 2.4 4.1 3.1
25%-75% 0.6 – 11.1 0.4 – 9.6 0.9 – 12.8 0.6 – 11.1
56. Number of RR intervals during the rest, spontaneous breathing (SPOINTER)
Amsterdam Erfurt Helsinki Total
N 366 427 468 1261
Mean (sd) 308 (55) 332 (53) 302 (41) 314 (51)
Min – Max 63 – 456 81 – 497 107 – 416 63 – 497
Median 305 330 303 312
25%-75% 271 – 348 297 – 364 273 – 331 280 – 345
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57. Power from spectral analysis of heart rate variability, overall band (0-0.4 Hz), the
rest, spontaneous breathing (SPOPOWER)
Amsterdam Erfurt Helsinki Total
N 359 426 465 1250
Mean (sd) 2147 (1997) 1665 (1734) 2002 (2402) 1930 (2085)
Min – Max 87 – 18981 44 – 14921 120 – 18633 44 – 18981
Median 1603 1096 1226 1289
25%-75% 846 – 2831 624 – 2042 630 – 2315 669 – 2418
58. Power from spectral analysis of heart rate variability, band 1 (0-0.0033 Hz), the rest,
spontaneous breathing (SPOPOW1)
Amsterdam Erfurt Helsinki Total
N 359 426 465 1250
Mean (sd) 137 (222) 91 (143) 115 (214) 113 (196)
Min – Max 0 – 1649 0 – 1176 0 – 2099 0 – 2099
Median 60 40 48 47
25%-75% 20 – 157 15 – 99 13 – 124 16 – 124
59. Power from spectral analysis of heart rate variability, band 2 (0.0033-0.04 Hz), the
rest, spontaneous breathing (SPOPOW2)
Amsterdam Erfurt Helsinki Total
N 359 426 465 1250
Mean (sd) 1180 (1257) 912 (1088) 843 (986) 963 (1112)
Min – Max 51 – 13138 23 – 8684 24 – 13182 23 – 13182
Median 820 555 545 651
25%-75% 475 – 1531 303 – 1074 287 – 994 330 – 1194
60. Power from spectral analysis of heart rate variability, band 3 (0.04-0.15 Hz), the
rest, spontaneous breathing (SPOPOW3)
Amsterdam Erfurt Helsinki Total
N 359 426 465 1250
Mean (sd) 513 (600) 410 (489) 581 (964) 503 (732)
Min – Max 8 – 4758 7 – 3542 14 – 8769 7 – 8769
Median 303 251 268 268
25%-75% 123 – 684 136 – 463 119 – 553 125 – 567
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61. Power from spectral analysis of heart rate variability, band 4 (0.15-0.4 Hz), the rest,
spontaneous breathing (SPOPOW4)
Amsterdam Erfurt Helsinki Total
N 359 426 465 1250
Mean (sd) 318 (528) 254 (484) 466 (900) 351 (685)
Min – Max 7 – 3329 3 – 5398 11 – 5764 3 – 5764
Median 125 95 161 128
25%-75% 56 – 324 43 – 219 66 – 372 55 – 305
62. Mean of all filtered RR intervals during the rest, paced breathing (PACMEAN)
Amsterdam Erfurt Helsinki Total
N 366 432 468 1266
Mean (sd) 1006 (422) 926 (133) 995 (132) 975 (255)
Min – Max 647 – 8327 371 – 1246 714 – 1380 371 – 8327
Median 968 925 974 954
25%-75% 854 – 1087 831 – 1027 900 – 1089 868 – 1065
63. Standard deviation of all filtered RR intervals during rest, paced breathing
(PACSDNN)
Amsterdam Erfurt Helsinki Total
N 366 432 468 1266
Mean (sd) 40 (24) 33 (19) 37 (22) 36 (22)
Min – Max 9 – 287 6 – 143 8 – 137 6 – 287
Median 36 28 31 31
25%-75% 24 – 47 21 – 39 22 – 44 22 – 43
64. Square root of the mean of the sum of squares of differences between adjacent
filtered RR intervals for all 5 minute segments during the rest, paced breathing
(PACRMSSD)
Amsterdam Erfurt Helsinki Total
N 366 432 468 1266
Mean (sd) 33 (32) 28 (27) 34 (31) 32 (30)
Min – Max 6 – 304 7 – 216 7 – 250 6 – 304
Median 23 20 23 22
25%-75% 15 – 36 13 – 31 15 – 38 15 – 35
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65. Percentages of differences between adjacent filtered RR intervals that are greater
than 50 ms during the rest, paced breathing (PACPNN50)
Amsterdam Erfurt Helsinki Total
N 366 432 468 1266
Mean (sd) 9.0 (13.3) 7.4 (12.4) 10.4 (16.9) 9.0 (14.5)
Min – Max 0 – 70.5 0 – 74.7 0 – 85.1 0 – 85.1
Median 2.5 1.8 2.3 2.1
25%-75% 0.3 – 13.5 0 – 8.5 0.3 – 11.7 0.3 – 10.9
66. Number of RR intervals during the rest, paced breathing (PACINTER)
Amsterdam Erfurt Helsinki Total
N 366 432 468 1266
Mean (sd) 308 (54) 326 (49) 303 (41) 312 (49)
Min – Max 119 – 463 212 – 496 179 – 419 119 – 496
Median 304 321 302 310
25%-75% 272 – 348 289 – 353 273 – 330 277 – 343
67. Power from spectral analysis of heart rate variability, overall band (0-0.4 Hz), the
rest, paced breathing (PACPOWER)
Amsterdam Erfurt Helsinki Total
N 358 431 465 1254
Mean (sd) 1293 (1324) 1134 (1759) 1496 (2061) 1314 (1777)
Min – Max 51 – 11281 21 – 17947 63 – 13834 21 – 17947
Median 1004 606 715 737
25%-75% 378 – 1620 332 – 1205 368 – 1495 355 – 1454
68. Power from spectral analysis of heart rate variability, band 1 (0-0.0033 Hz), the rest,
paced breathing (PACPOW1)
Amsterdam Erfurt Helsinki Total
N 358 431 465 1254
Mean (sd) 80 (142) 64 (160) 62 (210) 68 (176)
Min – Max 0 – 966 0 – 1705 0 – 3578 0 – 3578
Median 33 22 19 23
25%-75% 11 – 86 6 – 57 7 – 57 7 – 63
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69. Power from spectral analysis of heart rate variability, band 2 (0.0033-0.04 Hz), the
rest, paced breathing (PACPOW2)
Amsterdam Erfurt Helsinki Total
N 358 431 465 1254
Mean (sd) 505 (570) 412 (583) 423 (533) 443 (562)
Min – Max 19 – 4330 6 – 5750 15 – 6603 6 – 6603
Median 330 230 262 262
25%-75% 158 – 645 123 – 438 146 – 489 143 – 526
70. Power from spectral analysis of heart rate variability, band 3 (0.04-0.15 Hz), the
rest, paced breathing (PACPOW3)
Amsterdam Erfurt Helsinki Total
N 358 431 465 1254
Mean (sd) 285 (460) 313 (737) 378 (817) 329 (704)
Min – Max 5 – 4490 4 – 8558 7 – 7837 4 – 8558
Median 162 126 114 128
25%-75% 54 – 332 59 – 275 56 – 290 57 – 294
71. Power from spectral analysis of heart rate variability, band 4 (0.15-0.4 Hz), the rest,
paced breathing (PACPOW4)
Amsterdam Erfurt Helsinki Total
N 358 431 465 1254
Mean (sd) 423 (624) 345 (745) 633 (1168) 474 (907)
Min – Max 6 – 5254 6 – 6831 10 – 8145 6 – 8145
Median 176 126 205 161
25%-75% 80  - 480 49 – 298 75 – 586 68 – 436
72. Mean of all filtered RR intervals during standing (STAMEAN)
Amsterdam Erfurt Helsinki Total
N 366 432 464 1262
Mean (sd) 912 (162) 833 (107) 928 (140) 891 (143)
Min – Max 643 – 1519 531 – 1138 611 – 1346 531 – 1519
Median 894 830 904 880
25%-75% 791 – 1003 753 – 911 830 – 1024 789 – 973
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73. Standard deviation of all filtered RR intervals during standing (STASDNN)
Amsterdam Erfurt Helsinki Total
N 366 432 464 1262
Mean (sd) 53 (25) 47 (18) 51 (20) 50 (21)
Min – Max 12 – 185 14 – 124 15 – 172 12 – 185
Median 48 44 47 47
25%-75% 36 – 63 32 – 58 37 – 62 35 – 60
74. Square root of the mean of the sum of squares of differences between adjacent
filtered RR intervals for all 5 minute segments during standing (STARMSSD)
Amsterdam Erfurt Helsinki Total
N 366 432 464 1262
Mean (sd) 38 (123) 25 (15) 29 (23) 30 (68)
Min – Max 7 – 2336 7 – 142 7 – 168 7 – 2336
Median 24 20 22 21
25%-75% 16 – 40 15 – 29 16 – 32 15 – 33
75. Percentages of differences between adjacent filtered RR intervals that are greater
than 50 ms during standing (STAPNN50)
Amsterdam Erfurt Helsinki Total
N 366 432 464 1262
Mean (sd) 7.5 (9.7) 5.8 (8.4) 7.3 (11.0) 6.8 (9.8)
Min – Max 0 – 57.7 0 – 55.2 0 – 63.0 0 – 63.0
Median 3.2 2.2 2.7 2.7
25%-75% 0.6 – 11.6 0.5 – 7.6 0.9 – 8.3 0.6 – 8.5
76. Number of RR intervals during standing (STAINTER)
Amsterdam Erfurt Helsinki Total
N 366 432 464 1262
Mean (sd) 335 (56) 360 (52) 321 (51) 339 (55)
Min – Max 196 – 466 246 – 564 175 – 461 175 – 564
Median 334 354 322 336
25%-75% 295 – 378 322 – 395 285 – 356 300 – 376
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77. Power from spectral analysis of heart rate variability, overall band (0-0.4 Hz),
standing (STAPOWER)
Amsterdam Erfurt Helsinki Total
N 360 430 462 1252
Mean (sd) 2560 (2564) 1887 (1593) 2321 (2047) 2241 (2092)
Min – Max 125 – 17549 99 – 13757 183 – 16478 99 – 17549
Median 1749 1382 1751 1657
25%-75% 913 – 3282 791 – 2558 1011 – 2757 893 – 2801
78. Power from spectral analysis of heart rate variability, band 1 (0-0.0033 Hz),
standing (STAPOW1)
Amsterdam Erfurt Helsinki Total
N 360 430 462 1252
Mean (sd) 250 (557) 170 (288) 228 (375) 214 (413)
Min – Max 1 – 6608 1 – 3416 1 – 4390 1 – 6608
Median 84 72 105 88
25%-75% 29 – 221 25 – 202 38 – 274 30 – 235
79. Power from spectral analysis of heart rate variability, band 2 (0.0033-0.04 Hz),
standing (STAPOW2)
Amsterdam Erfurt Helsinki Total
N 360 430 462 1252
Mean (sd) 1514 (1664) 1114 (1057) 1306 (1088) 1300 (1280)
Min – Max 35 – 10676 31 – 11767 69 – 8785 31 – 11767
Median 964 803 998 930
25%-75% 531 – 1765 431 – 1530 558 – 1724 508 – 1659
80. Power from spectral analysis of heart rate variability, band 3 (0.04-0.15 Hz),
standing (STAPOW3)
Amsterdam Erfurt Helsinki Total
N 360 430 462 1252
Mean (sd) 544 (643) 430 (461) 496 (711) 487 (616)
Min – Max 17 – 5176 11 – 3126 10 – 5779 10 – 5779
Median 334 266 261 285
25%-75% 139 – 705 136 – 521 109 – 592 128 – 593
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81. Power from spectral analysis of heart rate variability, band 4 (0.15-0.4 Hz), standing
(STAPOW4)
Amsterdam Erfurt Helsinki Total
N 360 430 462 1252
Mean (sd) 251 (373) 174 (257) 292 (642) 239 (466)
Min – Max 5 – 3530 4 – 2302 6 – 7686 4 – 7686
Median 110 78 88 90
25%-75% 47 – 297 39 – 193 47 – 225 44 – 239
82. Mean of all filtered RR intervals during stress (STRMEAN)
Amsterdam Erfurt Helsinki Total
N 327 411 371 1109
Mean (sd) 802 (148) 735 (78) 672 (60) 734 (112)
Min – Max 567 – 1395 529 – 1052 536 – 893 529 – 1395
Median 783 737 653 716
25%-75% 698 – 868 687 – 780 633 – 700 652 – 784
83. Standard deviation of all filtered RR intervals during stress (STRSDNN)
Amsterdam Erfurt Helsinki Total
N 327 411 371 1109
Mean (sd) 36 (18) 37 (15) 34 (19) 35 (18)
Min – Max 9 – 152 10 – 103 11 – 150 9 – 152
Median 31 34 29 31
25%-75% 23 – 43 26 – 45 22 – 39 24 – 43
84. Square root of the mean of the sum of squares of differences between adjacent
filtered RR intervals for all 5 minute segments during stress (STRRMSSD)
Amsterdam Erfurt Helsinki Total
N 327 411 371 1109
Mean (sd) 29 (21) 21 (15) 24 (15) 25  (17)
Min – Max 8 – 149 7 – 97 7 – 103 7– 149
Median 23 16 21 20
25%-75% 15 – 35 11 – 26 15 – 30 13 – 30
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85. Percentages of differences between adjacent filtered RR intervals that are greater
than 50 ms during stress (STRPNN50)
Amsterdam Erfurt Helsinki Total
N 327 411 371 1109
Mean (sd) 7.8 (11.9) 4.7 (9.5) 5.0 (7.2) 5.7 (9.7)
Min – Max 0 – 74.2 0 – 79.9 0 – 58.2 0 – 79.9
Median 2.6 0.7 2.4 1.7
25%-75% 0.3 – 9.9 0 – 4.7 0.6 – 6.1 0.2 – 6.7
86. Number of RR intervals during stress (STRINTER)
Amsterdam Erfurt Helsinki Total
N 327 411 371 1109
Mean (sd) 384 (62) 410 (46) 446 (45) 414 (56)
Min – Max 214 – 528 255 – 559 160 – 559 160 – 559
Median 382 405 458 417
25%-75% 345 – 429 383 – 435 426 – 472 379 – 459
87. Mean of all filtered RR intervals during the rest, recovery (RECMEAN)
Amsterdam Erfurt Helsinki Total
N 366 431 463 1260
Mean (sd) 996 (181) 903 (121) 941 (116) 944 (144)
Min – Max 660 – 1679 604 – 1198 645 – 1350 604 – 1679
Median 970 911 927 932
25%-75% 866 – 1095 810 – 995 861 – 1004 845 – 1021
88. Standard deviation of all filtered RR intervals during rest, recovery (RECSDNN)
Amsterdam Erfurt Helsinki Total
N 366 431 463 1260
Mean (sd) 51 (26) 43 (19) 44 (24) 45 (23)
Min – Max 11 – 200 8 – 135 13 – 192 8 – 200
Median 47 39 38 40
25%-75% 33 – 63 29 – 53 28 – 52 29 – 55
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89. Square root of the mean of the sum of squares of differences between adjacent
filtered RR intervals for all 5 minute segments during the rest, recovery (RECRMSSD)
Amsterdam Erfurt Helsinki Total
N 366 431 463 1260
Mean (sd) 38 (41) 28 (22) 34 (26) 33 (30)
Min – Max 8 – 547 6 – 237 8 – 157 6 – 547
Median 26 23 25 25
25%-75% 18 – 46 15 – 35 18 – 39 17 – 38
90. Percentages of differences between adjacent filtered RR intervals that are greater
than 50 ms during the rest, recovery (RECPNN50)
Amsterdam Erfurt Helsinki Total
N 366 431 463 1260
Mean (sd) 10.3 (12.7) 7.5 (10.9) 9.1 (13.8) 8.9 (12.6)
Min – Max 0 – 63.2 0 – 79.2 0 – 78.1 0 – 79.2
Median 4.4 3.2 3.6 3.6
25%-75% 0.8 – 16.8 0.5 – 9.6 0.9 – 10.8 0.7 – 12.3
91. Number of RR intervals during the rest, recovery (RECINTER)
Amsterdam Erfurt Helsinki Total
N 366 431 463 1260
Mean (sd) 309 (51) 337 (47) 318 (43) 322 (49)
Min – Max 178 – 453 250 – 495 117 – 464 117 – 495
Median 308 328 321 319
25%-75% 273 – 345 300 – 369 292 – 346 292 – 353
92. Power from spectral analysis of heart rate variability, overall band (0-0.4 Hz), the
rest, recovery (RECPOWER)
Amsterdam Erfurt Helsinki Total
N 361 426 458 1245
Mean (sd) 2478 (2546) 1786 (1863) 1932 (2562) 2040 (2357)
Min – Max 114 – 23124 46 – 16662 85 – 18510 46 – 23124
Median 1733 1171 1091 1269
25%-75% 862 – 3107 631 – 2344 572 – 2153 651 – 2501
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93. Power from spectral analysis of heart rate variability, band 1 (0-0.0033 Hz), the rest,
recovery (RECPOW1)
Amsterdam Erfurt Helsinki Total
N 361 426 458 1245
Mean (sd) 171 (408) 108 (170) 101 (182) 124 (267)
Min – Max 0 – 5112 0 – 1537 0 – 1490 0 – 5112
Median 66 51 39 49
25%-75% 24 – 184 17 – 124 15 – 103 18 – 128
94. Power from spectral analysis of heart rate variability, band 2 (0.0033-0.04 Hz), the
rest, recovery (RECPOW2)
Amsterdam Erfurt Helsinki Total
N 361 426 458 1245
Mean (sd) 1267 (1389) 947 (1185) 819 (1071) 992 (1222)
Min – Max 61 – 8986 24 – 12447 32 – 10797 24 – 12447
Median 787 572 479 586
25%-75% 416 – 1504 318 – 1205 259 – 992 322 – 1205
95. Power from spectral analysis of heart rate variability, band 3 (0.04-0.15 Hz), the
rest, recovery (RECPOW3)
Amsterdam Erfurt Helsinki Total
N 361 426 458 1245
Mean (sd) 616 (687) 485 (594) 589 (1087) 561 (833)
Min – Max 15 – 4437 1 – 6126 7 – 8309 1 – 8309
Median 383 308 244 300
25%-75% 143 – 833 138 – 625 107 – 553 125 – 652
96. Power from spectral analysis of heart rate variability, band 4 (0.15-0.4 Hz), the rest,
recovery (RECPOW4)
Amsterdam Erfurt Helsinki Total
N 361 426 458 1245
Mean (sd) 366 (533) 248 (451) 423 (815) 347 (634)
Min – Max 5 – 3537 4 – 4474 6 – 6200 4 – 6200
Median 150 110 144 130
25%-75% 63 – 416 51 – 236 63 – 338 57 – 324
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97. Average absolute QT interval, the rest spontaneous breathing (SPOQTAV)
Amsterdam Erfurt Helsinki Total
N 413 452 507 1372
Mean (sd) 372 (38) 368 (43) 383 (42) 375 (42)
Min – Max 264 – 542 281 – 770 133 – 531 133 – 770
Median 371 363 386 374
25%-75% 343 – 401 344 – 390 355 – 408 347 – 401
98. Average absolute QTc interval, the rest spontaneous breathing (SPOQTCAV)
Amsterdam Erfurt Helsinki Total
N 413 452 507 1372
Mean (sd) 380 (32) 388 (39) 388 (37) 385 (37)
Min – Max 267 – 554 282 – 808 119 – 556 119 – 808
Median 381 387 388 385
25%-75% 361 – 397 367 – 402 366 – 410 366 – 403
99. Average absolute QT interval, stress (STRQTAV)
Amsterdam Erfurt Helsinki Total
N 372 450 385 1207
Mean (sd) 319 (29) 340 (38) 307 (28) 323 (35)
Min – Max 219 – 403 243 – 544 233 – 438 219 – 544
Median 320 337 305 321
25%-75% 300 – 337 317 – 359 290 – 322 299 – 341
100. Average absolute QTc interval, stress (STRQTCAV)
Amsterdam Erfurt Helsinki Total
N 372 450 385 1207
Mean (sd) 361 (28) 397 (39) 375 (32) 379 (37)
Min – Max 257 – 489 265 – 606 282 – 571 257 – 606
Median 360 394 373 374
25%-75% 344 – 372 374 – 416 360 – 389 357 – 397
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101. Average absolute QT interval, the rest recovery (RECQTAV)
Amsterdam Erfurt Helsinki Total
N 411 456 504 1371
Mean (sd) 347 (32) 360 (41) 355 (38) 354 (38)
Min – Max 228 – 448 273 – 682 166 – 580 166 – 682
Median 346 355 355 352
25%-75% 325 – 370 335 – 385 334 – 374 331 – 376
102. Average absolute QTc interval, the rest recovery (RECQTCAV)
Amsterdam Erfurt Helsinki Total
N 411 456 504 1371
Mean (sd) 353 (28) 381 (38) 368 (36) 368 (36)
Min – Max 248 – 481 260 – 738 153 – 662 153 – 738
Median 351 380 367 364
25%-75% 337 – 364 358 – 400 350 – 385 347 – 386
103. Atrial fibrillation in the ambulatory ECG (ATRFIBR)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Not reported/missing 416 97 463 94 489 94 1368 95
Yes 13 3 28 6 29 6 70 5
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3.9 DIARY
1. Chest pain today (CHPAIN)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 163 3 0 0 126 2 289 1
No 5755 92 5716 76 7249 93 18720 87
Slight 279 4 1678 22 413 5 2370 11
Severe 31 1 97 1 40 0 168 1
2. Chest pain at physical exertion today (CHPAINPH)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 159 3 0 0 129 2 288 1
No 5672 91 5886 79 7038 90 18596 86
Slight 370 6 1479 20 629 8 2478 12
Severe 27 0 126 2 32 0 185 1
3. Shortness of breath today (SHBREATH)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 159 3 0 0 120 2 279 1
No 5155 83 5705 76 6353 81 17213 80
Slight 797 13 1664 22 1105 14 3566 17
Severe 117 2 122 2 250 3 489 2
4. Feeling tired or weak today (TIRED)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 159 3 0 0 129 2 288 1
No 4797 77 5402 72 5962 76 16161 75
Slight 1164 19 1970 26 1520 19 4654 22
Severe 108 2 119 2 217 3 444 2
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5. Tripping or racing heart today (TRIHEART)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 160 3 0 0 150 2 310 1
No 5675 91 6625 88 6819 87 19119 89
Slight 383 6 788 11 699 9 1870 9
Severe 10 0 78 1 160 2 248 1
6. Cold hands or feet today (COLDHAND)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 159 3 0 0 141 2 300 1
No 5443 87 6135 82 5113 65 16691 77
Slight 621 10 1313 18 2059 26 3993 19
Severe 5 0 43 1 515 7 563 3
7. Cough today (COUGH)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 159 3 0 0 92 1 251 1
No 4625 75 6780 91 6008 77 17413 81
Slight 1310 21 656 9 1558 20 3524 16
Severe 134 2 55 1 170 2 359 2
8. Phlegm today (PHLEGM)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 159 3 0 0 109 1 268 1
No 4017 64 6479 86 5901 75 16397 76
Slight 1920 31 972 13 1685 22 4577 21
Severe 132 2 40 1 133 2 305 1
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9. Woken up with breathing problems today (WAKEUP)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 159 3 0 0 148 2 307 1
No 5792 93 6921 92 7176 92 19889 92
Slight 179 3 547 7 457 6 1183 5
Severe 98 2 23 0 47 1 168 1
10. Wheeze today (WHEEZE)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 159 3 0 0 134 2 293 1
No 5681 91 7001 93 7102 91 19784 92
Slight 299 5 460 6 530 7 1289 6
Severe 89 1 30 0 62 1 181 1
11. Common cold or flu today (COMMCOLD)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 161 3 0 0 137 2 298 1
No 5374 86 6730 90 7032 90 19136 89
Slight 670 11 703 9 581 7 1954 9
Severe 23 0 58 1 78 1 159 1
12. Fever today (FEVER)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 160 3 0 0 146 2 306 1
No 5951 96 7441 99 7623 97 21015 98
Slight 110 2 45 1 42 1 170 1
Severe 7 0 5 0 17 0 29 0
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13. Did you avoid physically demanding activities because of symptoms today?
(AVOIDACT)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 293 5 0 0 169 2 462 2
No 5173 83 6388 85 6827 87 18388 85
Slight 711 11 826 11 679 9 2216 10
Severe 51 1 277 4 153 2 481 2
14. How would you rate your overall health today? (HEALTH)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 256 4 0 0 107 1 363 2
Good 2607 42 2484 33 2771 35 7862 36
Quite good 2558 41 3021 40 1639 21 7218 34
Average 739 12 1734 23 2872 37 5345 25
Bad 68 1 225 3 422 5 715 3
Very bad 0 0 27 0 17 0 44 0
15. How long have you been outside today? (OUTSIDE)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 227 4 0 0 160 2 387 2
0 1760 28 621 8 1328 17 3709 17
1 1861 30 1637 22 3159 40 6657 31
2 1148 18 2113 28 2028 26 5289 25
3 or more 1232 20 3120 41 1153 14 5505 26
16. Have you been out of town for more than 8 hrs today? (AWAY)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 166 3 0 0 151 2 317 1
No 5653 91 7048 94 7168 92 19869 92
Yes 409 7 443 6 509 7 1361 6
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3.10 ON NEED / ADDITIONAL MEDICATION (BASED ON THE DIARY)
1. Nitrates (NITROEX)
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 0 0 0 0 203 3 203 1
No 5995 96 7295 97 7017 90 20307 94
Yes 233 4 196 3 608 8 1037 5
	
	 2-agonists AGONEX)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 151 2 151 1
No 6219 100 7490 100 7192 92 20901 97
Yes 9 0 1 0 433 6 443 2
3. Inhalable anticholinergs (ANTICEX)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 0 0 0 0 203 3 203 1
No 6193 99 7491 100 7504 96 21188 98
Yes 35 1 0 0 121 2 156 1
4. Inhalable dinatriumcromoglicate / nedocromile (CROMOGEX)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 203 3 203 1
No 6228 100 7491 100 7625 97 21344 99
5. Inhalable glucocorticosteroids (GLUCOREX)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 203 3 203 1
No 6173 99 7491 100 7549 96 21213 98
Yes 55 1 0 0 76 1 131 1
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6. Leukotriene receptor blockers (RECBLOEX)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 203 3 203 1
No 6228 100 7491 100 7625 97 21344 99
7. Anti-arrhythmic medication (ARREX)
Amsterdam Erfurt Helsinki Total
n % n % n % n %
Missing 0 0 0 0 203 3 203 1
No 6229 100 7491 100 7614 97 21333 99
Yes 0 0 0 0 11 0 11 0
" blockers (BETABLEX)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 203 3 203 1
No 6146 99 7482 100 7625 97 21253 99
Yes 82 1 9 0 0 0 91 0
9. Ca++ -blockers (CABLOEX)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 203 3 203 1
No 6226 100 7472 100 7625 97 21323 99
Yes 2 0 19 0 0 0 21 0
10. ACE-inhibitors (ACEEX)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 203 3 203 1
No 6227 100 7491 100 7625 97 21343 99
Yes 1 0 0 0 0 0 1 0
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11. ASA (ASAEX)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 0 0 0 0 203 3 203 1
No 6194 99 7477 100 7624 97 21295 99
Yes 34 1 14 0 1 0 49 0
12. Digitalis (DIGITAEX)
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 0 0 0 0 203 3 203 1
No 6228 100 7491 100 7622 97 21341 99
Yes 0 0 0 0 3 0 3 0
13. Dipyridamole (DIPYRIEX)
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 0 0 0 0 203 3 203 1
No 6228 100 7491 100 7625 97 21344 99
14. Diuretics (DIURETEX)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 203 3 203 1
No 6109 98 7402 99 7623 97 21134 98
Yes 119 2 89 1 2 0 210 1
15. Moksonidine (MOKSOEX)
Amsterdam Erfurt Helsinki Total
n % n % N % n %
Missing 0 0 0 0 203 3 203 1
No 6228 100 7491 100 7625 97 21344 99
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16. Warfarine (WARFAREX)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 203 3 203 1
No 6162 99 7491 100 7625 97 21278 99
Yes 66 1 0 0 0 0 66 0
17. Hyperlipidaemia medication (HYPLIPEX)
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 0 0 0 0 203 3 203 1
No 6228 100 7487 100 7625 97 21340 99
Yes 0 0 4 0 0 0 4 0
18. Diabetes medication (DIABETEX)
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 0 0 0 0 203 3 203 1
No 6228 100 7491 100 7625 97 21344 99
19. Medication affecting central nervous system (CNSEX)
Amsterdam Erfurt Helsinki Total
N % n % n % n %
Missing 0 0 0 0 203 3 203 1
No 6093 98 7458 100 7579 97 21130 98
Yes 135 2 33 0 46 1 214 1
20. Other medication (OTHMEDEX)
Amsterdam Erfurt Helsinki Total
n % n % n % N %
Missing 0 0 0 0 203 3 203 1
No 5460 88 5450 73 6586 84 17496 81
Yes 768 12 2041 27 1039 13 3848 18
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3.11 AIR HYGIENE 24-HOUR DATA (FROM NOON TO NOON)
1. Number concentration of particles in size range 0.01-0.1 µm (1/cm3) (NC1)
Amsterdam Erfurt Helsinki Total
N 216 177 182 575
N missing 21 0 0 21
Mean
Sd
17 338
6 069
21 124
11 992
17 040
9 328
18 409
9 414
Min
Max
5 699
37 195
3 867
96 678
2 305
50 306
2 305
96 678
Median 17 147 19 198 14 886 16 580
25%
75%
12 614
21 322
12 401
27 933
11 052
20 879
12 296
22 392
2. Number concentration of particles in size range 0.01-0.1 µm (1/cm3) without any
imputations (NC1NOIMP)
Amsterdam Erfurt Helsinki Total
N 202 177 176 555
N missing 35 0 6 41
Mean
Sd
17 456
6 137
20 902
11 714
17 223
9 399
18 481
9 376
Min
Max
5 699
37 195
3 867
89 295
2 305
50 306
2 305
89 295
Median 17 233 18 289 15 132 16 586
25%
75%
12 766
21 639
12 348
27 715
11 004
21 055
12 296
22 514
3. Number concentration of particles in size range 0.1-1.0 µm (1/cm3) (NC2)
Amsterdam Erfurt Helsinki Total
N 202 177 176 555
N missing 35 0 6 41
Mean (sd) 2131 (1139) 1829 (1277) 1390 (674) 1800 (1107)
Min - Max 413 - 6413 303 - 6848 344 - 3782 303 - 6848
Median 1874 1492 1200 1492
25%-75% 1212 - 2795 964 - 2237 909 - 1672 1012 - 2276
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4. Number concentration of particles in size range 1.0-2.5 µm (1/cm3) (NC3)
Amsterdam Erfurt Helsinki Total
N 209 177 176 562
N missing 28 0 6 34
Mean (sd) 0.3 (0.3) 0.7 (1.2) 2.3 (1.1) 1.1 (1.3)
Min - Max 0.01 - 1.9 0.1 -10.5 0.5 - 6.6 0.01 - 10.5
Median 0.2 0.4 2.1 0.6
25%-75% 0.1 - 0.5 0.3 - 0.8 1.5 - 2.9 0.2 - 1.6
5. Total number concentration of particles in size range 0.01-2.5 µm (1/cm3) (TNC)
Amsterdam Erfurt Helsinki Total
N 202 177 176 555
N missing 35 0 6 41
Mean
Sd
19 588
6 437
22 732
12 577
18 616
9 824
20 282
9 937
Min
Max
6 836
40 142
4 656
94 861
3 027
54 092
3 027
 94 861
Median 20 078 19 847 16 596 18 263
25%
75%
14 496
23 904
13 378
30 008
12 426
22 455
13 601
24 484
6. CPC particle total number concentration (1/cm3) (CPCTNC)
Amsterdam Erfurt Helsinki Total
N 212 162 174 548
N missing 25 15 8 48
Mean
Sd
24 536
8 521
23 724
12 749
22 594
9 655
23 679
10 295
Min
Max
9 117
51 861
4 827
111 771
4 594
58 919
4 594
111 771
Median 24 212 21 323 20 843 22 119
25%
75%
17 906
29 631
15 299
29 608
16 290
26 103
16 659
29 335
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7. Number concentration of particles in size range 0.01-0.03 µm (1/cm3) (NC1A)
Amsterdam Erfurt Helsinki Total
N 202 177 176 555
N missing 35 0 7 41
Mean
Sd
10 403
4 269
16 409
8 792
11 097
6 257
12 539
7 116
Min
Max
2 991
24 448
2 787
64 592
1 182
34 009
1 182
64 592
Median 9 829 14 933 9 980 10 780
25%
75%
6 953
13 431
9 701
21 278
6 747
13 891
7 599
15 706
8. Number concentration of particles in size range 0.03-0.1 µm (1/cm3) (NC1B)
Amsterdam Erfurt Helsinki Total
N 202 177 176 555
N missing 35 0 6 41
Mean
Sd
7 054
2 695
4 493
3 382
6 126
3 378
5 943
3 317
Min
Max
1 468
16 985
895
24 703
1 123
19 930
895
24 703
Median 7 019 3 429 5 320 5 382
25%
75%
5 195
8 778
2 253
5 623
4 088
7 249
3 458
7 595
9. Number concentration of particles in size range 0.1-0.5 µm (1/cm3) (NC2A)
Amsterdam Erfurt Helsinki Total
N 202 177 176 555
N missing 35 0 6 41
Mean (sd) 2127 (1136) 1807 (1257) 1381 (670) 1788 (1099)
Min - Max 412 - 6369 295 - 6797 342 - 3766 295 - 6797
Median 1873 1485 1194 1487
25%-75% 1210 - 2783 958 - 2216 902 - 1661 1002 - 2265
10. Number concentration of particles in size range 0.5-1.0 µm (1/cm3) (NC2B)
Amsterdam Erfurt Helsinki Total
N 210 177 176 563
N missing 27 0 6 33
Mean (sd) 4.7 (6.6) 22.2 (31.5) 9.5 (4.7) 11.7 (19.7)
Min - Max 0.2 - 42.7 0.7 - 174.7 1.9 - 28.3 0.2 - 174.7
Median 2.3 9.0 8.7 6.1
25%-75% 1.3 - 4.6 4.2 - 25.3 6.0 - 11.6 2.7 - 12.1
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11. Mass concentration* of particles in size range 0.01-0.1 µm (µg/m3) (MC1)
Amsterdam Erfurt Helsinki Total
N 202 177 176 555
N missing 35 0 6 41
Mean (sd) 1.8 (0.7) 0.5 (0.4) 0.7 (0.4) 1.0 (0.8)
Min - Max 0.4 - 4.5 0.1 - 2.8 0.2 - 2.3 0.1 - 4.5
Median 1.7 0.4 0.6 0.8
25%-75% 1.2 - 2.3 0.3 - 0.7 0.5 - 0.8 0.4 - 1.4
*
 In Helsinki volume concentration.
12. Mass concentration of particles in size range 0.1-1.0 µm (µg/m3) (MC2)
Amsterdam Erfurt Helsinki Total
N 193 177 176 546
N missing 44 0 6 50
Mean (sd) 14.3 (9.3) 21.1 (18.4) 5.9 (2.8) 13.8 (13.4)
Min - Max 2.3 - 63.0 2.6 - 88.6 1.4 - 16.5 1.4 - 88.6
Median 12.0 14.6 5.2 9.5
25%-75% 7.0 - 18.4 9.2 - 27.3 3.9 - 7.5 5.6 - 17.1
13. Mass concentration of particles in size range 1.0-2.5 µm (µg/m3) (MC3)
Amsterdam Erfurt Helsinki Total
N 209 177 176 562
N missing 28 0 6 34
Mean (sd) 1.0 (1.0) 1.2 (1.8) 4.3 (2.1) 2.1 (2.2)
Min - Max 0.04 - 7..0 0.1 - 14.4 1.0 - 13.3 0.04 - 14.4
Median 0.7 0.8 3.7 1.3
25%-75% 0.3 - 1.6 0.5 - 1.3 3.0 - 5.2 0.5 - 3.1
14. Total mass concentration of particles in size range 0.01-2.5 µm (µg/m3) (TMC)
Amsterdam Erfurt Helsinki Total
N 193 177 176 546
N missing 44 0 6 50
Mean (sd) 17.1 (10.0) 22.9 (19.8) 10.9 (4.9) 16.7 (13.9)
Min - Max 3.2 - 68.0 2.9 - 98.7 2.6 - 28.7 2.6 - 98.7
Median 15.3 15.7 9.6 12.8
25%-75% 9.6 - 22.1 10.7 - 29.4 7.5 – 13.2 8.6 - 20.3
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15. Mass concentration of particles in size range 0.01-0.03 µm (µg/m3) (MC1A)
Amsterdam Erfurt Helsinki Total
N 202 177 176 555
N missing 35 0 6 41
Mean
Sd
0.075  
0.028
0.050  
0.029
0.042  
0.023
0.057  
0.031
Min
Max
0.023
0.168
0.009
0.219
0.005
0.125
0.005
0.219
Median 0.075 0.043 0.038 0.050
25%
75%
0.052
0.093
0.028
0.066
0.026
0.052
0.033
0.078
16. Mass concentration of particles in size range 0.03-0.1 µm (µg/m3) (MC1B)
Amsterdam Erfurt Helsinki Total
N 202 177 176 555
N missing 35 0 6 41
Mean (sd) 1.7 (0.7) 0.5 (0.4) 0.6 (0.4) 1.0 (0.8)
Min - Max 0.4 - 4.4 0.1 - 2.6 0.1 - 2.2 0.1 - 4.4
Median 1.6 0.4 0.6 0.7
25%-75% 1.2 - 2.2 0.2 - 0.6 0.4 - 0.8 0.4 - 1.4
17. Mass concentration of particles in size range 0.1-0.5 µm (µg/m3) (MC2A)
Amsterdam Erfurt Helsinki Total
N 202 177 176 555
N missing 35 0 6 41
Mean (sd) 12.9 (8.0) 17.1 (13.7) 4.5 (2.2) 11.6 (10.6)
Min - Max 2.0 - 53.6 2.4 - 75.6 1.1 - 13.4 1.1 - 75.6
Median 11.2 12.7 4.0 8.1
25%-75% 6.6 - 17.4 8.1 - 22.3 3.0 - 5.7 4.5 - 15.4
18. Mass concentration of particles in size range 0.5-1.0 µm (µg/m3) (MC2B)
Amsterdam Erfurt Helsinki Total
N 210 177 176 563
N missing 27 0 6 33
Mean (sd) 1.2 (1.5) 4.0 (6.0) 1.4 (0.7) 2.1 (3.7)
Min – Max 0.1 - 9.2 0.2 - 38.3 0.3 - 4.4 0.1 - 38.3
Median 0.7 1.7 1.3 1.2
25%-75% 0.3 - 1.3 0.9 - 4.3 0.9 - 1.8 0.6 - 2.1
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#$%&'		 ((µg/m3) (PM10)
Amsterdam Erfurt Helsinki Total
N 208 155 182 545
N missing 29 22 0 51
Mean (sd) 36.2 (16.6) 27.1 (20.2) 19.5 (9.6) 28.0 (17.3)
Min - Max 13.6 - 112.0 5.2 – 104.2 6.4 - 67.4 5.2 - 112.0
Median 31.9 20.0 17.5 24.2
25%-75% 25.7 - 41.9 13.0 – 32.7 12.4 - 23.8 15.8 - 34.1
$%&'		 ((µg/m3) (PM25)
Amsterdam Erfurt Helsinki Total
N 228 161 181 570
N missing 9 16 1 26
Mean (sd) 20.0 (13.3) 23.1 (18.9) 12.7 (6.7) 18.5 (14.2)
Min - Max 3.8 - 82.2 4.5 – 118.1 3.1 - 39.8 3.1 - 118.1
Median 16.9 16.3 10.6 14.1
25%-75% 10.4 - 23.9 10.5 – 27.4 8.1 - 16.0 9.6 - 22.6
21. Coarse particulate matter (2.5-10 µm) (PMC)
Amsterdam Erfurt Helsinki Total
N 199 154 181 534
N missing 38 23 1 62
Mean (sd) 15.3 (8.1) 3.7 (6.2) 6.7 (5.9) 9.0 (8.5)
Min - Max -16.3 – 45.3 -28.7 - 51.3 -0.2 – 37.0 -28.7 - 51.3
Median 14.9 2.9 4.8 6.7
25%-75% 10.1 – 19.4 0.6 - 5.8 3.0 – 8.5 3.0 - 13.7
22. Absorption coefficient for PM2.5 filter  (*10-6) (PM25BS)
Amsterdam Erfurt Helsinki Total
N 229 160 168 557
N missing 8 17 14 39
Mean (sd) 17 (9) 25 (15) 20 (8) 20 (11)
Min - Max 3 – 55 5 - 78 5 - 49 3 - 78
Median 15 20 19 18
25% - 75% 10 – 23 13 - 34 14 - 25 12 - 26
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23. Carbon monoxide (mg/m3) (CO)
Amsterdam Erfurt Helsinki Total
N 237 176 173 586
N missing 0 1 9 10
Mean (sd) 0.6 (0.2) 0.4 (0.4) 0.4 (0.2) 0.5 (0.3)
Min – Max 0.4 - 1.6 0.1 - 2.5 0.1 - 1.0 0.1 - 2.5
Median 0.6 0.3 0.4 0.5
25%-75% 0.5 - 0.7 0.2 - 0.5 0.3 - 0.6 0.3 - 0.6
24. Nitrogen monoxide (µg/m3) (NO)
Amsterdam Erfurt Helsinki Total
N 237 177 182 596
N missing 0 0 0 0
Mean (sd) 25.0 (33.4) 19.3 (31.5) 20.4 (20.8) 21.9 (29.6)
Min – Max 0 - 208.2 0.2 - 264.6 2.3 - 172.7 0 - 264.6
Median 11.9 7.2 14.0 12.0
25%-75% 5.8 - 28.9 2.8 - 22.4 8.8 - 23.0 5.5 - 25.5
25. Nitrogen dioxide (µg/m3) (NO2)
Amsterdam Erfurt Helsinki Total
N 237 177 182 596
N missing 0 0 0 0
Mean (sd) 42.7 (15.8) 28.9 (14.4) 31.1 (11.9) 35.0 (15.6)
Min - Max 8.5 - 93.5 6.7 - 81.7 10.7 - 67.5 6.7 - 93.5
Median 42.5 26.5 29.7 32.4
25%-75% 30.8 - 53.9 18.5 - 36.8 22.8 - 35.5 23.4 - 44.5
26. Ozone  (µg/m3) (O3)
Amsterdam Erfurt Helsinki Total
N 237 177 182 596
N missing 0 0 0 0
Mean (sd) 31.1 (20.4) 32.1 (18.2) 38.2 (19.7) 33.5 (19.8)
Min - Max 1.4 - 85.5 0 - 67.9 5.7 - 94.3 0 - 94.2
Median 28.5 31.5 36.3 31.8
25%-75% 13.3 - 45.8 18.1 - 46.5 22.9 - 54.2 17.4 - 47.6
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27. Sulphur dioxide  (µg/m3) (SO2)
Amsterdam Erfurt Helsinki Total
N 237 177 180 594
N missing 0 0 2 2
Mean (sd) 6.7 (4.5) 5.6 (5.8) 5.8 (4.5) 6.1 (5.0)
Min – Max 0.2 - 32.8 0.5 - 46.7 0.2 - 35.0 0.2 - 46.7
Median 5.5 3.8 4.6 4.7
25%-75% 3.5 - 8.8 2.7 - 6.0 2.8 - 7.5 3.0 - 8.1
28. Mean temperature (oC) (TEMP)
Amsterdam Erfurt Helsinki Total
N 237 177 182 596
N missing 0 0 0 0
Mean (sd) 7.8 (4.9) 3.7 (4.8) -1.7 (6.4) 3.7 (6.7)
Min - Max -4.0 - 20.1 -7.8 - 13.6 -24.3 - 11.5 -24.3 - 20.1
Median 7.5 4.4 -0.4 4.2
25%-75% 4.6 - 11.6 0.8 - 6.7 -4.6 - 2.2 -0.2 - 7.9
29. Relative humidity (%) (RH)
Amsterdam Erfurt Helsinki Total
N 237 177 182 596
N missing 0 0 0 0
Mean (sd) 86 (8.6) 86 (6.6) 86 (9.0) 86 (8.2)
Min – Max 48 - 100 64 - 99 51 - 98 48 - 100
Median 87 86 88 87
25%-75% 81 - 92 82 - 90 82 - 92 81 - 91
30. Ambient air pressure (mbar) (AP)
Amsterdam Erfurt Helsinki Total
N 237 176 181 594
N missing 0 1 1 2
Mean (sd) 1014 (10) 1016 (10) 1012 (14) 1014 (12)
Min – Max 988 - 1041 992 – 1040 961 - 1040 961 - 1041
Median 1014 1016 1011 1014
25%-75% 1008 - 1021 1008 – 1023 1001 - 1022 1006 - 1022
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31. Wind speed (m/s) (WS)
Amsterdam Erfurt Helsinki Total
N 237 177 181 595
N missing 0 0 1 1
Mean (sd) 5.4 (2.5) 1.6 (0.9) 4.3 (1.8) 3.9 (2.5)
Min – Max 1.4 - 15.7 0.4 - 5.1 0.3 - 10.9 0.3 - 15.7
Median 5.1 1.4 3.9 3.5
25%-75% 3.3 - 6.6 0.9 - 2.1 3.1 - 5.2 1.9 - 5.3
32. Daily pollen counts (sum of all species) (POLLEN)
Amsterdam Erfurt Helsinki Total
N 237 177 182 596
N of days with pollen 195 44 30 269
Mean (sd) 51 (88) 5 (16) 69 (445) 42 (253)
Min – Max 0 – 566 0 - 140 0 – 4952 0 - 4952
Median 13 0 0 0
25%-75% 2 – 52 0 - 0 0 – 0 0 - 13
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Spearman correlations of  air pollutants and meteorological factors (24-hour averages). All correlations
statistically significant (p-value<.05) except those marked with *.
PM10 PM25 PM25BS NC1 NC2 CPCTNC NO NO2 CO
PM25
AMS
ERF
HEL
.78
.95
.76
PM25BS
AMS
ERF
HEL
.61
.88
.51
.73
.82
.71
NC1
AMS
ERF
HEL
-.06*
.65
.07*
-.15
.62
.14*
.28
.77
.54
NC2
AMS
ERF
HEL
.71
.83
.65
.80
.84
.80
.80
.87
.86
.16
.67
.53
CPCTNC
AMS
ERF
HEL
-.09*
.64
.05*
-.18
.61
.09*
.27
.79
.53
.95
.97
.98
.08*
.70
.49
NO
AMS
ERF
HEL
.36
.74
.03*
.48
.68
.11*
.83
.93
.58
.44
.80
.83
.59
.80
.50
.44
.82
.86
NO2
AMS
ERF
HEL
.39
.84
.31
.49
.82
.35
.82
.87
.69
.49
.82
.72
.67
.82
.72
.48
.80
.74
.91
.87
.73
CO
AMS
ERF
HEL
.42
.76
.22
.58
.77
.40
.83
.81
.55
.22
.72
.35
.60
.78
.51
.25
.72
.35
.80
.77
.54
.76
.86
.32
SO2
AMS
ERF
HEL
.52
.63
.27
.48
.69
.44
.63
.63
.46
.48
.56
.49
.67
.57
.49
.50
.58
.46
.63
.56
.33
.72
.63
.41
.50
.68
.19
O3
AMS
ERF
HEL
-.43
-.68
.13*
-.58
-.67
-.06*
-.79
-.85
-.41
-.24
-.65
-.56
-.59
-.75
-.31
-.22
-.66
-.57
-.86
-.87
-.74
-.82
-.80
-.33
-.76
-.76
-.60
TEMP
AMS
ERF
HEL
.07*
-.33
.16
-.14
-.44
-.07*
-.37
-.22
-.25
-.18
-.34
-.55
-.10*
-.36
-.17
-.28
-.37
-.55
-.57
-.15
-.42
-.49
-.42
-.29
-.59
-.62
-.08*
RH
AMS
ERF
HEL
.10*
.20
-.30
.27
.24
-.03*
.34
.33
-.12*
.18
.19
-.24
.22
.24
-.09*
.13*
.24
-.21
.50
.37
.05*
.45
.35
-.17
.46
.47
.14*
AP
AMS
ERF
HEL
.38
.61
.17
.34
.59
.23
.32
.58
.17
-.06*
.42
.08*
.35
.54
.25
-.08*
.42
.03*
.16
.47
-.01*
.12*
.58
.15
.28
.56
.07*
151
0
20
40
60
80
100
25.10 9.11 24.11 9.12 24.12 8.1 23.1 7.2 22.2 9.3 24.3 8.4 23.4 8.5 23.5 7.6
-10
-5
0
5
10
15
20
0
20
40
0
20
40
60
0
20
40
60
80
100
120
0
20
40
60
80
NO2 (µg/m
3)
Figure 1. Levels of air pollutants and temperature in Amsterdam. Horizontal line is the average over all centers and over
the whole study periods. NC1 = number concentration of particles in size range 0.01-0.1 µm; NC2 = number concentration
of particles in size range 0.1-1.0 µm; PM2.5 = mass of particles less than 2.5 µm in diameter; PM10 = mass of particles
less than 10 µm in diameter; NO2 = nitrogen dioxide.
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Figure 2. Levels of air pollutants and temperature in Erfurt. See figure 1 for legends.
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Figure 3. Levels of air pollutants and temperature in Helsinki. See figure 1 for legends.
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4 APPENDICES
Can be found as separate links on the web site
